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Abstract of the Dissertation
Targeted Genome-Scale Gene Activation and Gene Editing in Human Cells to Understand
Disease Models
By Michael De La Cruz
Keck Graduate Institute of Applied Life Sciences: 2019
Since the discovery of sequence directed DNA editing reagents such as CRISPR-Cas9 RNAguided and TALEN DNA endonucleases, there has been a snowball of advances in the life sciences
due to the ability to efficiently edit and control genomes within living cells. CRISPR-Cas9 based
genomic tools, which facilitate the high-throughput precise manipulation of genes, allow for
unbiased functional genomic screens. We used a human CRISPR-Cas9 Synergistic Activation
Mediator pooled library which utilizes an engineered protein complex for transcriptional activation
of 23,430 endogenous genes to investigate the development of novel resistance mechanisms to
lung cancer targeted therapy, Erlotinib. We set out to identify genes that when activated cause
resistance to Erlotinib, with the ultimate aim to develop parallel therapies to systematically inhibit
the pathways that these genes control or their product so as to prevent the evolution of drug
resistance. Unlike current methods, these genes, when targeted, should not affect cancer cell
metabolism, thereby decreasing the chances for cytotoxic effects. We have identified at least six
potential candidate genes that could be targeted to prevent resistance to tyrosine kinase inhibitor,
Erlotinib. In a separate study, we attempted to develop an isogenic (same genetic background
besides the disease mutation) Huntington’s Disease (HD) human cell lines through TALEN
mediated gene editing. Multiple cellular pathways have been implicated in HD pathogenesis, but
normal function of the gene, essential for embryogenesis in mouse, has remained controversial.
Moreover, the effects of genetic variation at other loci on the abnormal Huntingtin protein toxicity

have been indicated, yet remain poorly studied. An isogenic set of HD cell lines should allow for
an unbiased look into these effects. HEK293 cells were co-transfected with TALEN expression
constructs, a reporter plasmid, and donor DNA with part of the mutant (high-CAG) HTT gene. The
reporter plasmid allowed for selection of transfected clones (RFP+) and confirmation of nucleolytic
activity in clones (eGFP+). RFP+ and eGFP+ cells were FACS-sorted into individual wells and
subcultured. Trinucleotide Repeat Sizing analysis indicated the presence of high CAG allele at an
estimated targeting frequency (without the use of any selectable marker) of 38% for the FACS
selected cell lines.
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1. Chapter 1- Section I Introduction
1.1. Gene Activation in Lung Cancer Targeted-Drug Resistance
Despite progress in the development of better diagnostic technologies and therapeutic
strategies, lung cancer is still the major cause of cancer related mortality. Lung cancer is
ranked first among causes of death by cancer in men and the second in women worldwide
(Torre et al., 2015). The GLOBOCAN database reports that lung cancer deaths comprise
the largest number of cancer deaths, accounting for 18.4% of total estimated number of
deaths due to cancer in both sexes and all ages in 2018 (Bray et al.). Globally, tobacco
smoking is still the major etiological factor in the pathogenesis of lung cancer. More than
85% of lung cancer cases are caused by voluntary or involuntary “second-hand” cigarette
smoking. In several western countries, lung cancer is responsible for more cancer related
deaths than the next three most common types of cancer combined. The number of new lung
cancer cases for 2018 is estimated to be 2,093,876 worldwide, paralleled only by the number
of breast cancer cases in the same year and accounts for 11.6% of total new cancer cases.
This is not only due to a high incidence rate, which has decreased slightly in recent years,
but also due to late diagnosis. Regrettably, only 16% of lung cancer cases are diagnosed at
an early stage. The majority of patients have locally advanced or metastatic disease (Stage
IIIB or IV) at presentation making it difficult to use other therapeutic options, such as
surgery and radiation. Consequently, prognosis remains poor with an overall survival
2

between 10 and 14 months for non-small cell lung cancer (NSCLC) cases (Fenchel et al.,
2016) and a 5-year survival rate for stage IVA NSCLC of about 10%, and for stage IVB of
less than 1%. The need for novel lung cancer prevention, diagnosis, and treatment strategies
remains a key challenge of paramount importance.
1.2. Drug Resistance in Non-Small Cell Lung Cancer
Histologically, lung cancer is described by the types of cells present in patients’ tumor
specimen. About 15% of lung cancers are small cell lung cancer (SCLC), while about 85%
are NSCLC. There are three major types of NSCLC: adenocarcinoma, squamous cell lung
cancer (also called epidermoid carcinoma) and large cell lung cancer. Lung adenocarcinoma
accounts for about 40% of all lung cancers. Adenocarcinomas tend to grow more slowly
than other kinds of lung cancer (American Cancer Society website). Lung cancer can be
divided further by driver mutation. KRAS gene mutation represents the highest percentage
of NSCLC adenocarcinoma cases at 25% (Román et al., 2018). Epidermal Growth Factor
Receptor (EGFR; HER1 in humans) sensitizing mutation is the second highest, being
present in 10% to 15% of adenocarcinoma non-squamous non-small cell lung cancers cases
in Caucasian and 30% to 40% of Asian patients (Bartholomew et al., 2017; Ettinger et al.,
2010).
Sensitizing mutations of EGFR occur in about 15% of NSCLC patients in western countries
(Lynch et al., 2004; Paez et al., 2004). There are numerous treatment options available to
3

people affected by NSCLC harboring EGFR mutations, which have changed the prognosis
in this specific group of patients. Multiple generations of small molecule tyrosine kinase
inhibitors (TKIs) that interfere with the binding of adenosine triphosphate (ATP) to the
tyrosine kinase domain of EGFR have been developed.
Several large phase III clinical trials have substantiated the superiority of EGFR TKIs
compared with platinum-doublet chemotherapy in the treatment of EGFR-mutant NSCLC
patients (Kuan et al., 2015; Maemondo et al., 2010; Mitsudomi et al., 2010; Mok et al.,
2009; Rosell et al., 2012; Sequist et al., 2013; Wu et al., 2014, 2015a; Zhou et al., 2011).
First-generation EGFR TKIs gefitinib (Iressa: AstraZeneca, approved in May 2003) and
erlotinib (Tarceva: OSI-Genentech, approved in November 2004) have been shown to
prolong progression-free survival (Lee et al., 2013). However, the median overall survival
in any individual trial did not improve, most likely because the high treatment crossover
rates from the chemotherapy arm to EGFR TKI at progression. This confounded the
detection of any advantage of the latter treatment.
1.3. Acquired Resistance in NSCLC
Conversely, the vast majority of patients developed acquired resistance to EGFR TKIs
within 8- to 14-month period, with symptomatic multisite disease progression (Maemondo
et al., 2010; Mitsudomi et al., 2010; Mok et al., 2009, 2009; Rosell et al., 2012). Gandara et
al. proposed three different subtypes of progressive disease in the setting of acquired
4

resistance to TKIs: oligoprogression, central nervous system (CNS) sanctuary progression,
and systemic progression. Patients with oligoprogression have regrowth or new lesion sites
in a limited number of areas with a maximum of four progression sites. CNS sanctuary
progression is when progression is isolated to the CNS and manifest primarily as
parenchymal brain metastasis. In the large majority of EGFR-mutated lung cancer patients,
acquired resistance manifests as a systemic progressive disease, with multiple new tumors
or regrowth in multiple areas (Melosky et al., 2018).
Primary and acquired are two types of patient resistance that limit clinical applications of
TKIs and direct treatment routines. A patient that lacks treatment response has what is
known as primary or de novo resistance. This type of resistance may be generally attributed
to patients and drug-specific factors or to tumor inherent factors. For example, NSCLC
without an associated EGFR activation are resistance to treatment with TKIs. Patients that
go through disease progression after an initial response to a TKI are said to have “acquired
resistance”. Two distinct but probably simultaneously occurring evolutionary paths are most
likely responsible for acquired resistance to EGFR TKIs. One possible mechanism is the
selection of cancer clonal cells which contain preexisting resistance mutations. The second
is the de novo acquisition of genetic defects due to random mutagenesis (Friedman, 2016).
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1.4. EGFR Biology
EGFR, also known as ERBB1 belongs to the ERBB gene family of receptor tyrosine
kinases. The gene is located in chromosome seven (7p11.2). The gene has several
polymorphisms that may regulate transcription and protein expression. For example, CA
simple sequence repeat 1 (CA-SSR1), a polymorphic dinucleotide repeat in close proximity
to a second enhancer near the 5’ end of intron 1 of the EGFR gene, was found to upregulate
transcription and protein translation. The increase in EGFR corresponded to higher
sensitivity to TKIs (Amador et al., 2004). In addition to CA-SSR1, the promoter region of
the gene may contain two single nucleotide polymorphisms (SNPs) may correlate with
increased promoter activity and expression of EGFR mRNA. One SNP, -216 G/T is located
in the binding site of a transcriptional factor (SP1) that is essential in the activation of EGFR
promoter activity. The second SNP, −191 C/C is located near one of four transcription
regions (−214 to −200) and may also be associated with increased protein expression and
thereby higher sensitivity to TKIs (Nomura et al., 2007).
The 170 kDa protein encoded by EGFR gene is one of four transmembrane glycoproteins
belonging to the erbB family of tyrosine kinase receptors. In humans, the family includes
EGFR (Her1, ErbB1), Her2 (Neu, ErbB2), Her3 (ErbB3), and Her4 (ErbB4). The singlechain transmembrane protein contains an extracellular binding region consisting of four
domains (I, II, III, IV), a short single-pass transmembrane helix , and a cytoplasmic region
6

that includes a protein tyrosine kinase domain composed of two globes (N and C-lobe) and
a regulatory region with a C-terminal phosphorylation domain (Figure 1) (Lee et al., 2006).
EGFR is a tyrosine kinase that normally functions as a receptor for seven different growth
factors which bind to the to the extracellular portion of the receptor (Table 1) (MacdonaldObermann and Pike, 2014; Voldborg et al., 1997). This interaction results in EGFR homoor heterodimerization with other erbB family members at the cell surface (Dawson et al.,
2005). The dimerized receptor internalizes, then transphosphorylates several tyrosine (Y)
residues (including Y992, Y1045, Y1068, Y1148 and Y1173) in the C-terminal of its
cytoplasmic domain, activating cellular signaling pathways such as the signal transducers
and activators of transcription (STAT) pathway, the mitogen-activated protein kinases
(MAPK) pathway and the phosphatidylinositol 3-kinase and Akt/Protein Kinase B (PI3KAKT) pathway (Figure 2) (Downward et al., 1984). The activation of these pathways
ultimately leads to increased cell proliferation, migration and survival. However, EGFR
oncogenic mutations lead to ligand independent activation of these signaling pathways by
stably activating auto-phosphorylation (Guo et al., 2015; Yu et al., 2002a).
1.5. EGFR Activating Mutations
Activating mutations are limited to the first four exons, exons 18 through 21 in the tyrosine
kinase domain (Figure 1). The most common EGFR activating mutations are in-frame
deletions in exon 19 (44% of all EGFR-activating mutations), e.g. E746 - A750 deletion and
7

the L858R point-mutation in exon 21 which accounts for 41% of all EGFR-activating
mutations (Sharma et al., 2007; Su et al., 2017).
The exon 19 in-frame deletion mutations are located in helix C at the N-terminus of the Nlobe of the kinase domain. “Deletions in exon 19 cause truncation of the C-helix and
restrains it in an active "in" conformation, imparting resistance to inhibitors like
vemurafenib that bind the C-helix "out" conformation” (Figure 3) (Foster et al., 2016).
The L858R point-mutations is found in a closely packed hydrophobic pocket in the proteins
inactive site. Upon replacement of small hydrophobic leucine with a large polar arginine the
active conformation is stabilize, promoting EGFR dimerization by quelling the disorder in
the A-loop region (Figure 3) (Kumar et al., 2008; Shan et al., 2012).
First-generation EGFR TKIs, gefitinib and erlotinib show increased affinity for the mutated
EGFR as compared to the wild type EGFR receptor. Meta-analyses of 16 phase III
randomized trials showed that NSCLC patients with exon 19 deletion had higher response
rates and longer progression-free survival compared to patients with L858R mutation upon
EGFR TKI therapy. In the case of L858R substitution, standard chemotherapy was superior
over EGFR TKIs (Zhang et al., 2016). Other, mostly activating point and deletion mutations
occur less frequently in exon 18, e.g. G719S/A/C, E709K, Del18: delE709_T710insD.
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1.6. Acquired Resistance to First-Generation EGFR TKI
Insertions in exon 20 of EGFR have been generally associated with resistance to EGFR
TKIs (De Pas et al., 2011; Lund-Iversen et al., 2012). The point mutation T790M in exon
20 is detected in up to 60% of acquired resistant cases (Yu et al., 2013). Consistent with the
National Comprehensive Cancer Network guidelines, NSCLC patients should be routinely
tested for the T790M mutation. This substitution leads to conformational changes that
increase the affinity of the mutant EGFR for ATP, thereby outcompeting erlotinib and
gefitinib (Yun et al., 2008). Interestingly, recent published data showed direct evidence that
clones with drug resistant T790M mutation can both preexist and evolve from drug tolerant
cells during persistent EGFR inhibition (Hata et al., 2016). Patients with T790M positive
tumors typically do not progress as fast and generally have better prognosis (Oxnard et al.,
2011).
In approximately 20% of cases of acquired resistance, the oncogene MET encoding the
hepatocyte growth factor receptor c-MET is amplified (Engelman et al., 2007). This
amplification occurs with or without T790M mutations in mutant EGFR tumors with
acquired resistance to TKIs (Bean et al., 2007). The overexpressed MET receptor leads to
aberrant activation of downstream signaling pathways including phosphoinositide 3-kinase
(PI3K) and AKT, signal transducer and activator of transcription 3 (STAT3), or RAS and
mitogen-activated protein kinase (MAPK). The abnormal signaling through the receptor c9

MET promotes cellular invasion, migration, angiogenesis, and enables metastasis of TKIs
resistant cells (Christensen et al., 2005).
There are a number of other less common mutations that lead to acquired resistance to EGFR
TKIs. For example, the upregulation of AXL receptor tyrosine kinase either alone or in
combination with its ligand, GAS6 has been implicated in acquired resistance to EGFR
TKIs (Zhang et al., 2012). In addition, AXL has been previously been implicated in
epithelial-mesenchymal transition (EMT), which enhances the tumor’s migratory capacity,
invasiveness and resistance to apoptosis (Kalluri and Weinberg, 2009). Normally, the
phosphoinositide 3-kinases (PI3K)/Akt signal transduction pathway plays an essential role
downstream from EGFR, promoting metabolism, proliferation, cell survival, growth and
angiogenesis in response to extracellular signals. The activation of the PI3K/Akt pathway
by Insulin-like growth factor 1 receptor (IGF1R) has been implicated as a mechanism of
resistance by bypassing the EGFR signaling blockade by gefitinib (Cortot et al., 2013; Guix
et al., 2008). Furthermore, the mutation of the PI3KCA gene, a member of the PI3K lipid
kinase family, has been associated with acquired resistance to TKIs (Wu et al., 2016). A
homozygous deletion in the tumor suppressor gene PTEN, which “induces a significant
reduction in apoptosis sensitivity in EGFR-mutant cells by activation of Akt and EGFR”
(Sos et al., 2009) is also implicated in acquired resistance. HER2 amplification has been
reported as a possible mechanism of acquired resistance that occurs in a subset of tumors
lacking the EGFR T790M mutation (Takezawa et al., 2012). Interestingly, HER2
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amplification occurs independently of the EGFR T790M secondary mutation in EGFRmutant NSCLC tumors.
1.7. Acquired Resistance to Second-Generation EGFR TKI
Following the discovery that T790M is the main mechanism of resistance, several small
molecule drugs have been developed including neratinib, afatinib and dacomitinib (Sullivan
and Planchard, 2017). These compounds showed promising results in pre-clinical studies;
however, high toxicity and low efficacy (response rates smaller than 10%) none of the
second-generation agents are considered as an effective monotherapy. A possible
explanation could be that these compounds inhibit wild-type EGFR. Nevertheless, when
afatinib, an irreversible inhibitor of the ErbB family of receptors, was tested in combination
with cetuximab, an anti-EGFR monoclonal antibody, the objective response rate was higher
than 25%. Yet, the phase Ib study results where almost indistinguishable between the
T790M-positve and T790M-negative tumors (Janjigian et al., 2014). Moreover, therapyrelated grade 3 adverse events (rash and diarrhea) and grade 4 (fatigue, pneumonitis, and
lung infiltration) occurred in 44% and 2% of patients respectively. Two patients died
because of dyspnea and pneumonitis. Regardless, a phase II randomized trial comparing the
combination therapy began enrolling patients in 2016 and has an estimated study completion
date of January 2020 (ClinicalTrials.gov).
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1.8. Acquired Resistance to Third-Generation EGFR TKI
Pharmaceutical companies are continuing to develop novel, third-generation EGFR TKIs
that target EGFR activating and T790M resistance mutations and have low inhibitory effect
on wild type EGFR (Tan et al., 2015). To date several molecules are in either on-going or
have completed clinical trials including, avitinib, brigatinib, dacomitinib, nazartinib and
osimertinib. Of these, osimertinib, an oral irreversible pyrimidine-based EGFR TKI gained
FDA accelerated approval in November 2015 followed by a full indication in March 2017
(Greig, 2016). Osimertinib forms an irreversible covalent bond via the cysteine-797 residue
with EGFR mutation or EGFR T790M (Cross et al., 2014). The small-molecule drug is
selective for T790M resistance mutation and EGFR sensitizing mutations over wild type
EGFR. A confirmatory phase III study showed that osimertinib was superior to
chemotherapy in chemotherapy-naïve patients with EGFR mutant NSCLC. Moreover, these
patients had disease progression after an EGFR TKI treatment, and had tumors harboring
T790M EGFR mutation. The study results showed a longer median duration of progressionfree survival of 10.1 months for the osimertinib arm of the trial versus 4.4 months for
patients receiving platinum-based chemotherapy alone (Wu et al., 2015b). The objective
response rate was also better with osimertinib (71%) than with chemotherapy at 31%. In
addition, it was reported that among patients with metastases to the central nervous system
(CNS), osimertinib was associated with higher CNS response rate compared to
chemotherapy: 70% vs 31% respectively. The CNS progression-free survival was also
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longer for patients treated with osimertinib (11.7 versus 5.6 months) compared with
chemotherapy (Mok et al., 2017; Odogwu et al., 2018). This small molecule therapeutic
agent has been well tolerated in clinical studies. The most common side effects were
diarrhea, rash, nail toxicity, dry skin and fatigue, yet at lower rates than those reported in
studies of first- or second-generation EGFR TKIs. Some important risks identified for
osimertinib include interstitial lung disease/pneumonitis, QT interval adjusted for heart rate
(QTc) prolongation and cardiomyopathy.
1.9. Histologic Transformation in NSCLC
A subset of patients experienced a histologic transformation of their tumors from NSCLC
to small-cell lung cancer (SCLC) during or after therapy with EGFR TKIs leading to
resistance (Sequist et al., 2011). Although the mechanisms of transformation to SCLC
remain unclear, retinoblastoma gene (RB) deficiency, a common feature of SCLC, has been
implicated (Niederst et al., 2015). Moreover, the observed low E-cadherin expression and
increased vimentin expression in these tumors help the mechanism of transformation with
activation of the EMT program (Sequist et al., 2011).
1.10. Proposed Treatment for Resistant TKI-treated NSCLC
One can imagine an alternate paradigm of lung cancer treatment, in which a novel class of
drugs is less toxic than current anti-cancer drugs and do not by themselves target a cancer
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cell’s ability to survive. On the other hand, the drug is designed to target the adaptive
strategies of TKI-treated cancer cells.
Using a novel approach to target identification, applying systems biological methods that
employ genome-wide techniques, next-generation sequencing, and high-volume
computational data mining, this innovative class of drugs may be developed (Figure 4). The
identified targets will be used to chart, as a network of genes and proteins, the evolutionary
landscape of resistance development to a targeted chemotherapeutic agent. Computational
analysis of this network may allow the identification of nodal points that when disrupted do
not alone cause toxicity to the cancer or normal cells, but prevent the rewiring of networks
that makes the cells resistant to the drug.
In this thesis, this concept of deciphering and preventing the emergence of drug resistance
in NSCLC cells will be approached by a genome wide gene activation experiment conducted
on an Erlotinib exposed NSCLC cell line, HCC827. Like others before, we will couple
CRISPR/dCas9

SAM

(Clustered

Regularly

Interspaced

Short

Palindromic

Repeats/defective-CRISPR-associated protein 9 Synergistic Activation Mediators)
activation and Next-Generation sequencing to identify the novel targets (Joung et al., 2017;
Konermann et al., 2015).
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2. Chapter 2- Section I Methods
2.1. Generation of Lung Cancer Cell Bank
Two cell banks were generated with lung cancer lines HCC827 (ATCC, CRL-2868) and
NCI-H2228 (ATCC, CRL-5935) using a protocol adapted from the ATCC product sheet for
the cell lines. The vials were quickly thawed in a 37°C bath, and within approximately two
minutes, the vials were surface sterilized and transferred into the aseptic hood. The vial
contents were transferred into a 15 ml conical flask with 10 ml of prewarmed RPMI-1640
growth medium (ATCC, cat. no. 30-2001) supplemented with 10% fetal bovine serum
(FBS) (Thermo Fisher, cat. no. 10438026), and centrifuged at 100× g for 5 minutes. In the
aseptic hood, the supernatant was carefully removed without disturbing the cell pellet. The
cell pellet was suspended in 5 ml of warm media, and transferred the content into a T-25
flask. Mixed and dispersed the cells throughout the T-flask surface by gently moving the
flask laterally in both directions while lying on a flat surface. Allowed the cells to settle and
cultured overnight inside a humidified incubator set 37°C and 5% CO2.
The day after, checked the percent confluency of the surface adherent cells using an inverted
microscope. Once the confluency reached above 80%, the cells were passaged every two to
three days. The cells were subcultured at a targeted starting cell density between 1.3 and 3.3
× 104 viable cells per cm2, and the viability was maintained above 90%. The cells were
harvested by adding Trypsin 0.5% EDTA solution (Life Technologies, cat. no. 15400054)
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diluted to 0.05% in D-PBS buffer (ATCC, cat. no. 30-2200) directly to the culture flask,
and incubating it at 37°C for five minutes until the cells began to dislodge. The enzymatic
reaction was stopped by diluting the trypsin with at least 1x volume of fresh growth medium
with FBS. At each passage a 1 ml sample was taken to enumerate the cell density and
viability of the culture determined using an automated cell viability analyzer, Vi-CELL
(Beckman Coulter).
Once the culture reached a confluence across four T-75 flasks, the cells were sampled for
cell density and viability, harvested, pooled and centrifuged. The spent medium was
suctioned out and the pellet was resuspended in the same growth medium supplemented
with 10% cell culture-tested DMSO (ATCC, cat. no. 4-X), targeting 1 × 106 viable cells per
ml. The 2 ml cryopreservation vials were filled with 1 ml each, labeled and stored in the 80°C freezer overnight in a Mr. Frosty container filled with isopropanol. This container and
therefore the cell vials are designed to achieve a rate of cooling very close to -1°C per
minute, ensuring proper cell freezing. The vials are then transferred to the liquid nitrogen
storage for at least 24 hours before thawing. The cell banks were sampled to test cell
viability after the freeze-thaw cycle, and passaged for at least three consecutive passages
before use.
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2.2. Subculturing Lung Cancer Cell Line, HCC827
The cell banks were passaged for a maximum of fifteen 3-day passages. A 15 ml conical
tube and a T-25 flask were prepared each with 5ml of warm (~37ºC) growth medium, RPMI
1640 medium with 10% FBS. Retrieved an HCC827 cell bank vial(s) from liquid nitrogen
storage and carefully flipped upside down to allow any liquid to escape. Without
submerging, placed the vial(s) in 37°C bath and closely monitored for about two minutes
until it began to thaw. Before it could completely thaw, disinfected the vial(s) with 70%
ethanol solution and transferred it into laminar flow hood. Mixed to suspend the cells with
5ml of medium and transferred the contents from the vial(s) into the conical tube. The cell
suspension was centrifuged at 100× g for five minutes at room temperature. While in the
laminar flow hood, we carefully aspirated medium containing DMSO as to not disturb the
pellet. Almost immediately, we suspended the pelleted cells with 2 ml of fresh warmed
growth medium by pipetting the contents up and down. Transferred the entire cell culture
solution from the tube into the T-25 flask with 5 ml of growth medium, and mixed well
spreading the cells evenly across the flask surface.
The cultures grew for two days at 37°C in a humidified incubator with 5% CO2. The cells
typically settled in about 6 hours, but they were normally inspected on the next day after
plating. When the cells reached 60% to 90% confluency, in this case two days, the cells
were passaged typically into a larger flask with fresh growth medium. The adherent cells
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were passaged by first aspirating the spent media from the flask. After aspiration 0.05%
Trypsin/PBS solution was added to the flasks: 0.75 ml to a T-25, 2 ml to a T-75 or 5 ml to
a T-225 and incubated for five minutes at 37°C inside 5% CO2 incubator. To disrupt the
cells, we gently tapped the flask and examined under microscope to make sure the cells
were fully detached. The Vi-CELL requires that the sample is diluted to a concentration
between 2 × 105 and 1 × 107 to be properly read by the sensor. Therefore, when diluting the
cultures treated with trypsin with growth medium with FBS add either 3 ml into the T-25
flask, 6 ml into the T-75 flask and 25 ml into a T-225 flask to stopped the enzymatic reaction.
Pipetted the flask contents up and down to mix and washed sides of each flask to collect as
many cells as possible. The Vi-CELL requires at least 700 µl of sample to produce cell
density and viability measurements. The rest of the cell suspension was transferred into
conical tubes while noting the actual transferred volume to use in the passage calculations.
The conical tubes were centrifuged for five minutes at 100× g.
The inoculum volume was calculated by applying the C (initial) × V (initial) = C (final) ×
V (final) equation, where C represents the desired concentrations, V are desired volumes
and V (final) is the inoculum volume. In the case of the T-25 flask, the inoculum was
suspended to a density of 3 × 105 viable cells per ml. We then added 1ml of the inoculum
to 4 ml of fresh growth medium per flask. For the T-75 flasks, the inoculum was suspended
to a density of 1 × 106 viable cell per ml. We then added 1ml of inoculum into 13 ml of
fresh growth medium per flask. Finally, for the T-225 flasks, the inoculum was suspended
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to a density of 3 × 106 viable cells per ml. We then added 1ml of inoculum to 49 ml of fresh
growth medium per flask. We mixed the flasks well to disperse the cells across the entire
surface of the T-flask and placed them inside the incubator set at 37°C and 5% CO2. From
then on, the cells were passaged after they had reached 60 to 80% confluency which was
typically every three days.
2.3. Preparation and Purification of the SAM sgRNA Library DNA
2.3.1. Trial Transformation Run with MS2-P65-HSF1 Plasmid
A trial transformation of electrocompetent cells with MS2-P65-HSF1 plasmid (AddGene,
cat. no. 89308) was initially performed to determine the optimal DNA concentration to use
during the actual transformation with the more precious SAM sgRNA Library DNA. Three
plasmid DNA solutions were prepared at 5 ng per µl, 25 ng per µl and 50 ng per µl, then
added 1 µl of the DNA solutions into 25µl of aliquots of E. cloni 10G ELITE
electrocompetent cells (> 2 × 10^10 cfu/µg) (Lucigen, cat. no. 60052-1) while on ice. The
cells were gently mixed by pipetting and then transferred into a chilled 1mm cuvette (BTX,
cat. no. 45-0124). The cuvette was gently flicked to get rid of any bubbles and help the
solution settle down across the bottom of the well. The ECM630 Electroporation System
(BTX) was set to the parameters: 10 µF, 600 Ohms and 1800 Volts. Each cuvette was placed
into the chamber and a short pulse of electric charge was sent through them. Almost
immediately, added 975 ml of Recovery Medium (RM) provided in the electrocompetent
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cell kit. Mixed and transferred the cuvette contents into a culture tube (VWR, cat. no. 60818725) containing another 1ml of RM and incubated cells for one hour at 37ºC while mixing
at 250 rpm. Plated two 14.5 cm lysogeny broth (LB) agar plates per reaction with 100 µg
per ml Ampicillin sodium salt (Life Technologies, cat. no. 115930270), one plate at 1×
dilution (2 µl of cell in 98 µl of RM) and the other at 10× dilution (20 µl cells in 80 µl of
RM) and incubated for one-hour in a 37ºC incubator. Let the plates incubate for 12 hours
and checked the transformation efficiency by counting the number of colonies in each plate.
2.3.2. SAM sgRNA Library DNA Transformation and Purification
1 µl of a 5 ng per µl DNA solution of Human SAM Library in lenti sgRNA (MS2) puro
backbone (Puromycin resistance) (AddGene, cat. no. 1000000074) DNA was added to eight
25 µl aliquots of E. cloni 10G ELITE electrocompetent cells (> 2 × 10^10 cfu/µg) (Lucigen,
cat. no. 60052-1) while on ice. The cells were gently mixed by tapping and then performed
a quick centrifuged to consolidate the mixture. The mixtures were carefully pipetted into a
chilled 1 mm cuvette (BTX, cat. no. 45-0124) without introducing bubbles, then very gently
flicked the cuvette to deposit the cell mixture across the bottom of the well. We programmed
the ECM630 Electroporation System (BTX) with the parameters set to 10 µF, 600 Ohms
and 1800 Volts and pulsed the cuvette with an electric charge. Within ten seconds of the
pulse, 975 ml of RM was added to the cuvette, then mixed and transferred the cells to a
culture tube (VWR, cat. no. 60818-725) containing another 1 ml of RM. The cells were
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incubated for one hour at 37ºC while mixing at 250 rpm. Meanwhile, we preheated thirtythree 14.5 cm LB agar plates with 100 µg per ml of Ampicillin in a 37ºC incubator. After
the one-hour incubation time, the eight cultures were pooled and mixed well. Added 20 µl
of the transformed E. coli culture to 1 ml of RM then, after mixing well, plated 100 µl onto
a prewarmed 10 cm LB agar plate with 100 µg per ml of Ampicillin. This was the 10,000fold dilution to estimate transformation efficiency. Plated 0.5 ml of pooled electroporated
cells onto each 14.5cm plate, and grew in a 37ºC incubator for about 13 hours. After the
incubation period, we calculated transformation efficiency by counting the number of
colonies in the 10cm plates, and multiplying by 80,000 for the total number of colonies.
Since the number exceeded 7 × 107 colonies, which is at least 100 colonies per gRNA, we
continued to harvest the thirty-three 14.5 cm plates by scrapping off the colonies while
adding liquid LB medium. First, added 5 ml onto each plate, scrapped off colonies and then
pipette the broth into a 50 ml conical tube kept on ice. Repeated the serial scrapping with 3
ml of LB medium, then followed by 2 ml of LB medium, adding both to the collected broth.
Once all colonies from the thirty-three plates were collected, the broth was centrifuge and
the pellet was weighted. The plasmid DNA was extracted and purified using the EndoFree
Plasmid Maxi Kit (Qiagen, cat. no. 12362) from roughly 2 grams of bacterial cell pellet per
column. The purified DNA was stored in the 4°C refrigerator until it was transferred to the
Sanford Burnham Prebys Medical Discovery Institute for lentivirus production.
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2.4. Production and Purification of the MS2-p65-HSF1 and dCas9-VP64 Plasmids
We plated bacteria from agar stabs of the MS2-P65-HSF1 plasmid (AddGene, cat. no.
89308) and a dCas9-VP64 plasmid (AddGene, cat. no. 61425) by streaking each onto
individual agar plates with 100 µg per ml Ampicillin so as to produce single colonies of
each. The plates were then incubated overnight at 37°C for approximately 16 hours. A single
colony was picked from each plate and inoculated 5 ml LB medium starter cultures of each
plasmid in 14 ml culture tubes (VWR, cat. no. 60818-725). We incubated the cultures for
approximately eight hours at 37°C while shaking at 250 rpm. For each plasmid, three 250ml
cultures of LB selective media in 1-L flasks were inoculated with 500ul of starter culture
for a 1/500 dilution. The cultures grew for approximately 16 hours at 37°C while shaking
at 250 rpm. The bacterial cells where then harvested by centrifugation 4000× g for 20
minutes at 4°C. One column was used from the EndoFree Plasmid Maxi Kit (Qiagen, cat.
no. 12362) per 250 ml culture to purify the plasmid DNA. The purified DNA was stored in
the 4°C refrigerator until it was transferred to the Sanford Burnham Prebys Medical
Discovery Institute for lentivirus production.
2.5. Lentivirus Production at Sanford Burnham
Large-scale lentivirus production was performed by Dr. Chung-Teng Huang from the viral
vector core facility at Sanford Burnham Prebys Medical Discovery Institute (La Jolla).
Briefly, co-transfected one of three lentivector, MS2-P65-HSF1 plasmid (AddGene, cat. no.
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89308), dCas9-VP64 plasmid (AddGene, cat. no. 61425) or Human SAM Library in lenti
sgRNA (MS2) puro backbone (Puromycin resistance) (AddGene, cat. no. 1000000074) with
second generation lentiviral packaging plasmid psPAX2 (AddGene, cat. no. 12260), and
envelope protein plasmid pVSVg (AddGene, cat. no. 8454) into HEK-293T cells in a ratio
of 3:2:1. The viral supernatant was collected every 24 hours from day 2 to day 4 posttransfection. All of the viral supernatant was pooled and filtered through 0.22 µm filter. The
viral supernatant was then concentrated and purified using 20% sucrose gradient ultracentrifugation at 21,000 rpm for 2 hours. After resuspension, the pellet containing
concentrated viral particles in 1× PBS solution was aliquoted. All of the aliquots were kept
in the -80°C freezer for long term storage.
2.6. Determination of Selection Agents Dose Response
2.6.1. MTT Assay
Prepared in advance a 5 mg per ml tetrazolium colorimetric dye MTT 3-(4,5dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (Thermo Fisher cat no. M6494)
solution in D-PBS and sterile filter it using a 0.2 µm sterile syringe filter (Millipore Sigma,
cat. no. SLGV033RS). The assay was performed by first removing the spent medium from
each well and replacing it with 100ul of fresh growth medium. 10 µl of MTT stock solution
was added to each well and incubated the 96-well plate at 37°C for 4 hours. After the
incubation period, we removed all but 25 µl of medium and added 50µl of DMSO (Millipore
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Sigma, cat. no. 276855) to each well. The well contents were thoroughly mixed via pipette,
then again incubated the plates at 37 °C this time for only 10 minutes. After the incubation
period, the absorbance was read at 570 nm using a spectrophotometer. The absorbance
readings were correlated to percent viability of the cell population.
2.6.2. Blasticidin S and Hygromycin B MTT Dose-Response Assays of HCC827 naïve
cell line
An MTT dose-response assay was performed to find the EC50 and IC90 of the HCC827
cancer cell line under Blasticidin S hydrochloride (Corning, cat. no. 71002-676) and
Hygromycin B from Streptomyces hygroscopicus (Millipore-Sigma, cat. no. H3274)
selection, dosed individually and in combination. The experiment was set up as a seven-day
assay with absorbance measurements taken after the fifth and on the final seventh day. The
internal 60 wells of a 96-well plate were seeded with 10,000 cells per well of the HCC827
cancer cell line in 100 µl of RPMI-1640 growth medium supplemented with 10% FBS. Up
to ten freshly prepared stock solutions in PBS at 2× the final tested antibiotic concentrations.
100 µl of antibiotic(s) stocks solutions of increasing concentration were added across the
columns of the 96-well plate, for a total working volume of 200 µl per well. The final PBS
concentration was maintained constant across all conditions, added at 1% for the Blasticidin
S conditions and 2% for the Hygromycin B conditions. The plates were placed in a 5% CO2,
humidified incubator set at 37°C, and the media was exchanged on the second, fourth, sixth,
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and eight day. The tested concentrations ranged between 0.5 µg per ml and 25 µg per ml for
Blasticidin S and between 0.5 µg per ml and 300 µg per ml for Hygromicyn B. The
combined antibiotics were tested at concentrations ranging between 0.5 and 25 µg per ml
of Blasticidin S and 0.5 and 300 µg per ml of Hygromycin B. The actual tested
concentrations in all experiments can be found on Table 2. The colorimetric MTT assay was
described above was performed and the absorbance of each well was read after the fifth and
seventh day.
2.7. Puromycin MTT Dose-Response Assays of Transduced HCC827 Cell Line 52
An MTT dose-response assays was performed to determine the EC50 and IC90 of the
HCC827 transduced cancer cell line 52 with the two lentiviral constructs, dCas9-VP64 and
MS2-P65-HSF1 under Puromycin selection for five days or less. The 60 internal wells of a
96-well plate were inoculated with 1 × 104 cells per well in 100µl of medium, RPMI-1640
supplemented with 10% FBS. Freshly prepared ten antibiotic stock solutions ranging in final
concentration from 0.5 µg per ml and 10 µg per ml. 100 µl of each stock solutions were
added to six wells with antibiotic concentration increasing across the columns of the 96well plate, for a total working volume of 200 µl per well. The plates were placed in the
humidified 37°C incubator with 5% CO2 to incubate. The media were exchanged after three
days and the assay lasted a total of five days. An MTT assay was performed as described
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above on the third and seventh day. A table with the actual tested concentration can be found
in Table 2.
2.8. Determination of Erlotinib’s Dose Response for Transduced HCC827 Cell Line,
52
A dose-response experiment with Erlotinib hydrochloride (OSI-744) (Selleckchem, cat. no.
S1023) and the transduced HCC827 cell line, 52, were performed to determine the EC50
and IC90 after nine days of treatment. In 96-well plates, inoculated six wells (for up to ten
tested conditions) with 10,000 cells per well in 100µl of medium, RPMI-1640 supplemented
with 10% FBS. Nine Erlotinib stock solutions were prepared fresh at 2× the final tested
concentration and added 100µl to each well for a final working volume of 200µl. The final
tested concentrations ranged from 0.001µM and 15µM while maintaining the final DMSO
concentration constant across all conditions at 0.83% of the final volume. Incubated the 96well plates in a humidified 37°C incubator with 5% CO2, and the media were exchanged
after two, four, six and eight days. Measured cell proliferation after three, five, seven, and
nine days using the MTT assay described above. The exact tested conditions are listed on
tables in Table 2.
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2.9. Transduction of HCC827 Cell Line with all SAM Vectors in Series
Closely following the protocol defined earlier by Joung et al., a small-scale transduction of
the original HCC827 cell line was performed. The naïve cell line was cultured in growth
medium RPMI-1640 supplemented with 10% FBS and passaged every three days.
Generated 1.2 × 107 cells and inoculated twelve wells in a 12-well plate at 1 × 106 cells per
well in 1 ml of growth medium. To each well, added 1 ml of growth medium supplemented
with polybrene for a final concentration of 8 µg per ml in 2 ml. To each well, added 20 µl
of lentiviral supernatant of two constructs, dCas9-VP64 and MS2-p65-HSF1 for a combined
MOI of 0.2 particles per cell. The plate was then centrifugated for two hours at 1,000× g in
an Eppendorf 5810R Centrifuge (Eppendorf, cat. no. 022625101) with the temperature set
at 33 ºC. Approximately 24 hours following spinfection the cells were detached with trypsin
and counted. The cells were plated at 5× 106 cells per T225 flask and incubated overnight.
After approximately 48 hours after transduction, the medium was exchanged with growth
medium supplemented with Blasticidin S and Hygromycin B at 1.5 µg per ml and 5 µg per
ml, respectively. The cells were monitored daily and the medium was exchanged every two
days for a total of seven days of selection. The experiment was stopped after the selection
failed; cells in the cultures died.
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2.10. Transduction of HCC827 Cell Line with dCas9-VP64 and MS2-p65-HSF1
Lentiviral Vectors
Inoculated 1.5 × 104 cells per well in 6-well plates in 3 ml of growth media, RPMI-1640
with 10% FBS. The cells were left to settle and grow overnight in a 5% CO2 humidified
incubator set at 37°C. The next day, two hours before transduction, replaced the growth
medium from all the wells with 1.5 ml of fresh medium. The polybrene (Hexadimethrine
bromide) (Millipore Sigma, cat. no. H9268) solution was prepared fresh as a 16 g per ml
stock in growth medium and added 1.5 ml to half of the wells for a final concentration of 8
µg per ml. Continued to incubate the 6-well plates in the 37°C, 5% CO2 incubator for two
hours. We followed three transduction strategies to generate an HCC827 cell line with
stable expression of the dCas9-VP64 and MS2-p65-HSF1 lentiviral constructs.
The transduction experiments were conducted according to three strategies (Figures 5 – 7).
In the first strategies, added 3, 6, 9 or 12 µl of dCas9-VP64 construct lentiviral supernatant
to one well with and one without polybrene supplemented cultures. Since the lentiviral
supernatant had approximately 104 infective particles per µl (IVP/µl), the final multiplicity
of infection (MOI) were approximately 2, 4, 6 and 8 infective lentiviral particles per cell,
respectively. After each addition, we mixed the plates well by gently sliding them in either
direction while flat. Immediately placed the plates in the 5% CO2 humidified incubator set
at 37°C. For the next three consecutive days, the medium was exchanged with fresh growth
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medium and let the plates incubate overnight in the 5% CO2 humidified incubator set at
37°C. On the fourth day, added trypsin to detached cells and split the cells from all the wells,
each into three wells in three separate 12-well plates. Additionally, set up three negative
transduction controls in each of the three plates that was treated with the antibiotic selection
media.
The resistance markers for the dCas9-VP64 construct is against Blasticidin S. Added growth
medium with either 0.75, 1.5 or 3 µg per ml of Blasticindin S (Figure 5). Added the medium
supplemented with Blasticidin S at the same concentrations to two out of the three controls
in each plate. All plates were placed in the humidified incubator to grow overnight.
Monitored the cells daily and exchanged media every two days. We checked that control
cells treated with Blasticidin S were either dead or dying, and that the control without
selection grew well. Passaged the cells once they had reached higher than or equal to 60%
confluency or about four days, and increased the Blasticidin S concentration in all
conditions to 3 µg per ml. Incubated the cells for a total of four days then determined
whether to discard or passage the cell lines. Chose two from the best growing cell lines to
passage, and cryo-preserved the rest of the cell lines. Both cell lines were established by
subculturing them over the course of a month with growth media with 3 µg per ml for
Blasticidin S, and cryo-preserved cells from each cell lines.
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The same protocol was followed in the second single vector transduction strategy, this time
with the MS2-P65-HSF1 construct which has an antibiotic resistance marker against
Hygromycin B (Figure 6). On day four, added growth medium with 10, 20 or 40 µg per ml
of Hygromycin B to the eight transduced cell lines and culture for four days exchanging the
medium on day two. Increased the concentration to 40 µg per ml of Hygromycin B at the
passage, and then after two days increased the concentration to the highest used 80 µg per
ml. The cells were passaged for another two days before decreasing the Hygromycin B
concentration back to 40 µg per ml. The cell lines that showed low selection were discarded.
Continued to passaged, choosing the best growing cell lines to subculture while cryopreserving the others. Two cell lines were subcultured over the course of a month with
growth media supplemented with 40 µg per ml of Hygromycin B. A cryo-preserved cell
bank was established for the two final cell lines.
For the third transduction strategies, set up three conditions of increasing MOI each either
with or without polybrene. Added either 3, 6 or 9 µl of both lentivector supernatants to one
well with and one without polybrene for a total of six wells. The final combined MOIs were
approximately 4, 8 and 12 infectious viral particles per cell, respectively. Also, set up six
negative control wells, three with and three without polybrene. Made sure to mixed the wells
well after each addition by gently sliding them in either direction while flat. Placed the plates
in the 5% CO2 humidified incubator set at 37°C right away. Let the plates incubate
overnight and performed medium exchange with fresh growth medium for the next three
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consecutive days. On the fourth day, trypsinized and split cells from all conditions into three
wells in three separate 12-well plates. In addition, set up six negative control wells in each
of the three plates half with cells treated with polybrene.
We followed three selection protocols (Figure 7). The double transduced cells were selected
with either Blasticindin S at 1.5 µg per ml or Hygromycin B at 10 µg per ml, and with both
antibiotics combined at those same concentrations. Added the appropriate antibiotic
selection medium to three out of the six controls in each plate and placed all plates in the
humidified incubator to grow overnight. Monitored the cells daily and exchanged media
every two days. We checked that the cells in the positive control cells were either dead or
dying, and that the negative control grew well. The cells were passaged once they had
reached higher than or equal to 60% confluency or about four days. Kept the concentration
at 10 µg per ml in the six single selection conditions with Hygromycin B for a total of eight
days, yet observed low selection. Harvested all cells from these conditions and cryopreserved them. In the six single selection conditions with Blasticidin S, switch to
Hygromycin B selection at 10 µg per ml for nine days exchanging the medium every two
days. Observed high amount of cell death with the Hygromycin B treatment, therefore
decreased the concentration to 5 µg per ml for the next eleven days.

Again, swapped

antibiotic selection back to Blasticidin S at 3 µg per ml and subcultured the cells for ten
more days in this medium. Harvested and cryo-preserved the surviving cell lines after 28
days of selection.
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For the double selection protocol, six cell lines were subcultured in medium with antibiotic
concentrations at 1.5 µg per ml for Blasticidin S and 10 µg per ml for Hygromycin B
exchanging the medium every two days for a total of ten days (Figure 7). Divided the cells
into two cultures and continued to select the cultures one with 3 µg per ml of Blasticidin S
and the other with 40 µg per ml Hygromycin B for another ten days. After ten days, switched
the antibiotics in both cultures and continued selecting them at the same concentrations for
another ten days. Harvested and cryo-preserved the surviving cell lines after 40 days of
selection.
2.11. Verification of dCas9-VP64 and MS2-p65-HSF1gene insertion
Eight stable HCC827 transduced cell lines were selected, two single and six double
transductants, to verify the insertion of dCas9-VP64 and MS2-p65-HSF1 constructs.
Thawed cryo-preserved cells of each cell line, spun down to get rid of DMSO and
transferred to 5 ml of warmed growth medium (RPMI-1640 with 10% FBS) in a T25 flask.
The cells grew for three days or until 60% they reached confluency. Added trypsin to the
flasks to detach the cells and transferred them to a 15 ml conical tube for centrifugation.
Pelleted the cells to get rid of the medium and resuspend the pellet in 100 µl of PBS. 300 µl
of TRI Reagent (Zymo Research, cat#R2050), an acid-guanidinium-phenol based reagent,
was added to lyse the cells. We thoroughly pipetted up and down to mix the solution. The
samples were incubated at room temperature for five minutes. Added 400 µl of 100%
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ethanol (ABC, cat#) and mixed thoroughly by again pipetting up and down. Transferred the
mixed solution into a Zymo-Spin IIC Column from the Direct-zol RNA MiniPrep Kit
(Zymo Research, cat#R2051) and centrifuged at 13,000 g for one minute. Treated the
column with DNase I dissolved in DNA digestion buffer and incubated for 15 minutes at
room temperature. Washed columns with wash buffers provided in the kit and eluted with
DNase-free and RNase-free water. Quantified the RNA concentrations and stored the
samples in the -80ºC freezer until they were needed or proceeded directly to complementary
DNA (cDNA) synthesis.
qScript cDNA Synthesis Kit (Quanta Biosciences, cat. no. 95047) was used to generate
cDNA to measure dCas9 and p65 gene expression in the different cell lines using real-time
PCR (RT-PCR). We used 1 µg of RNA in the 20 µl reaction in nuclease-free water in a 0.2
ml PCR tube. Programed the thermal cycler to run one cycle at 22ºC for 5 minutes, follow
by one cycle at 42ºC for 30 minutes, then finally one cycle at 85ºC for 5 minutes. The final
cDNA solutions were stored in the -20ºC freezer until they were needed for RT-PCR.
Designed and acquired three PCR primer (Table 3) pairs targeting the Glyceraldehyde 3phosphate dehydrogenase (GAPDH) gene as the positive control, the dCas9 gene from the
dCAs9-VP64 construct and p65 gene from the MS2-p65-HSF1 construct (Eurofins
Genomics). The expected amplicons for each primer pair are 219 base pairs (bp), 262-bp
and 174-bp respectively. 10 µM stock solutions were prepared for each primer. The 20 µl
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RT-PCR reactions were prepared in white 96-well PCR plates (Phenix Research Products,
cat. no. MPC-480W) by mixing 10 µl of AzuraQuant Green Fast qPCR Mix LoRox master
mix (Azura Genomics, cat. no. AZ-2101) with 0.8 µl of each primer (10 µM stock
solutions), 6.4 µl of PCR-grade water and 2 µl of each cDNA solution to be tested. Set up
positive controls using the GAPDH primers for each of the solutions to normalize the
quantitation cycle (Cq) results. Covered the 96-well plate with ThermalSeal RT2 film
(Phenix Research Products, cat. no. LMT-RT2). Programed the LightCycler 96 RT-PCR
System (Roche Life Sciences), then loaded and incubated the plates. The cycler program
consisted of a preincubation cycle at 95ºC for 120 seconds, forty repetitions of a two-step
amplification cycle, first at 95ºC for five seconds then at 60ºC for thirty seconds, followed
by a melting cycle at 95ºC for ten seconds, 65ºC for sixty seconds and 97ºC for one second,
then finally a cooling cycle at 40ºC for thirty seconds. Set the acquisition mode to
continuous in the last step of the melting cycle.
2.12. Transduction of HCC827 dCas9-VP64 and MS2-p65-HSF1 Expressing Cell
Lines with SAM sgRNA Library
2.12.1. SAM sgRNA Library Transduction Experiments 1 and 2
Three separate transductions were executed with the Human SAM Library in lenti sgRNA
(MS2) with Puromycin backbone (AddGene, cat. no. 1000000074 DSHK) and the HCC827
cell lines expressing both the dCas-VP64 and MS2-p65-HSF1 genes. For the first two
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transduction, chose two HCC827 cell lines based on their dCas9 and p65 gene expression
levels (Figures 8 - 9). Generated 15 million cells per cell line and inoculated ten wells per
cell line in 12-well plates at 1.5 × 106 cells per well in 1 ml of growth medium RPMI-1640
supplemented with 10% FBS. Library lentivirus supernatant were added to each well for a
MOI of 0.1 (15 µl/well). Spinfected by centrifuging the plates in an Eppendorf 5810R
Centrifuge (Eppendorf, cat. no. 022625101) at 1,000× relative centrifugal force (rcf) for two
hours with the temperature control set at 33ºC. The 12-well plates were placed in the 37ºC,
humidified 5% CO2 incubator to incubate overnight.
The next day, passaged all cells into T225 flasks (USA Scientific, cat. no. CC7682-4225) at
approximately 5 × 106 cells per flask in 45 ml of growth medium, and continue to incubate
in the 37ºC incubator. In parallel, grew cultures of each cell line without transduction as a
negative control for Puromycin. Passaged 5 × 106 cells of each cell line in one T225 flask
every two to three days. Four days after transduction, passaged cell lines and started
selection with medium containing Puromycin at 0.5 µg per ml (Figures 10 – 11). The next
day, increased the Puromycin concentration to 1 µg per ml and continued to cultivate the
cell lines for four more days. Eight days post-transduction, passaged 5 × 106 cells into one
T225 flask for each cell line and continued to grow for eight more days, exchanging the
medium with 1 µg per ml Puromycin every two days. Passaged cell lines at approximately
50 × 106 cells per flask in growth medium with 1.5 µg per ml Puromycin for two two-day
passages. Twenty days post-transduction, passaged the surviving one out of two cell lines
35

at approximately 5 × 106 in T225 flasks in medium with Erlotinib at 1 µM. A parallel culture
of the same cell line was passaged and DMSO was added at the same concentration as the
tested condition, which served as the negative control for Erlotinib. The cell line was
continually passaged every three to four days while increasing the Erlotinib concentration
up to 10 µM for a total of nine days.
2.12.2. SAM sgRNA Library Transduction Experiment 3
For the third transduction, chose the HCC827 cell line from transduction Experiment 1, 52.
3.3 × 107 cells were generated to inoculate 22 wells of a 12-well plate at 1.5 × 106 cells per
well. 1 ml of growth medium with polybrene was added for a final concentration of 8 µg
per ml. 15 µl of SAM sgRNA Library lentivirus supernatant were added to each well for a
MOI of 0.1 particles per cell. Spinfected by centrifuging the plates at 1,000× rcf for two
hours with the temperature control set at 33ºC. The 12-well plates were placed in the 37ºC,
humidified 5% CO2 incubator to incubate overnight.
One day post-transduction, harvested and passaged all cells into five T225 flasks and let
them grow for three days in the 37°C incubator. After three days, passaged cells into ten
T225 flasks into growth medium supplemented with 1 µg per ml of Puromycin (Figure 12).
The next day increased the Puromycin concentration to 1.5 µg per ml. Noticed a possible
contamination, therefore decided to exchange the medium the next day while keeping the
Puromycin concentration at the same level. Confirmed the contamination the next day and
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exchanged the medium with growth medium supplemented with Antibiotic-Antimycotic
(Anti-Anti) solution (Thermo Fisher Scientific, cat no. 15240062) at 1x. Passage all cells
into a single T25 flask with medium supplemented with Anti-Anti at 1x, 1.5 µg per ml of
Blasticidin S and 5µg per ml of Hygromycin B, and continued to incubate at 37°C overnight.
The next day exchanged the medium with growth medium supplemented with PenicillinStreptomycin solution (Life Technologies, cat. no. 15140122), and Amphotericin B (Life
Technologies, cat. no. 15290026) both at 1x, and Puromycin at 1 µg per ml. Let it grow for
11 days in the 37C incubator while exchanging the medium every 2 to 3 days. Once the
cells reached 70% confluency, passaged them into two T25 flasks with growth medium
supplemented with 1 µg per ml Puromycin and no other antibiotic or antifungal supplement
and monitored for the absence of contamination.
Continually passaged every two to three days into medium supplement with just Puromycin
for a total of 17 days until the density reached almost 47 × 106 total cells. Passaged cells
into six T225 flasks at a density of 7.7 × 106 cells per flask in growth medium supplemented
with 1x Penicillin-Streptomycin, 1x Amphotericin B and 1 µg per ml of Puromycin. The
next day exchanged the medium but did not add Puromycin and continue to incubate for
four days. After four days, Passage cells into eight T225 flasks at a density of 7.5 × 106 cells
per flask with growth medium supplemented with 1.5 µM Erlotinib.
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At this point the screen requires two controls for the sgRNA library; a baseline Day 0 NGS
control and an Erlotinib negative control. Both of these controls serve as points of
comparison to which the final day sample sgRNA frequencies will be compared. For the
negative Erlotinib control culture, passaged cells into two T225 at the same density and
supplemented medium with DMSO at the same concentration as the Erlotinib treated
conditions. In addition, genomic DNA was collected from approximately 75 × 106 cells for
the Day 0 NGS control sample.
The cells were allowed to grow for six days while exchanging the medium supplemented
with 1.5 µM Erlotinib every two days. Passaged all cells into eleven T225 flasks at a density
of 3.75 × 106 cells per flask with growth medium supplemented with 1.5 µM Erlotinib.
Three days later, exchanged the medium with growth medium supplemented with 3 µM
Erlotinib, and continued to incubate the flask at 37°C for three more days. Passaged all cells
into eleven T225 flasks at a density of 7.5 × 106 cells per flask with medium supplemented
with 5 µM Erlotinib. Continue to cultivate the cells in medium supplemented with 5 µM
Erlotinib for six more days, exchanging the medium every two days. In other words, the
transduced cells were exposed to increasing concentration of Erlotinib for 18 days. This was
labeled as Selection B.
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2.13. Purification of Genomic DNA for Next Generation Screening (NGS) Analysis
The cells were harvested and the genomic DNA (gDNA) was extracted using the QuickgDNA MidiPrep Kit (Zymo Research, cat. no. D3100). Processed 25 × 106 cells per ZymoSpin V-E Column and eluted with 150 µl of DNA Elution Buffer provided in the kit. DNA
concentration was measured using a NanoQuant spectrophotometer (Tecan, Switzerland)
and stored samples in the -20ºC freezer until they were processed further.
Two Next Generation Sequencing (NGS) SAM Library Forward primers and three NGS
SAM Library Reverse barcode primers (Eurofins Genomics) were selected. See Table 4 for
more information on the primers. Used NEBNext High Fidelity PCR 2× Master Mix (New
England BioLabs, cat. no. M0541L) to set up the 50 µl reactions with 4% DMSO and 0.25
µM of forward and reverse primers in 96-wells PCR plates.
For each sample, the Day 0 NGS controls treated with vehicle, the final day controls, and
the samples from the final day of Erlotinib selection, set multiple reactions using each of
the forward primers with one distinct reverse barcode primer. 4 µg of gDNA from each
sample were added to each 50 µl reaction. Programed the thermocycler to incubated the
samples at 98ºC for three minutes to fist denature the DNA, followed by 25 cycles at 98ºC
for ten seconds to also denature, then at 63ºC for 30 seconds to anneal, and finally 72ºC for
25 seconds to extend. The final cycle is the final extension time at 72ºC for two minutes.
Gel purified the expected ~270 to 280-bp amplicons using a 2% high resolution MetaPhor
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agarose gel in 1× Tris-Acetate-EDTA (TAE) electrophoresis buffer. Finally, used QIAquick
PCR Purification kit (Qiagen, cat. no. 28104) to purify the excised gel fragments with the
desired PCR products and eluted them into nuclease-free water. Quantified the samples
using the NanoQuant and stored them at -20C until they were prepared for shipping to our
collaborators for NGS.
2.14. Next Generation Sequencing (NGS) of gDNA samples from transductions 1 and
3
The DNA NGS deep sequencing of sample Selection A was performed by. Dr.
Subramaniam Shyamalagovindarajan from Dr. Ranjan Perera’s group at Sanford Burnham
Prebys (Lake Nona, FL) core facility. Dr. Kumkum Ganguly at Los Alamo National
Laboratory (LANL) provided NGS service for the second transduction (Sample Selection
B). Their methods are described below
2.14.1. NGS at Sanford Burnham Prebys (Lake Nona, FL)
Quality control for the DNA was performed using both the Agilent Bioanalyzer 2100 HS
DNA assay and the Invitrogen Qubit DNA HS assay. Libraries were prepared using the
TruSeq ChIP Library Preparation Kit (Illumina, cat no. IP-202-1012). The final libraries
were purified using an E-Gel EX Agarose Gels, 2% (ThermoFisher Scientific, cat. no.
G402002) and the MinElute Gel Extraction Kit (Qiagen, cat. no. 28604). The quality control
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for the libraries was performed using the Agilent Bioanalyzer 2100 HS DNA assay and
Invitrogen Qubit DNA HS assay. Libraries were quantified by qPCR using the Library
Quantification Kit – Illumina/ABI Prism (KAPA BioSystems, cat. no. KK4835). The
libraries were sequenced on the Illumina MiSeq using a MiSeq Reagent Kit v3 (600 cycle)
(Illumina, cat. no. MS-102-3003). The run type was a paired end 300bp cycle run (2 × 300).
The number of reads generated for the three samples were 4,686,099 for Day 0 NGS Control
sample, 6,624,577 for Day 9 Erlotinib Negative Control sample and 5,557,981 for Day 9
Erlotinib sample.
2.14.2. NGS at Los Alamos National Laboratory
The concentration of DNA was obtained using the Qubit DNA Assay Kit (ThermoFisher
Scientific, cat. no. Q32854). The quality of the DNA was determined by running the sample
on an E-Gel 1% agarose gel (ThermoFisher Scinetific, cat. no. G402001) with Lambda
DNA/HindIII Marker (ThermoFisher Scientific, cat. no. FER SM0103). Illumina libraries
were prepared using NEBNext Ultra DNA II Library Preparation Kit (New England
BioLabs, cat. no. E7645L). DNA was fragmented using a Covaris E220, the ends made
blunt and adapters and indexes was added onto the ends of the fragments to generate
Illumina libraries that can be sequenced on an Illumina sequencer. Illumina libraries were
eluted in DNA Elution Buffer (Zymo Research, cat. no. D3004-4-10). The concentration of
the libraries was obtained using the Qubit dsDNA HS Assay (ThermoFisher Scientific, cat.
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no. Q32854). The average size of the library was determined by the Agilent High Sensitivity
DNA Kit (Agilent, Cat. #5067-4626). An accurate library quantification was determined
using the Library Quantification Kit, Illumina/Universal Kit (KAPA BioSystems, cat. no.
KK4824). Libraries were normalized to the same concentration based on the qPCR results.
The libraries were sequenced on the Illumina NextSeq generating paired-end 151 bp reads.
2.15. Analysis of NGS data
To account for the different yields of amplicons after the PCR reactions, calculated the mean
of the sequencing reads of each of the three samples, Final Day with Erlotinib selection
(m1), Day 18 control treated vehicle (m2) and Day 0 NGS control (m3). Normalized
sequencing reads by multiplying the Day 18 control treated vehicle (m2) reads by the factor
m1/m2, and the reads Day NGS 0 control (m3) reads by the factor m1/m3. This readjust the
means of the three samples to the same value, |m1|. Calculated the log (2) of the adjusted
(normalized) reads, then calculated the following: log (2) X1 – log (2) X2, and log (2)X1 –
log (2) X3, where X1, X2 and X3 are adjusted (normalized) reads of Final Day with
Erlotinib selection, Day 18 control treated vehicle and Day 0 NGS control, respectively.
Finally, calculated log (2) X1 – log (2) ((X2+X3)/2) and ordered the final calculated values
by numeric rank from highest to lowest. Eliminated any value where the delta log (2) was
not at least a log (2) difference. Chose the top eleven values and matched them to their genes
using .csv file provided by the Broad Institute at:
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https://www.addgene.org/static/cms/filer_public/37/15/3715268e-a318-409a-932fc828472b8ec9/sam-target-sequences.csv.
3. Chapter 3- Section I Results
3.1. Genome-Scale Gain-of-Function Screen for Erlotinib Resistant Genes
We set out to identify genes that when activated confer resistance to EGFR inhibitor,
Erlotinib, in a lung cancer cell line. This knowledge can then be used to develop parallel
therapies to systematically inhibit the products of these genes, or the pathways that these
genes control, so as to prevent the evolution of drug resistance (Figure 13). Unlike current
methods, many of these genes, when targeted, should not affect cancer cell metabolism
because they were not selected for toxicity of the cancer cell, thereby decreasing the chances
for cytotoxic effects. This constitutes a new concept of anti-evolutionary drug development.
3.2. Synergistic Activation Mediator (SAM) System
Like others before (Konermann et al., 2015), we performed a genome-scale transcriptional
activation screening using the CRISPR-Cas9 system, named Synergistic Activation
Mediator (SAM) developed at the Massachusetts Institute of Technology in Dr. Feng
Zhang’s laboratory. This system allows for the activation of single genes using individual
sgRNA targeting every coding isoform established from the NCBI Reference Sequence
Database (23,430 isoforms). Three sequences are targeted within 200-bp upstream of the +1
43

transcriptional start site of each gene for a total of 70,290 guides in the sgRNA library.
Along with the RNA library, the SAM system contains a Cas9 endonuclease engineered
into a transcriptional activator by the inactivation of its two catalytic domains and a Cterminal fusion to VP64, a transcription activation domain. During normal transcription
activation, endogenous transcription factors generally act in synergy with co-factors.
Therefore, the SAM system includes a fusion protein containing the NF-kB transactivating
subunit p65 and the activation domain from human heat-shock factor 1 (HSF1) fused to a
MS2 bacteriophage coat protein. The fused protein is recruited to the sgRNA that has been
engineered with a minimal hairpin aptamer, which selectively binds dimerized MS2 coat
proteins, and affixes the fused protein to the tetraloop and stem loop 2 domains of the
sgRNA, which protrude outside of the Cas9–sgRNA ribonucleoprotein complex
(Nishimasu et al., 2014). By combining the pooled guide RNA library with the engineered
dCas9 transcription activator, SAM allows for a phenotype to genotype mapping
methodology; the mapping of specific genetic perturbations to a phenotype of interest. In
our case, single gene activation is interrogated for its ability to confer resistance to TKIs in
a human lung cancer cell line.
3.3. HCC827 Cell Line
We selected the Erlotinib sensitive NSCLC cell line HCC827, because it has been well
documented in becoming resistant to TKIs including Erlotinib (Bivona et al., 2011; Li et al.,
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2013b; Okamoto et al., 2012; Sos et al., 2009; Zhang et al., 2012). This lung
adenocarcinoma cell line, has an acquired deletion mutation in exon 19 in the gene encoding
the EGFR tyrosine kinase (E746 – A750 deletion), which is a classical mutation frequently
found (44%) in patients with EGFR-activating mutations (Foster et al., 2016; Gazdar, 2009).
3.4. Transduction of Naïve HCC827 with SAM System
In March 2017, Joung et al. published a protocol with a set of guidelines to follow when
using genome-scale CRISPR-Cas9 screening tools developed in the Zhang laboratory
(Joung et al., 2017). The protocol calls for an initial large-scale lentivirus transduction of
the investigated cell line with the first two components, dCas9-VP64 and MS2-P65-HSF1
construct at a MOI < 0.7 infective particles per cells. The cells are then selected as a bulk
population and subcultured until sufficient cells are generated to maintain sgRNA
representation after library transduction at a low MOI, < 0.3 and selection. The author
suggests at least 500 cells per sgRNA before the final selection with Erlotinib, which in our
case would mean at least 3.5 × 107 cells per transduction. One would need to generate at
least 1.2 × 108 cells transduced with the first two components for the sgRNA library
transduction and selection. Since our lentiviral supernatant stock had approximately 104
infective viral particles per µl (IVP/µl), we would need to use at least 1 ml of sgRNA library
supernatant per transduction, expecting a very high efficiency. Unfortunately, we had a total
volume of 250 µl of the sgRNA library supernatant lentiviral stock. This amount gives us
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enough to transduce a total of 8.3 × 106 cells at a MOI of 0.3 infective particles per cells.
We decided that it would be wise to first try a small-scale experiment closely following the
Joung protocol.
To do this, 1.2 × 107 cells were transduced with lentiviral dCas9-VP64 and MS2-P65-HSF1
vectors at a MOI of 0.1 of each, and the simultaneous selection with 1.5 µg per ml of
Blasticidin S and 5 µg per ml of Hygromycin B was started 48 hours post-transduction.
After approximately 4 days under selection the cells in these cultures completely perished.
Although we had used half of the lentiviral supernatant stocks in this experiment, in
retrospect the MOI was too low to expect integration of both vectors in a large number of
cells. There was a 1 in 10 chance of integration for each of the genes, thereby 1 in 100
chance of double integration. With a starting population of 1.2 × 107 cells, we can only
expect a total of 1.2 × 105 cells to be double transductants. If the plating efficiency is 10%
with the double antibiotic selection, then we would expect only 1.2 × 104 cells to survive.
In addition, it was possible that the selection was started too soon after transduction to
expect high enough expression of the antibiotic resistance genes, even though the published
protocol suggests starting selection 24 hours after spinfection.
At this point, since we had used up 120 µl of each construct (at 104 IVP/µl), which was half
of the total stock, it was decided that we would not be able to transduce the lentiviral vectors
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(including the sgRNA library) in series without pausing, but instead we needed to construct
a stable cell line expressing both dCas9-VP64 and MS2-P65-HSF1 genes simultaneously,
and then would transduce this line with the sgRNA library.
3.5. Stable Transduction of Naïve HCC827 Cell Line and Selection
Since integration of lentiviral DNA could occur at random locations, thus causing position
dependent gene expression, multiple independent stable expressing lines of the dCas9-VP64
and MS2-P65-HSF1 constructs were made, and gene expression levels were confirmed and
compared. To increase the chances of success, three transduction strategies were used: (a)
single transduction of dCas9-V64 first followed by MS2-P65-HSF1, (b) single transduction
of MS2-P65-HSF1 first followed by dCas9-VP64, and (c) simultaneous transduction of both
constructs. We also explored the efficiency of stable integration with and without polybrene.
Furthermore, to increase the probability of integration the MOI was increased to a range
between 2 and 12 infective viral particles per cell. In addition, to allow for robust gene
expression, the selection was started 96 hours after transfection, and to increase the
probability of successfully generating cell lines, several strategies were employed in the
selection of the transduced cells, as described below.
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3.5.1. Single Transductions with Single Selection Schemes
For the construction of the single transductants, the cells were transduced at four levels of
MOI (2, 4, 6 and 8 IVP/µl) and selected with the corresponding antibiotic, either Blasticidin
S or Hygromycin B, at three concentrations (Figures 5 - 6). The highest tested
concentrations used 3 µg per ml of Blasticidin S and 40 µg per ml of Hygromycin B were
determined by dose-response experiments to completely kill the naïve HCC827 cell line
within seven days (Figures 14 and 15). For a more conservative selection approach, the
other two concentrations of the antibiotics were set at 50% and 25% of the highest
concentration (1.5 and 0.75 µg per ml of Blasticidin S and 20 and 10 µg per ml of
Hygromycin B, respectively). From the start of selection, two days passed before any
growth was observed in any of the conditions.
By the third day, most Blasticidin S selected cells transduced with the Cas9-VP64 construct
had grown well compared to the negative transduction control at 3 µg per ml, reaching up
to 25% confluency. The Blasticidin S treated cells that were transduced without polybrene
appeared to grow faster than the cells treated with polybrene.
There was however observable growth, up to 30% confluency in the Blasticidin S negative
controls treated at the lowest concentration of 0.75 µg per ml and the middle concentration
of 1.5 µg per ml of Blasticidin S during the first three days of selection. Subsequently, the
Blasticidin S concentration was increased to 3 µg per ml in all conditions which lead to
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complete cell death in the negative controls after five more days of selection. On the other
hand, the negative control cells treated with 3 µg per ml from the start did not grow to a
quantifiable confluency and completely perished after eight days of selection. Since the cells
selected with the two lowest Blasticidin S antibiotic concentrations showed poor selection,
it was decided to terminate and cryo-preserved all surviving lines. For the cells selected with
3 µg per ml Blasticidin S, the fastest two growing cell lines, transductants with MOIs of 6
and 8 without polybrene were continued while the rest were terminated and cryo-preserved.
These cell lines were continually cultured in growth medium with 3 µg per ml of Blasticidin
S, exchanging medium every two days. The cells were passaged when their growth became
consistent reaching at least 60% confluency in less than or equal to 3 days. Meanwhile, cells
were cryo-preserved at every passage and total RNA samples were collected from aliquots
of these cultures for expression level measurements.
All of the single construct transductants selected with Hygromycin B first (MS2-P65-HSF1
construct), transduced at four levels of MOI (2, 4, 6 and 8 IVP/µl) grew well in the three
tested concentrations, 10, 20 and 40 µg per ml (Figure 6), with four conditions (Cell lines
23, 29, 35, 41) reaching 40 to 60% confluency by day four. Unfortunately, the negative
transduction controls treated with Hygromycin B at the same concentrations also grew well,
without showing any sign of death by day four. The Hygromycin B concentration was then
increased to 40 µg per ml for all conditions and the cultures continued to grow for two
additional days. Since the negative controls continued to grow, it was decided to increase
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the Hygromycin B concentration up to 80 µg per ml, and to continue the incubation for two
more days. After eight days in culture the cells initially dosed at the lowest concentration
showed no signs of Hygromycin B induced death, and therefore were discarded. Since all
other conditions from the other two initial concentrations showed significant cell death at
80 µg per ml concentration, it was decided to lower the concentration to 40 µg per ml and
to continue to culture for two more days. After ten days, good growth was observed in the
conditions that started at 20 µg per ml of Hygromycin B and had polybrene during
transduction, while the conditions that did not have polybrene had very low confluency
(<10%). The low confluency cultures were discarded and the rest were cryo-preserved. The
four remaining cell lines that started at the highest Hygromycin B initial concentration in
medium with 40 µg per ml of the selection agent were subcultured until growth became
consistent, reaching <60% confluency in less than or equal to three days. Meanwhile, cells
were cryopreserved at every passage and total RNA samples were collected from the
respective aliquots for expression level measurements. Unfortunately, two lines (Cell lines
34 and 40) were lost to contamination before they could be cryo-preserved.
3.5.2. Double Transductions with Successive Selection Scheme
For the cells that were transduced with both constructs simultaneously, three selection
strategies were followed: (a) single selection with Blasticidin S followed by Hygromycin B
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(Figure 5), (b) single selection with Hygromycin B followed by Blasticidin S (Figure 6),
and (c) double selection with both antibiotics right from the start (Figure 7).
For the Blasticidin S single selection conditions, the initial antibiotic concentration was 1.5
µg per ml Blasticidin S. The experimental cultures transduced with both constructs at
combined MOIs of 4, 8 and 12 IVP per µl and negative controls with Blasticidin S were
cultured for 8 days until the negative control cells completely died. At that point, to prevent
the complete loss of any successfully transduced cells, the cultures were aliquoted into two
equal portions and the cells were passage into medium with either 1.5 µg per ml Blasticidin
S or 10 µg per ml Hygromycin B, respectively. For the next three days the cultures on
Hygromycin B grew but began to slow down and showed signs of cell death after the first
passage. The cultures continued to incubate for six more days. Since little growth was
observed under these conditions, it was decided to lower the Hygromycin S concentration
to 5 µg per ml. The cell lines were further subcultured in this condition for eleven days until
their growth became consistent reaching at least 60% confluency in three or less days.
Several cell lines were lost due to cell death and or contamination. The last two surviving
lines were then subcultured in medium with 3 µg per ml of Blasticidin S for ten days. Cells
were cryo-preserved and total RNA was extracted from an aliquot for gene expression level
measurement.
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In the second, single antibiotic selection scheme for the double transductans, the cell lines
were subcultured in selection medium with 10 µg per ml of Hygromycin B. These cells
grew to high confluency (≤80%) after eight days in culture. Unfortunately, the negative
transduction controls also grew to high confluency, showing no sign of sensitivity to the
selection agent. For this reason, all of these cell lines were cryopreserved but not further
analyzed.
3.5.3. Double Transduction with Simultaneous Double Selection Schemes
In the third and final selection strategy, both selection agents were added concurrently.
Although we had already determined the single selection antibiotic concentrations, these
were determined to be toxic when added simultaneously. Therefore, the selection agents’
concentrations added simultaneously during the double selection were freshly determined
by a dose-response experiment (Figure 16).
The double selection was performed with cells transduced at three combined MOIs of 4, 8
and 12 IVP per µl, with medium containing 1.5 µg per ml of Blasticidin S and 10 µg per ml
of Hygromycin B (Figure 7). During the first four days of culture, all of the cell lines under
double selection, including the negative transduction controls treated with the same
concentrations of antibiotics grew well, reaching ≤ 60% confluency. After the first passage,
on the fourth day of selection, we observed consistent growth in only the cell lines that were
transduced with polybrene. The double transductant cell lines, transduced without
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polybrene, and the negative controls completely perished after a total of nine days under
selection. To ensure complete selection, each surviving cell line was further selected for ten
days with a relatively higher concentration of each antibiotic in two parallel single selection
schemes: either Blasticidin S at 3 µg per ml or Hygromycin B at 40 µg per ml. After ten
days, the cell lines were treated with the other antibiotic, Hygromycin B and Blasticidin S,
respectively at the same corresponding concentrations and cultured for another ten days.
The surviving cell lines were then cryo-preserved and total RNA was collected for
confirmation of gene expression.
3.6. Confirmation of Gene Expression of Transduced Cell Lines
We completed the selection schemes for 10 cell lines and cryopreserved them; two
Blasticidin S single transductants, two Hygromycin S single transductants, and six double
transductants (Table 5). To determine which transduction and selection strategy
combination worked best, we measured the abundance of transcript for each of the
transduced genes via RT-PCR analysis.
Six double transductant and two dCas9-VP64 construct single transductant cell lines were
selected to confirm expression of the transduced genes (Table 5). None of the MS2-P65HSF1 construct single transductant cell lines were chosen to move forward since the
Hygromycin B selection had proven to be more difficult than and not as efficient as with
Blasticidin S.
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The Livak Method was used to quantify the fold expression difference by quantitative RTPCR relative to a reference gene, using the cycle quantification (Cq) values. The
housekeeping gene glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as the
reference gene to normalize the fold expression level across all tested cell lines.
In the first quantitative RT-PCR analysis, we compared the fold expression levels of dCas9
gene in the chosen eight cell lines and found that for the double transductant cell lines, the
dCas9 gene expression levels are either similar or higher when compared to the single
transductant cell lines (Figure 8). The two single dCas9 gene transductants had expression
fold differences of 12 and 16, while the double transductant cell lines ranged between 8and 46-fold difference. We therefore chose the top four double transductant cell lines to test
for the transactivating subunit p65 gene expression level.
Analysis of the data from the second quantitative RT-PCR run showed that all four samples
had very high expression level increase relative to control (Figure 9); as compared to dCas9
gene fold expression levels, ranging between 7 and 12. The p65 gene expression fold
difference for the four tested cell lines ranged between 2,313 and 3,746. The dCas9 gene
expression level was tested again as well, the results showing lower fold expression levels
when compared to the first analysis. The dCas9 gene expression fold difference ranged
between 6 and 32.
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The cell line with the highest and most consistent expression fold difference values was an
easy choice for transduction with the sgRNA library. This cell line originated from the
double transduction with a combined MOI of 4 and with polybrene added to the medium
(Figure 7). As a backup strategy, a second cell line was chosen for transduction with the
sgRNA library. This cell line was transduced at a higher MOI of 12 while using polybrene
as well. Both cell lines were derived from the same selection strategy. They were first double
selected for 20 days, followed by single selection at higher concentrations, first with
Blasticidin S for ten days followed by Hygromycin B selection for another ten days (Figure
7).
3.7. SAM sgRNA Library Transduction of Double Transductant Cell Lines
The SAM sgRNA library transduction was attempted in three independent experiments as
describe below. The entire selection regimes for obtaining Erlotinib resistant cells and NGS
analysis were successfully conducted on two of the three experiments.
To avoid confounding the screening results we had to ensure that most cells receive only
one genetic perturbation. To achieve this, Joung et al. suggested that the transduction of the
sgRNA library be done at < 0.3 MOI. Additionally, to avoid losing sgRNA representation
during Erlotinib selection and thereby biasing the screening results, we needed to generate
a large number of cells after the sgRNA library transduction. To realize this, at least 1.5 to
2.5 × 107 initial library-transduced cells were selected and subcultured until at least 3 × 107
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cells were generated to select with Erlotinib. Therefore, to have enough cells for the Day 0
NGS control, the negative Erlotinib control, and 3 × 107 cells to select, the librarytransduced cells were subcultured until there were more than 1.5 × 108 cells.
3.7.1. sgRNA Library Transduction Experiment 1
The first sgRNA library transduction experiment was conducted with 1.5 × 107 cells of the
cell line with the highest expression levels for the two transduced genes (Figure 9). The
targeted MOI was 0.1. After four days following transduction, the Puromycin selection to
select cells stably expressing the lentiviral genes was started at 0.5 µg per ml on 1.7 × 107
cells (Figure 10). The Puromycin concentrations used for selection were determined by a
dose response experiment (Figure 17). After one day, the Puromycin concentration was
increased to 1 µg per ml. After three more days of selection, it was suspected that Puromycin
concentration was too low because little cell death was detected. For this reason, the cells
were passaged onto fresh medium supplemented with 1.5 µg per ml of Puromycin. For the
next 8 days the cells appeared to stop proliferating, segregating into large clumps of cells
covering the entire surface of the flasks. Some cells were actually growing within the
clumps, proliferating up to 2.5 × 108 total cells. The Puromycin selection at 1.5 µg per ml
was continued for another 4 days for a total of 20 days, and the cultured cells grew up to 6.4
× 108 total cells. Subsequently, an aliquot of 1.1 × 108 cells was treated with Erlotinib at 1
µM, and a second aliquot of 3.7 × 107 was used as the negative Erlotinib control. The
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remaining cells were stored at -80ºC freezer to serve as the Day 0 NGS control. The
Erlotinib selection concentrations were determined using a dose response experiment
(Figure 18). After three days, 3 × 107 selected cells were passage onto medium with
Erlotinib at 2 µM and cultured for another two days. The Erlotinib concentration was
increased to 5 µM for two incubation days, then raised to 10 µM for the last two days. The
selection with Erlotinib lasted a total of nine days and 5 × 107 cells were harvested to extract
the gDNA. gDNA was also extracted from 5 × 107 cells corresponding to the Day 0 NGS
control and from 5.7 × 107 cells of the negative Erlotinib control.
3.7.2. sgRNA Library Transduction Experiment 2
The second sgRNA library transduction experiment was conducted with 1.5 × 107 cells of
the cell line with the second highest expression levels for the transduced genes, at a MOI of
0.1 (Figure 11). Four days after transduction, Puromycin selection was started with medium
supplemented with 0.5 µg per ml. After one day, Puromycin concentration was increased to
1 µg per ml. After one more day, the Puromicyn treated culture and the negative
transduction control cells that was also treated with Puromycin began to show signs of cell
death, which at the time was believe to be a sign of selection. By the next day, that is after
four days of selection with Puromycin, the library-transduced cells had perished. Most
likely, the transduction efficiency and therefore the expression level of the Puromycin
resistance gene of this cell line was too low.
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3.7.3. sgRNA Library Transduction Experiment 3
For the third sgRNA library transduction experiment, we generated 3.3 × 107 cells of the
cell line also transduced in the first experiment, and was transduced at 0.1 MOI (Figure 12).
After subculturing the cells for four days, they were treated with Puromicyn at 1 µg per ml.
On the fifth day, Puromycin concentration was increased to 1.5 µg per ml by adding the
stock solution directly into the cultures. After two days of further culturing the cells under
selection, a contamination was confirmed by microscopy. The contamination was attributed
to a Puromycin stock solution addition that was added on the fifth day after transduction.
To recover the experiment, the cultures were treated with a series of antibiotics and
antifungal solutions for two weeks. After decontamination was confirmed, we continued the
Puromycin selection for eighteen days at 1.5 µg per ml. The cells were then subcultured for
three days without selection before treatment with Erlotinib. At this stage, we generated
1.5 × 108 cells and treated an aliquot of 6 × 107 cells with Erlotinib at 1.5 µM. We also
harvested 5 × 107 cells and extracted the gDNA for the Day 0 NGS control. Another aliquot
of 1.5 × 107cells were passaged and used as the negative Erlotinib control culture. There
was also a control of cells not transduced with the sgRNA library, which were treated with
1.5 µM of Erlotinib. The Puromycin selected cells were treated with 1.5 µM of Erlotinib for
nine days. We then raised Erlotinib the concentration to 3 µM and selected the cells for three
more days. The Erlotinib concentration was further increased to 5 µM and 8 × 107 cells were
selected for another six days for a total of 18 days. We harvested 2.5 × 107 Erlotinib treated
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cells and extracted the gDNA from these cells. Simultaneously, we harvested and extracted
gDNA from 5 × 107 cells of the negative Erlotinib control cultures. The cultures of cells not
transduced with the sgRNA library and treated with Erlotinib as expected, perished after
nine days of selection.
3.7.4. PCR Amplification of gDNA
The gDNA samples from Experiments 1 and 3 were PCR amplified in multiple reactions
using two forward primers (NGS-Lib-Fw) and three distinct reverse barcode primers (NGSLib-SAM-Rev), which amplify the sgRNA target region (Table 4). To barcode the samples,
NGS-Lib-SAM-Rev 1 barcode primer was used for the Day 0 NGS control samples, NGSLib-SAM-Rev 2 for the negative Erlotinib control samples, and NGS-Lib-SAM-Rev 3 for
the Erlotinib treated samples. More PCR reactions were set up for Experiment 1 in
comparison to Experiment 3, because higher amounts of cells were harvested and thereby
higher amounts of gDNA was extracted. The generated amplicons were within the expected
range of 270 to 280-bp (Appendix- Figures 1 - 6). The amplicons were purified from the
agarose gel. The DNA concentration was measured and 500 ng from each Forward 1 primer
amplified samples was combined with 500 ng from the Forward 2 primer amplification. The
three 1 µg samples from each experiment were sent for NGS to be performed by our
collaborators.
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3.7.5. Experiment 1 NGS
The samples from Experiment 1 were sent to the Sanford Burnham Prebys, Lake Nona, FL
sequencing core for NGS analysis. The sequencing results were analyzed with FastQC
(Babraham Institute Bioinformatics) for several quality control checks including: per base
sequence quality, per tile sequence quality, per sequence quality scores, per base N content
and sequence length distribution (Table 6). The per base sequence quality results show the
range of quality scores across all bases at each position in the raw sequencing data. The per
base sequence quality check for the all Experiment 1 raw data had very unusual results, with
some scores falling below a score of 20 which indicates a higher than 1 in 100 probability
of error (Appendix- Figure 7). The sequence length distribution results were slightly
abnormal for all Experiment 1 samples as well (Appendix- Figure 8). The per base N
content is the number of unclear base calls by base and should be a flat line at 0 (AppendixFigure 9). Three out of six samples had very unusual results for the per base N content check
(Appendix- Figure 10). The sequence length distribution is the dispersal of fragment sizes
in the raw sequencing data which should be of uniform length, but were not for the
Experiment 1 samples (Appendix- Figure 11). These results suggest that the raw sequencing
data was not of good quality. We think the sequencing reactions did not work at a
sufficiently high frequency.
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We looked at the gene frequency data from the experiment 1 samples. Analysis of the NGS
results of the 9 days post drug treatment samples did not show significant difference in the
gene frequency between the cells treated with Erlotinib and those treated with vehicle. In
hindsight, 9 days of Erlotinib treatment might have not been long enough selection time.
This might be another reason why the next generation sequencing results from this
experiment were invalid.
3.7.6. Experiment 3 NGS
The samples from experiment 3 were sent to Los Alamos National Laboratory sequencing
core for NGS analysis. Similar quality control checks were executed on the raw sequencing
data using FastQC. All of the sequencing data from Experiment 2 showed acceptable results
for all of the quality control checks (Appendix- Figures 12 - 16).
The NGS results are the set of frequencies for each gene for each of the three samples, Day
0 control, Day 18 no treatment control and Day 18 Erlotinib treatment sample. First, we
looked at the difference in the frequencies between the Day 0 control sample and Day 18
Erlotinib treatment sample. The top eleven genes with large fold difference between these
two samples, which ranged between 3 and 10,000 × were selected. To help further confirm
these results the difference between Day 18 Erlotinib treatment sample and the Day 18 no
treatment control sample was calculated and compared to the difference between Day 18 no
treatment control sample and Day 0 control sample. In the `best-case scenario, the
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frequencies for the Day 18 no treatment control sample should have remained low and the
difference to the Day 18 Erlotinib treatment sample should be high. Similarly, if the
frequency remains low for the Day 18 no treatment control, the difference to the Day 0
control should be low. None of the top eleven genes had multiple representation of the
guides targeting the same gene. The eleven most significant hits were distributed throughout
the genome.
The three calculated fold differences are shown on Table 7. The difference between the Day
18 Erlotinib treated sample and Day 18 no treatment control sample ranged between 5 and
22 × for the top eleven candidate genes. Meanwhile, the difference between Day 18 no
treatment control sample and Day 0 control sample ranged from 1 and 1,500 × in the top
eleven candidate genes. Of the eleven top genes with large values for the difference between
Day 18 Erlotinib treated sample and Day 0 control sample, SPATA31A2, SPATA31A5,
MAPKAP1, RGPD8, ARMCX5-GPRASP2 and ZNF701 had also relatively large
differences between Day 18 treated sample and Day 18 no treatment control, as well as low
values for the difference between Day 18 no treatment control sample and Day 0 control.
IGFL1 and MUC7 had marginally high values for the difference between Day 18 no
treatment control and the Day 0 control compared to the difference between Day 18
Erlotinib treated sample and Day 18 no treatment control. Although SH3D19, NARFL and
RIMBP2 had comparatively large values for the difference between Day 18 Erlotinib treated
sample and Day 0 control sample, the difference between Day 18 no treatment sample and
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Day 0 control sample is also large particularly when compared to the difference between
Day 18 Erlotinib treated sample and Day 18 no treatment control sample. These may not be
involved with drug resistance, but it is possible that when the genes are over-expressed they
increased the proliferation rate of a cancer cells which is dependent on EGFR signaling.
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4. Chapter 4- Section I Discussion
Below we will describe the eleven identified genes (Table 8) in more detail and for some, a
possible mechanism of drug resistance is suggested. The first six described genes,
SPATA31A2, SPATA31A5, MAPKAP1, RGPD8, ARMCX5-GPRASP2 and ZNF701 are
the ones with the top fold changes in representation of genes upon selection for Lentiviral
DNA with gRNAs against the genes relative to their respective representation at the start of
selection, as evidenced by the NGS data. Of these, MAPKAP1 and ARMCX5-GPRASP2
confirm known resistance pathways. SPATA31A and SPATA31A5 have some association
to cancer. And RGPD8 and ZNF701 have no known direct link to cancer. The last four
suggest possible new mechanisms of TKI resistance (Figure 13). IGFL1 and MUC7 had
marginally high fold increase upon selection and could potentially be false positives. The
last three, SH3D19, NARFL and RIMBP2 are the over-represented genes relative to the
input gRNA sequences, which probably lead to higher proliferation rates than in the
untreated control. Therefore, these three genes also represent false positive results.
4.1. Spermatogenesis-Associated Protein 31A2 (SPATA31A2) and SpermatogenesisAssociated Protein 31A5 (SPATA31A5)
The National Center for Biotechnology Information (NCBI) Reference Sequence (RefSeq)
Database has been annotated since the SAM sgRNA library used in this project was
designed. For one of our candidate genes, Spermatogenesis-Associated Protein 31A2
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(SPATA31A2), the RefSeq was permanently suppressed because it is a redundant RefSeq of
Spermatogenesis-Associated Protein 31A1 (SPATA31A1). To note, none of the other guides
targeting these two gene variances were identified in the screen, but another member of the
SPATA31 gene family, also of subtype A was the top ranked candidate, SpermatogenesisAssociated Protein 31A5 (SPATA31A5).
The SPATA31 gene family belongs to the human families of core ancestral segmental
duplications, and it evolved from a single copy gene in ancestral mammals to multiple
functional and nonfunctional copies along chromosome 9 in hominoid primates and
humans. Segmental duplications are a source for novel gene functions and evolutionary
adaptations through nonallelic homologous recombination leading to gene and transcript
innovations (Dennis and Eichler, 2016; Jiang et al., 2007). Segmental duplications have
changed the architecture of hominid chromosomes, “creating complex lineage-specific
duplication blocks distributed throughout specific chromosomes where novel gene
structures have been formed by shuffling and juxtaposition of different exon cassettes”
(Marques-Bonet and Eichler, 2009). Moreover, SPATA31 is a member of the gene families
with the strongest signal of positive selection in hominoids (Han et al., 2009).
SPATA31 function in humans remains elusive, yet the knockout mice phenotype suggests
spermatogenesis and cell differentiation as its ancestral functions (Wu et al., 2015c). The
fact that SPATA31 is highly expressed in human testis, points to an involvement in
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spermatogenesis. Nonetheless, there is clear evidence that SPATA31 has acquired novel
functions in hominoids. It has been suggested that SPATA31 is involved in UV response and
DNA

repair

(Bekpen

et

al.,

2017).

An

evolutionarily

recently

acquired

cryptochrome/photolyase domain indicates that it may sense UV light and may play a role
in intrinsic apoptosis induced by UV-mimetic compounds. Also, SPATA31A protein has a
topoisomerase domain that along with a PCNA-interacting domain may recruit other DNA
repair proteins during translesion synthesis upon DNA base misincorporation.
Interestingly, the variability of SPATA31 copy number has been associated with the human
lifespan (Bekpen et al., 2018). In a control group, individuals older than 96 years were found
to carry significantly fewer copies of this gene family in their genome than younger
individuals. It appears that SPATA31 has antagonistic pleiotropic functions that may
provide a benefit during the reproductive phase of life, but negatively influence the overall
life span.
A search of the Cancer Cell Metabolism Gene Database for protein-protein interaction
network of co-expressed genes in a uterine corpus endometrial carcinoma (UCEC) tumor
reveals both SAPATA31A1 and SPATA31A5 as members (Pora et al., 2016). This suggests
that at least one of these genes has a known association with cancer; however, its precise
connection to drug resistance in lung cancer is unknown.
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4.2. Mitogen-Activated Protein Kinase Associated Protein 1 (MAPKAP1)
In a recent study, mitogen-activated protein kinase associated protein 1 (MAPKAP1) was
found to be overexpressed in human non-small cell lung adenocarcinoma cell lines, and that
its epigenetic activation promotes cell growth, proliferation, migration and tumor
development by affecting the epithelial-mesenchymal transition (EMT) (Hu et al., 2017).
MAPKAP1, also known as stress activated protein kinase interacting protein 1 (Sin1) was
capable of promoting invasion and metastasis of hepatocellular carcinoma, similarly by
facilitating EMT (Xu et al., 2013).
Mapkap1 is an essential component of the mTORC2 complex which includes three other
members: mechanistic target of rapamycin (mTOR), mLST8 (GßL) and rapamycininsensitive companion of mammalian target of rapamycin (Rictor) (Yang et al., 2006).
mTOR is an important regulator of cell growth and proliferation that is highly conserved in
all eukaryotes (Zoncu et al., 2011). In addition to cell growth, mTORC2 regulates cell
cycle–dependent cytoskeleton assembly. Mapkap1 is identified as a key regulator in the Akt
signaling pathway, whose activation is important in tumorigenesis and metastasis. The role
of Mapkap1-Rictor-mTOR protein complex in Akt-Ser473 phosphorylation is required for
mTORC2 function in cell survival (Jacinto et al., 2006).
Additionally, Mapkap1 phosphorylation can “impair mTORC2 complex integrity and
inhibit downstream Akt signaling to suppress tumorigenesis” (Liu et al., 2013).
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Furthermore, increase in mTORC2 complex formation due to overexpression of RICTOR
could enhance gliomas’ cell proliferation and invasiveness (Masri et al., 2007).
One can imagine that overexpression of MAPKAP1 may confer to Erlotinib resistance by
increasing Mapkap1-Rictor-mTOR protein complex formation, that leads to the activation
of the Akt pathway promoting cell survival. Figure 19 is a conceptual diagram of MAPKAP1
possible mechanism of resistance.
4.3. RANBP2-like and GRIP domain containing 8 (RGPD8)
RGPD8 was identified by searching databases for intrachromosomal duplications of genes
found in primates with single orthologs in all other metazoans (Ciccarelli et al., 2005;
Nothwang et al., 1998). Intrachromosomal segmental duplications of a region of human
chromosome 2 enclosing the genes coding for the nucleoporin, RAN binding protein 2
(RANBP2) and the trans-Golgi protein, GRIP And Coiled-Coil Domain Containing 2
(GCC2) produced eight paralog RGPD genes. As mentioned in section 4.1, segmental
duplications are a source for novel gene functions and evolutionary adaptations (Dennis and
Eichler, 2016; Jiang et al., 2007). Compared to RANBP2, RGPD8 has differences in domain
architecture including substitutions of important for Ran binding sites, and has acquired the
GRIP domain which proposes a novel role possibly in intracellular trafficking. In addition,
unlike RANBP2, which is almost exclusively found at the nuclear envelope, RGPD8 was
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found in discrete cytoplasmic regions. RGPD8 expression was detected in testis by PCR
analysis. No direct link to cancer has been identified for this gene.
4.4. Armadillo repeat containing, X-linked 5 - G-Protein Coupled ReceptorAssociated Sorting Protein 2 (ARMCX5-GPRASP2)
ARMCX5-GPRASP2 is a naturally occurring readthrough transcription among five adjacent
genes located on chromosome X: armadillo repeat containing, X-linked 5 (ARMCX5), G
protein-coupled receptor associated sorting proteins 1 and 2 (GPRASP1 and GPRASP2),
basic helix-loop-helix family member b9 (BHLHB9), and long intergenic non-protein
coding RNA 630 (LINC00630). An important paralog of this gene is GPRASP2, which
exhibits significant functions in modulating the activity of G-protein-coupled receptors
(GPCRs), eliciting multiple cellular events including: the modification of gene transcription,
modification of secondary messenger levels and desensitization and internalization of
receptor. GPRASP1 has been reported as an important breast cancer tumor biomarker
(Tuszynski et al., 2011). In addition, the DDX23-Linc00630-HDAC1 axis activates the
Notch pathway promoting metastasis and proliferation of NSCLCs (Mao et al., 2017). These
associations suggest that over expression of ARMCX5-GPRASP2 might rewire the signaling
pathways in such a way that the growth dependence of NSCLC cells on EGFR receptor
activity is bypassed through GPCR activity and the Notch pathway. (Figure 20)
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4.5. Zinc Finger Protein 701 (ZNF701)
The protein encoded by ZNF701 has the Cys2His2 zinc fingers which are the classical
DNA-binding motif that points at transcriptional regulation as a possible function. ZNF701
is differentially expressed across all tested normal tissue and in multiple cancer cell lines.
No other information relating this gene to cancer was found.
4.6. Insulin Growth Factor-Like Family Member 1 (IGFL1)
IGFL1 is a member of a recently determined gene family with four gene members transcribe
in humans (IGFL1–4) and one in mice (mIGFL) (Emtage et al., 2006). No biological
function has been designated to IGFL genes which were found to be expressed rarely and
at low levels in human tissues. Because the respective proteins have signal peptides but no
transmembrane domains they are most likely secreted.
IGFL1 is up-regulated in human psoriatic skin samples. Similarly, mIGFL is primarily
expressed in skin in mice and its expression is up-regulated during inflammation responses.
Both mIGFL and IGFL1 interact with IGF-like family receptor 1 (IGFLR1) which is a
member of the tumor necrosis factor receptor (TNFR) family. Mouse T cells abundantly
expressed this receptor, which suggest a regulatory function to T cell responses for both
mIGFL and IGFL1. No connection to cancer pathology has been yet identified for this
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candidate gene. However, it is plausible that an over-expression of this gene also leads to
rewiring of the signaling pathways to make the cells independent of EGFR signaling.
4.7. Mucin 7 (MUC7)
MUC7 encodes a small salivary glycoprotein, mucin, which as a group is the principal
organic constituent of mucus. MUC7 has no significant homology with any other protein,
including any other human or animal mucin. Mucins are part of the antimicrobial humoral
innate immune response in the oral cavity (Bobek and Situ, 2003). It appears that the
expression levels and patterns of mucins are varied during an inflammatory process, tumor
progression and carcinogenesis. In lung diseases such as asthma, mucins are known to
overexpress (Kirkbride et al., 2001). Mucins are also overproduced in many
adenocarcinomas, including in tissues from cancers of the breast, prostate, pancreas,
thyroid, ovary and lung (Kufe, 2009). MUC7 is differentially expressed in invasive bladder
carcinoma (Retz et al., 1998, 2003). Additionally, activation of EGFR by two of its ligands,
EGF and TGFα, causes MUC5AC expression in airway epithelial cells both in in vitro and
in vivo (Takeyama et al., 1999).
4.8. SRC homology-3 (SH3) domain protein D19 (SH3D19)
SH3D19 is located at the chromosome region 4q31, a known susceptibility locus for chronic
obstructive pulmonary disease and lung cancer (Young et al., 2010). Sh3d19 is a
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cytoplasmic protein containing multiple SH3 domains and is thought to play a role in the
regulation of cell morphology and cytoskeletal organization in human cancer cells (Bai et
al., 2011).
The analysis of over 400 expression arrays in ovarian cancer generated a network of genes
associated with the extracellular matrix (ECM). The network connects alpha V (ITGAV)
integrins and ADAM9, a disintegrin and metallopeptidase domain 9 protein to SH3D19
elucidating a possible mechanism of cancer progression (Liu et al., 2015). Integrin triggered
signal transduction leads to a change in the chemical composition and mechanical status of
the ECM, resulting in the regulation of cell motility, cell cycle progression and cell survival
or the addition of new receptors to the cell membrane. For example, “the FAK–Src complex
is activated in many tumor cells and generates signals leading to tumor growth and
metastasis” (Mitra and Schlaepfer, 2006). Sh3d19 regulates Adam12, a disintegrin and
metalloprotease 12 protein which functions in signaling of epidermal growth factor receptor
(EGFR)‐ligand shedding (Tanaka et al., 2004a).
Sh3d19 is also known as EEN binding protein (EBP) and may be involved in suppression
of Ras-induced cellular transformation, which is diminished by nuclear localization of
SH3D19 (Yam et al., 2004). Sh3d19 may also be involved in the activation of the Rasmediated transcription factor ELK-1, a nuclear target for the ras-raf-MAPK signaling
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cascade which is frequently deregulated in human cancer (De Luca et al., 2012; Yam et al.,
2004).
Additionally, Sh3d19 interacts with SOS2, a guanine-nucleotide exchange factor of RAS
which has oncogenic activity driving cellular transformation (Sheffels et al., 2018). Sh3d19
acts as an adaptor protein when forming the EEN-Sh3d19-SOS2 complex since EEN and
SOS2 do not interact with each other, and assist EEN in inhibiting the oncogenic activity of
SOS2 (Yam et al., 2004).
SH3D19 gene is overexpressed in second generation TKI-resistant lung cancer cell line
H1975CR (Galvani et al., 2015). H1975CR was derived from an Erlotinib-resistant
adenocarcinoma cell line, NCI-H1975 which carries the frequent heterozygous missense
mutation L858R in the EGFR gene.
Figure 21 depicts a model of a probable mechanism of resistance through the overexpression
of SH3D19 in Erlotinib sensitive NSCLC cells. In a SH3D19 signaling-dependent manner,
the levels and/or activity of ADAM12 metalloprotease is increased, leading to increased
ectodomain shedding of the EGFR ligand, the membrane-anchored heparin-binding EGFlike growth factor (proHB-EGF). The extracellular increased in levels of the released,
bioactive HB-EGF leads to a concentration-dependent activation of cell survival pathways,
circumventing the competitively TKI inactivated EGFR by Erlotinib.
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4.9. Nuclear Prelamin A Recognition Factor Like (NARFL)
NARFL is a component of the cytosolic iron-sulfur cluster assembly system and plays a key
role in the cellular defense against hyperoxia-induced stress in human cells (Corbin et al.,
2015). The iron-sulfur protein assembly is a targeted process in oxygen toxicity. It has been
proposed that the inhibition of EGFR by Erlotinib induces metabolic oxidative stress leading
to cytotoxicity in human head and neck cancer (HNSCC) cells (Orcutt et al., 2009).
Erlotinib-induced cytotoxicity is facilitated through the activation of a specific oxidative
stress mechanism where NOX4 signaling increases the generation of hydrogen peroxide
(Orcutt et al., 2011). Potentially, the activation of NARFL transcription in our screen led to
the amelioration of Erlotinib-induced cytotoxicity by counteracting the hyperoxia-induced
stress by the NOX4 signaling pathway (Figure 22).
4.10. RIMS binding protein 2 (RIMBP2)
RIMBP2 encodes a protein with three SH3-domains, one N and two C-terminal and three
tandem fibronectin III (FN3) repeats, and a proline-rich sequence in linker region between
the FN3 domains and the C-terminal SH3 domains. It is thought that RIMBP2 serves as a
functional and structural link between the synaptic-vesicle release machinery and Ca2+channels, acting as a scaffold for other regulatory proteins (Mittelstaedt and Schoch, 2007).
Proline-rich peptides bind the SH3 domains of proteins to assemble protein complexes.
RIMPB2 expression occurs in a limited number of tissues, including the testis, brain,
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placenta, ovary, small intestine and kidney, in order of decreasing expression (Nagase et al.,
1997). In addition, RIMBP2 was shown to interact with protein phosphatase-1 (PP1), a
conserved ubiquitous enzyme, and negatively regulate its activity (Hendrickx et al., 2009).
RIMBP2 was found to be overexpressed in a SCLC neuroendocrine carcinoma (Gong et al.,
2018). Again, it is plausible that this protein when over-expressed could lead to lesser
dependence of the NSCSC cell line on EGFR signaling.
4.11. Network Analysis with Top Genes
A gene network analysis was performed using the GeneMania app with the top candidate
genes (Figure 23). Out of the fourteen genes entered (including four genes from the
ARMCX5-GPRASP2 read-through transcript), thirteen formed into a cohesive network.
ZNF701 was the only gene left out of the network. The network comprises of forty-two
nodes and 305 edges signifying some type of link between the genes. The edges are based
on multiple independent studies, thereby multiple edges may form from each interaction.
There were thirty-five genetic interactions edges (Green) forming a subnetwork among
thirty nodes that included ten input genes (ARMCX5, GPRASP1, IGFL1, MAPKAP1,
MUC7, NRFL, RIMBP2, RGPD8, SH3D19 and SPATA31A1). There are two networks
formed by shared pathway edges (Blue); one small-open network with three nodes
(SH3D19, PUM1 and CLINT1) and two edges; the other, a closed network with six nodes
(MAPKAP1, AKT1, RICTOR, THEM4, MLST8 and PRR5) and twenty-one edges. There are
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four small-open subnetworks sharing edges denoting physical interactions between the
genes (Red edges). There is one node pair, MUC7 and HTN3 connected by three edges.
There is also a small-open network with three nodes (SH3D19, ADAM 10 and SH3YL1)
sharing seven red edges, a six-node open network (MAPKAP1, RICTOR, MLST8, PRR5,
AKT1 and THEM4) with twenty-five red edges, and a nine-node open network (GPRASP1,
GPRASP2, CHRM1, CHRM2, CALCR, TCP25, HRH2 and HRTR7) with fifty red edges.
The final network links, the Gold edges signify that the genes share protein domains. Six
distinct networks are produced by shared protein domain. There is one pair of nodes, NARFL
and NARF connected by two gold edges. There are two three-node networks that are also
connected because of having a protein domain in common; SPATA31A1, SPATA31A5 and
SPATA31D1 form a network connected by six gold edges and RIMBP2, SH3D19 and
SH3YL1 form a network connected by three gold edges. The four genes from the readthrough transcript form a shared protein domain network with eight other genes (ARMCX5,
GPRASP1, GPRASP2 and BHLHB9 with RTTN, ARMC10, ARMC12, ARMCX1, ARMCX2,
ARMCX3, ARMCX4 and ARMCX6) by 132 edges. IGFL1, IGFL2, IGFL3 and IGFL4
produced a network with twelve shared protein domain edges. One last network with shared
protein domain network links formed among five nodes that did not include any of the
original genes with eleven gold edges. When the network is weighted based on Gene
Ontology (GO) terms based on GO biological process, the epidermal growth factor receptor
signaling pathway, T cell costimulation and G-protein coupled receptor signaling pathway,
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coupled to cyclic nucleotide second messenger appear to be enriched processes all with a
false discovery rate q-value of 0.041.
4.12. Validation of candidate genes
Given the low signal-to-noise ratio in the screening process, it is essential to validate that
the activation of the candidate genes confers Erlotinib resistance in multiple NSCLC cell
lines. Each individual sgRNA that target the candidate gene may be cloned into the plasmid
backbone of the sgRNA library, and used to verified and quantify transcriptional activation
and upregulation of protein expression, to establish a phenotype-to-genotype relationship of
Erlotinib resistance in NSCLC. In a similar experiment, Konermann et al (2015), the top 13
candidate genes identified in the screen were all successfully validated in this manner. In
addition to the confirmatory experiments described above, Konermann et al. (2015) also
used an indirect validation strategy. In this method, they chose the top 13 candidate genes
and examined publicly available gene expression databases for correlation of these genes’
high expression with resistance to the drug for which these candidate genes imparted
resistance.
4.13. Potential Limitations
Genome-scale gain-of function CRISPR screens can produce noisy data, potentially
introducing false-positive and false-negative genes. There are many factors that could
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contribute to a low signal-to-noise ratio; here we discuss some that might be encountered in
this experiment.
Ideally, some of the gene activations confer growth advantages to a subpopulation of cells
that over a period of 18-days differentiated towards a different phenotype, in our case
Erlotinib resistant. But if any off-target genomic site with sequence similarity to the
intended guide target site was activated, it could have led to false-positive candidate gene
identification.
One could also argue that long-term culturing of cells after library transduction may bias
the starting sgRNA distribution, confounding the Erlotinib selection results. This could lead
to both false-positive and false-negative gene candidates. Analysis of the NGS results of the
Day 0 NGS control sample from Experiment 3 showed that the sgRNA distribution was
askew at the start of Erlotinib selection (Figure 24). Approximately 20% of the sgRNA
targets were not represented in the Day 0 NGS control results, and 77% had between 1 and
10 copies. To preserve sgRNA representation, the number of transduced cells should be 100
to 500-fold higher than the number of independent sgRNAs in the library. In addition, after
amplifying the sgRNA library DNA it should be validated by NGS to assess the quality and
the starting distribution of guides. The quality and distribution should be checked again after
the lentiviral sgRNA library production.
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It is recommended to conduct the experiment more than once to account for stochastic noise
and improve the probability of detecting true-positive candidate genes. As biological
replicate screens are completed, the number of identified candidates increases and those
found in multiple screens have a higher probability of being true-positive candidate genes.
In her screening protocol, Joung et al. recommended 2 to 4 infection replicates per screen.
Arguably, our results may be specific to the cell line and/or cell culture conditions used and
not generally applicable to resistance in cancer. Undoubtedly, candidate genes should be
validated with multiple lung cancer cell lines, including those that are Erlotinib sensitive
but have other driver mutations leading to NSCLC.
The contamination issues encountered are another possible source of noise in our screen. It
is quite possible that a large subset of library transduced cells died due to the contamination,
leading to a loss of many putative candidate genes (i.e., false negatives). This could have
contributed to the lack of representation of some of our genes in the screen. It is advisable
to supplement the medium with antifungal and antibiotics solutions throughout the entire
course of the experiment.
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5. Chapter 5- Section I Conclusion
The emergence of drug resistance is the major cause of death in patients with metastatic
lung cancer. Although a patient initially may respond well to targeted chemotherapy, with
continued treatment the cancer often returns in distant metastatic sites overcoming the
therapeutic efficacy of the drug. Drug resistance can develop by abrogation of drug-induced
apoptosis pathways, mutations affecting drug metabolism, drug efflux, and evolutionary
adaptation by activating compensatory signaling pathways that bypass the drug-inhibited
steps (Lin et al., 2014). All of these mechanisms are responsible for imparting resistance,
yet it has become quite clear that adaptive evolution may be a major component.
While under the selection of the growth inhibitory pressure of the targeted cancer
therapeutic, cancer cells exploit their high mutational rates to explore the fitness landscape
for any growth and/or survival advantage. Over time, incremental changes accumulate
ultimately gaining enough to impart resistance. To date, there exist no option to prevent
adaptive evolution. Since the signaling network in human cells is complex, comprising of
hundreds of overlapping pathways that cross talk in complex dynamics, it is difficult to
navigate the evolutionary space of adaptive drug resistance mechanisms. Thus, a novel
approach to the problem is needed. We hypothesize that by systematic genome-wide screens
for suppressors of the drug-sensitive phenotype of lung cancer cells, will enable a testable
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network-model of drug-resistance evolution, and thereby will enable a new class of antievolution drugs.
The NGS results from Experiment 2 were analyzed again by Ms. Heather Watkins
(Claremont Graduate University) using a method written in R and found 302 gene sequences
that were significantly over-represented (P <0.05) in the Erlotinib treated culture relative to
the gene sequences among the Erlotinib sensitive control cells with an enrichment ratio (log2
fold change) of at least 4x. The list was pared down by applying multiple hypothesis
correction (under the stringent requirement that each gene acts independently) to obtain a
final list of eighteen genes at a threshold of P <2 × 106. The independence criterion was then
relaxed while admitting high log2 fold change >4.7 (22×) to obtain 28 additional genes.
Most of these (37/46) resistance genes form a cohesive interaction network, which we term
the “Erlotinib Resistance Gene Network” (ERGN) generated by methods previously
described (Li et al., 2013a). The next goal of this project is to test ERGN for the promise of
a novel drug development paradigm.
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Section II
Targeted Gene Editing at the Huntington’s Disease Gene Locus
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6. Chapter 6- Cell-based in-vitro drug screening in Huntington’s disease: a case for
HEK 293
Huntington’s disease (HD) is a devastating neurological disorder, with autosomal dominant
inheritance, which leads to loss of motor function, problems with cognition and behavior
typically in the prime of adult life. The γ-aminobutyric acid (GABA)ergic medium-sized
spiny neurons of the basal ganglia and certain neuron subsets in the cortex are primarily
affected, yet HD is recognized as a disease of the whole brain and body (Bates et al., 2015;
Gil and Rego, 2008). The age of onset of the disease is inversely correlated with the length
of the poly-glutamine repeat found at the N-terminus of the protein (Huntingtin or Htt)
encoded by the Huntington’s disease gene (HTT). Individuals with the adult-onset form of
the disease usually live for about 15 to 20 years after the clinical symptoms begin. Most
patients succumb due to aspiration pneumonia because of swallowing difficulties
(Heemskerk and Roos, 2012). To date no treatment can prevent or slow the progression of
HD, they are merely palliative. HD is incurable, yet there is substantial supporting data that
show that it should soon be possible to therapeutically treat it.
HD is characterized by the expansion of Cytosine-Adenine-Guanine (CAG) trinucleotide
repeat that encodes for glutamine residues near the N-terminal of Htt, found within the first
exon. HTT is located at the short arm of chromosome 4 at position 16.3 and contains 67
exons. Htt protein is 3,144 amino acids in length and is about 350kD in size. HD patients
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who produce Htt with abnormally long poly-glutamine sequences exhibit neuronal
dysfunction and cell death in the brain, probably as a result of toxic gains of function by the
cleaved abnormal protein (Bates et al., 2015).
Normal, unaffected, individuals are polymorphic carrying between 6 and 35 CAG repeats
in exon 1 of HTT. Individuals with 28 to 35 CAG repeats are classified as intermediate, yet
unaffected. HD with reduced penetrance occurs in individuals with 36 to 39 CAG repeats.
These individuals exhibit the full spectrum from delayed age of onset and/or mild clinical
manifestations to normal lifespan without clinical diagnosis. Since there is anticipation in
HD, males with this genotype have a high propensity to transmit the gene with even longer
CAG repeats to their offspring. Affected individuals with 40 CAG or higher repeats display
an extensive range of clinical symptoms that are classified as full penetrance. The earlyonset of the disease tend to have more than 60 CAG repeats, and sometimes the repeat
number can be as high as 250. Thus, the resulting disease status of HD patients depends
largely on the number of CAG repeats.
6.1. Genetic modifiers of HD
Plotting the length of the expanded CAG repeat against the age at onset of diagnostic motor
signs shows that they are negatively correlated (Figure 25). Moreover, within any single
CAG repeat length there is a large variation in the observed age at motor onset, which shows
the potential for naturally occurring modifiers of HD. These genetic factors are disease84

modifying agents that could potentially delay onset by up to 20 to 25 years later than the
mean. Multiple genes have been proposed as likely genetic modifier gene or variants of HD,
yet none has been statistically verified (Gusella et al., 2014). The aim of this project was to
develop an isogenic set of cell lines as in vitro models of HD, such that the modifier genes
can be mutated or altered one-at-a-time to understand the effects of the modifiers on mHtt
toxicity.
6.2. Huntington’s disease epidemiology
HD is endemic to all populations, with higher frequencies occurring among individuals with
European ancestry. Because of the increase in availability of genetic testing, recorded
prevalence of HD in North America populations has increased over the past two decades to
about 7.33 per 100,000 persons (Rawlins et al., 2016). The disease prevalence is lower in
other populations, including people of Japanese, Chinese (Hong Kong), and African (South
African blacks) descent with approximately one-tenth as frequently as that in Europe and
countries of European descent (Liou, 2010). The estimated incidence of HD for Western
populations is between 1.1 to 8 new cases per million per year (Almqvist et al., 2001;
Pringsheim et al., 2012; Ramos-Arroyo et al., 2005).
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6.3. Pathobiology of Huntington’s disease

Although the genetics of HD are well defined, the pathogenic causes that fit the observed
penetrance and expressivity of the CAG length dependence remains poorly understood. The
evidence points at the participation of both the loss of function of the normal gene product
and a gain of toxic function of mutant-Htt (mHtt) as possible mechanisms of HD pathology
(Cattaneo et al., 2005; Reiner et al., 2011). Despite the discovery of the responsible gene in
1993 (MacDonald et al., 1993), much is still unknown about HTT’s normal function and its
involvement in the disease’s mechanism (Figure 26).

Htt is ubiquitously expressed, yet it is found at higher concentrations in the brain, in both
neurons and glial cells (Li et al., 1993; Strong et al., 1993). It is essential for the development
of the central nervous system, since complete HTT knockout in mice results in early
embryonic lethality (Reiner et al., 2003), yet the length of the CAG repeat does not appear
to affect Htt’s function during embryogenesis. It is also unclear whether the CAG repeat has
any important function within normal HTT gene (Wetzel, 2012). Htt associates with
microtubules and vesicles in synapses and in caveolae, and is found in various organelles,
including the nucleus, endoplasmic reticulum and Golgi complex, underscoring its
experimentally demonstrated role in endocytosis and exocytosis, and intra-cellular
trafficking. Htt can bind with various proteins, including its physiological partner
Huntingtin-interacting protein 1 (HIP1) (Kalchman et al., 1997; Wanker et al., 1997). Many
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forms of Htt are present in, and are capable of trafficking between the cytoplasm and the
nucleus. Htt is also reported to up-regulate the production, and aid in the transport, of brainderived neurotrophic factor (BDNF), a factor produced in the cortex which is necessary for
survival of GABA-ergic medium-sized spiny striatal neurons (Bathina and Das, 2015;
Zuccato et al., 2001). Given Htt’s ubiquitous expression, interaction, and neuronal
association, it is highly likely that the loss of normal function of Htt could play a crucial
part in HD pathology. One possible mechanism could be through the sequestration of
normal Htt by the mutant aberrant copy (Cattaneo et al., 2001).

The inheritance of expanded HTT and its behavior as the dominant allele in HD pedigrees
indicate that it is primarily caused by a gain-of-function (GOF) mechanism. Evidence
implicates Htt fragmentation as a key early step in HD’s pathogenic mechanism. Toxic
protein fragments are produced in two ways, through aberrant splicing during mature
messenger RNA (mRNA) processing, and through proteolytic cleavage of the translated
protein. The aberrant splicing product is a small fragment containing the amino-terminal
HTT exon 1 (Sathasivam et al., 2013). This HTT exon 1 is comprised of three disordered
domains: A N-terminal segment of 17 amino acids (N17), a polyglutamine repeat segment
of variable length, and a proline rich domain (PRD) of 51 amino acids. The N17 segment
provides the structural basis for oligomer formation due to its ability to form α-helix-rich
oligomer structure when fused to an expanded polyglutamine segment (Jayaraman et al.,
2012). It also possesses potential sites for regulatory posttranslational modifications to the
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fragment, and is involved in trafficking, nuclear export, membrane targeting. Lastly, N17
includes binding sites for chaperones. It is unclear whether the polyglutamine repeat has
any important function within normal Htt, but it appears that polyglutamine expansion
enhances the rate of nucleation and oligomer formation (Thakur et al., 2009). The HTT exon
1 PRD forms type II polyproline helices which are good protein binding motifs, in particular
for proteins with the WW domain. The PRD region appears to have no fundamental effect
on aggregation (Bhattacharyya et al., 2006).

The toxic fragment hypothesis postulates that proteolytic cleavage of Htt produces Nterminal fragments with the expanded polyglutamine tract, which are toxic to neurons and
stimulate additional proteolytic activity (Wellington and Hayden, 1997). HTT exon 1, as
well as multiple other N-terminal fragments are produced by proteolytic cleavage of Htt by
caspases, calpains, aspartic endopeptidases, and possibly other proteases. Htt has three, invitro confirmed, caspase cleavage sites (Wellington et al., 2002), and caspase-generated
fragments have been observed in both HD and control brains (Kim et al., 2001). Htt is
cleaved by caspases-3/7 at amino acids 513 and 552, caspase-6 at amino acid 586, and
caspase-2 at amino acid 552. The Htt fragments generated from calpain cleavage are smaller
than those generated from caspase cleavage. Calpain cleavage is modulated by
polyglutamine repeat length with increasing length of the tract correlating with increased
susceptibility of Htt to cleavage. (Gafni and Ellerby, 2002). There are multiple potential
calpain cleavage sites near the amino terminus of Htt, three of these are clustered between
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amino acids 437 and 540. This area overlaps with caspase cleavage sites, yet it is unknown
whether caspases and calpians work in concert or independently. The physiological
functions of calpains are unknown, but unlike many proteases, they tend to cleave substrates
at inter-domain boundaries, this modulates the function of their substrates and does not
inactivate them. Aspartyl endopeptidases act in concert with the proteasome to cleave Htt
producing two fragments termed cp-A, cleaved within aa 104–114 and cp-B cleaved within
aa 146–214, ensuring the normal turnover of Htt. In HD, ubiquitinated cytoplasmic
aggregates comprise of a heterogeneous mixture of the two accumulated fragments. These
fragments are small enough that they could diffuse through the nuclear membrane, yet only
cp-A is found in nuclear inclusions.

Reports show that mHtt’s toxic GOF is associated with multiple cellular mechanisms and
with numerous protein-protein interactions that result in pleiotropic cytotoxic effects. For
example, cells coping with misfolded and aggregated proteins engage in proteolysis,
sending these down a degradation pathway by the lysosomes in an effort to maintain
proteostasis. Yet mHtt cannot be properly cleared due to a macroautophagy malfunction,
i.e. the ability of vacuoles to recognize cytosolic cargo is diminished in HD cells (MartinezVicente et al., 2010). The peptide aggregates in the cytoplasm and forms toxic amyloid-like
aggregates which have many detrimental effects on the cell, including synaptic dysfunction,
axonal transport impairment, and mitochodrial toxicity and energy imbalance. Additionally,
the peptides may be translocated into the nucleus where they can form oligomers, eventually
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gathering into intranuclear ubiquitinated inclusions (DiFiglia et al., 1997). Nuclear
inclusions oligomerization leads to transcriptional dysregulation of basal and inducible gene
expression through the sequestration of other proteins and other undefined mechanisms
(Seredenina and Luthi-Carter, 2012). Aggregates accumulate inside the cell, perhaps in a
last-ditch effort to sequester the toxic oligomers away, yet the ongoing proteotoxic stress
overburdens cellular degradation pathways, leading to neuronal dysfunctions, finally
culminating in neuronal loss.

mHtt expression causes general dysfunction at cortico-striatal synapses, disrupting several
cellular processes including exocytosis, endocytosis, and signaling. This type of dysfunction
could be the result of altered fundamental synaptic molecular mechanisms, or just an
outcome of altered biochemical processes in the surrounding environment. Synaptic
dysfunction occurs initially in the cortex and striatum, preceding the extensive brain
dysfunction and neuronal loss observed in late-stage HD brains (Raymond et al., 2011).
Animal models of HD and in-vivo brain imaging studies have reveal that the striatal
projection neurons are most vulnerable, and their dysfunction contributes to motor
symptoms at early stages of the disease (Sepers and Raymond, 2014). It was observed that
mHtt expression alters glial glutamate transport capacity by decreasing both the expression
of glutamate receptors and glutamate uptake (Faideau et al., 2010). It also increases
signaling at N-methyl-D-aspartate receptors (NMDAR), and both promote excitotoxicity.
In addition, BDNF, dopamine and endocannabinoid signaling are all altered, eventually
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becoming dysfunctional as well. These abnormal effects are thought to render the cortical
neurons susceptible to degeneration.

In neurite cells, Htt colocalizes with microtubules, and interacts with proteins of the
molecular motor machinery, including huntingtin-associated protein-1 (HAP1) which itself
associates with p150Glued, a critical component of the dynein based transport system
(Gutekunst et al., 1995). In HD, impairment of axonal transport could occur by at least two
mechanisms; either the normal intracellular transport function of Htt is diminished or axonal
blockage ensues by the accumulation of mHtt aggregates leading to axonal poisoning. In
support loss of function mechanism, it was observed that the transport of BDNF vesicles is
obstructed by mHtt expression resulting in the loss of neurotrophic support and neuronal
toxicity (Gauthier et al., 2004). Several in-vivo and in-vitro models of HD have exhibited
accumulation of mHtt aggregates in neurites leading to blockage, then cell death (Lee et al.,
2004; Trushina et al., 2004).

To support neuronal activities such neurotransmission, synaptic function and axonal
maintenance, neurons put high demand on mitochondria for energy production. Evidence
suggest that mHtt inhibits mitochondrial biogenesis signaling pathway (Farshbaf and
Ghaedi, 2017), impairs axonal transport of mitochondria (Li et al., 2010), alters
mitochondrial morphogenesis with increased mitochondrial fission and reduced fusion
(Kim et al., 2010), and impairs Ca2 homeostasis (Milakovic et al., 2006). If mitochondria
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are impaired, reactive oxygen species (ROS) start to accumulate leading to oxidative stress
subsequently triggering neuronal death (Shirendeb et al., 2011).

Proteolytic cleavage of mtt produces N-terminal fragments that are translocate and form
intranuclear inclusions, where they can modulate transcription by aberrant protein-protein
interaction with the transcriptional machinery. Evidence suggest that mHtt does this either
through post-translational modification (PTM) of chromatin, or through direct interaction
with genomic DNA. In HD models, abnormal PTMs to histones and associated proteins lead
to anomalous transcriptional repression (e.g. hypoacetylation, polyamination, methylation,
and ubiquitylation) (Kumar et al., 2014a). In addition, mHtt can bind to DNA in a
polyglutamine-dependent manner and alter normal gene expression by altering DNA
conformation and transcription factor binding. The soluble form of mHtt was found to
interact with glutamine rich activation domains of nuclear transcription factors and perturb
their interaction with their transcriptional coactivators and their target DNA (Yu et al.,
2002b) Suggesting that the observed depletion of transcription factors in HD models is not
caused by nuclear inclusion sequestration.

6.4. Cellular models of Huntington disease
Multiple model cell lines have been generated to further investigate the pathology of HD
and find new therapeutic strategies. The vast majority of in-vitro HD models have focused
on the role of the mutant huntingtin (mHtt) in the pathogenesis of the disease. Many models
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express a truncated mHtt which resembles the disease at a delayed stage of poly-glutamine
toxicity, mimicking the production of the toxic N-terminal fragments. Increased frequency
of mutant protein aggregates is associated with toxicity in these models. The pathological
phenotype of these models develops much earlier and is more severe than in models
expressing the full-length protein. On the other hand models expressing full-length mHtt
better recapitulates the entire disease process, including the cleavage steps (Dong et al.,
2012). The best-case scenario would be to use primary neuronal cells to represent the full
aspects of the disease in-vitro, yet these cells suffer from low plasmid transfection efficiency
compared to immortal cell lines.
Many groups have transfected the rat pheochromocytoma (PC-12) neuronal cell line with
expanded poly-glutamine huntingtin (htt) construct. In 1999, a group at Emory University
School of Medicine stably transfected PC12 cells with a N-terminal Htt fragment containing
150 repeats which exhibited nuclear accumulation of mHtt, neuronal dysfunction including
defective neurite development (Li et al., 1999). Later that year, a group from Massachusetts
Institute of Technology (MIT) transfected PC12 with constructs containing htt N-terminal
sequences including the start codon, and the first 16 amino acids ligated to various expanded
polyglutamine repeats, ranging from 104 to 300 triplet repeats to directly study the effects
of mHtt aggregation in the nucleus (Kazantsev et al., 1999). Three years later, Song et al.
reported the stable transfection of two PC12 cell lines with full-length mHtt having 48 or
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89 polyglutamine repeats that showed disruption of the cellular signaling mediated by both
EGF and NGF receptors (Song et al., 2002).
PC12 HD in-vitro models have been used for testing and screening potentially therapeutic
compounds. A group in Taiwan transiently transfected PC 12 cells with plasmid containing
htt Exon 1 region harboring 109 polyglutamine repeats to investigate the therapeutic
potential of a Gastrodia elata, a Chinese herbal medicine in HD (Huang et al., 2011). Apostol
et al. developed an inducible construct with truncated htt exon 1 with the first 17 amino
acids and various expanded repeats ranging from 104 to 300 triplet repeats and used them
as an effective mean to screen chemical compounds that affect mHtt nuclear aggregation
(Apostol et al., 2003). More recently, Scotter et al. transfected PC12 cells with an inducible
plasmid encoding the first 67 amino acids with a polyglutamine tract of 97 repeats and a C
terminal enhanced green fluorescent protein (eGFP) tag, and used these cells to investigate
the effects of cannabinoid receptor 1 activation as potentially therapeutic for HD (Scotter et
al., 2010).
Other neuronal cell lines have been widely used as HD models. The mouse neuroblastoma
Neuro2a (N2a) neuronal cell line have also been transfected with various mHtt constructs
including, full length Htt, N-Terminal fragments with an expanded polyglutamine repeats,
as well as truncated Htt expression vectors; and are mostly used in conjunction with in-vivo
studies, e.g. heterozygous huntingtin exon-1−transgenic mice of strain R6/2 bearing 145
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CAG repeats (R6/2) studies (Cooper et al., 1998; Tanaka et al., 2004b; Zemskov et al.,
2003). These differentiated neurons are seemingly more susceptible to cell death in the
presence of aggregates (Wang et al.).
The most recent models have been generated by differentiation of HD patient fibroblasts
into neuronal lineage lines such as neural stem cells (NSC) (Liu et al., 2016). The generated
induced pluripotent stem cells (iPSCs) and neuronal cell lines recapitulated some of the
phenotypes observed in previously derived HD patient cell lines. For example, in 2012 the
HD iPSC Consortium showed transcriptional changes involved in signaling, cell cycle and
neuronal development in HD patient iPSCs (Consortium, 2012). Camnasio et al. saw an
increase in lysosomal activity in HD iPSCs derived NSC (Camnasio et al., 2012). Also in
2012, Juopperi et al. generated astrocytes from patient induced pluripotent stem cells that
showed elevated levels of cytoplasmic vacoulation which increased over time (Juopperi et
al., 2012). Nekrasov et al. efficiently differentiated induced pluripotent stem cells into
GABA MS-like neurons which “recapitulated disease pathology in vitro, as evidenced by
mutant

huntingtin

protein

aggregation,

increased

number

of

lysosomes

and

autophagosomes, nuclear indentations, and enhanced neuronal death during cell aging”
(Nekrasov et al., 2016). Additionally, Szlachcic et al. generated a HD iPSC with stable
depletion of mutant HTT, and found that p53 deregulation was reversed and subtle effects
of silencing on proteins of Wnt/β-catenin and ERK1/2 signaling pathways (Szlachcic et al.,
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2017). Two other examples from Zhang et al. and An et al. are described in more detail in
section 7.
6.5. Cellular models for high-throughput drug screening in HD and other
neurodegenerative disorders
High-throughput screening (HTS) allows for parallel testing of thousands to hundreds of
thousands of small molecules for activity through the rapid measurement of specific
biological and phenotypic characteristics in the chosen assay endpoints. Modeling
neurodegenerative disorders is very difficult because of the scarcity of validated targets,
complexity of pathology which can be multigenic and multifactorial, and the prolonged
disease course. In most of these a variety of pathological mechanisms have been proposed
to be relevant, yet no cellular model has completely recapitulated of all aspects of the
disease. For this reason, a broad range of phenotypes in different models have been used in
HTS campaigns with the hope that some agreement will emerge across several screens.
Numerous cell-based high-throughput drug screening assays have been successfully
developed for HD. Since partial recapitulation of the disease process is observed in most
cell-based models of HD, a limited number of phenotypes have been assayed in these
screens, which includes aggregation, caspase activity, toxic protein clearance, and cell
death. Although cell-based assays allow for the identification of compounds that affect a
phenotype in the complexity of a cellular environment, neither the mechanism of action or
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the involved target are easy to identified. Cell-based screens are also limited by the tradeoff
between assay complexity and screenability, i.e., how amenable the assay is to
miniaturization and automation. Nevertheless, a number of promising therapeutic
compounds for HD have been identified with these cell-based assays.
Several HD cell-based aggregation assays have been developed for HTS of chemical
compound libraries. Aggregation models are bound to the conjecture that intracellular
aggregates are the key cytotoxic event in HD pathology. Zhang et al. conducted a 16,000
compounds library screen using a yeast aggregation assay where growth was used as a
surrogate for aggregation and mutant toxicity (Zhang et al., 2005). A green fluorescent
protein (GFP)-tagged mHtt (Q103) fragment under an inducible promoter facilitated the
assaying of mHtt expression levels and aggregate formation in the yeast model. Nine
compounds were found to enhance growth, measured by change in OD 600 absorbance and
GFP fluorescence by more than 25%. Of these, four inhibited aggregation in a PC12
mammalian cell-based model. The authors then tested analogs of these optimizing for
potency and testing for activity, and found one to suppressed aggregation in an HD R6/2
mouse brain slice aggregation assay. Lastly, the efficacy of the compound was assesed in
a Drosophila model expressing the human pathogenic peptide Httex1 93QP that results in
ongoing neurodegeneration in adult flies seen most readily in the photoreceptor cells of the
compound eye. The progressive degeneration observed in the control flies was significantly
relieved when the flies were fed food containing the final compound.
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Another cell-based aggregation assay uses fluorescence resonance energy transfer (FRET)
to directly assay aggregate formation. Pollitt et al. screened 2,800 biologically active small
molecules, comprising the Annotated Compound Library (ACL) for inhibitory activity in a
HEK293 cell line transiently transfected with an androgen receptor (AR) N-terminal
fragment containing a pathologic expanded tract of 65 glutamine repeats, and fused at their
carboxyl termini either cyan fluorescence protein (CFP) or yellow fluorescence protein
(YFP) coding sequences (Pollitt et al., 2003). Truncated AR gene products have previously
been shown to form cytotoxic inclusions reproducing a neurodegenerative phenotype in
transgenic animals and cell models. This model is informative not only for HD but other
polyglutamine repeat expansion disorder including, dentatorubral-pallidoluysian atrophy
(DRPLA), SBMA and spinocerebellar ataxia 1, 2, 3, 6, 7 and 17 (SCA1/2/3/6/7/17). In this
assay, as the aggregates develop CFP and YFP fusion proteins come in close proximity
resulting in FRET. At the end a number of compounds were hits for decrease in FRET, and
thereby aggregation. One compound, an inhibitor of Rho-activated serine/threonine kinase
(Y-27632) was found to alleviate degeneration in a Drosophila model.
Using the same cell-based aggregation FRET assay, Desai et al. screened three libraries of
biologically active small molecules: the ACL, the National Institute of Neurological
Disorders and Stroke (NINDS) Custom Collection with 1,040 compounds, and a 300 kinase
inhibitors collection (Desai et al., 2006). Ten compounds were identified as positive hits for
inhibiting aggregation by 20% to 30% in a reproducible and dose dependent manner.
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Subsequently, nine out of ten compounds reduced aggregation in a PC-12 model, and five
out of nine partially rescued a HD Drosophila model. Interestingly, three of the five
compounds that were effective in the fly model are Food and Drug Administration (FDA)
approved drugs.
To identify compound that rescues cells from induced mutant polyglutamine toxicity,
Coufal et al. developed a PC-12 based model inducibly expressing a eGFP-tagged mHtt
(N17) fragment with 103 polyglutamine repeats, in which toxic protein clearance could be
monitored in high-throughput mode (Coufal et al., 2007). The 96-well plate, flouresence
based assay was used in a HTS of 37,200 compounds from multiple sources; 30,000
compounds combinatorial library comprising the Diverse™ and CNS™ Sets, 5,000 diverse
heterocyclic chemicals, 2,000 natural products, and a 200-compound library of aspartyl
protease inhibitors. The screen generated over 14,000 hits that were found to decrease
fluorescence by at least 35% or higher than three standard deviations. These were
subsequently cherry-picked and screen in cytotoxicity and a dose-response assays to
eliminate any false positives, finally selecting 114 compounds. After some prioritization,
31 hits were further validated in a secondary screen. One final compound was found to
selectively clear mHtt but the wild type, and reduce cytotoxicity in a PC-12 HD model,
although only at high concentrations.
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Recent evidence demonstrates that the inclusions observed in many neurodegenerative
disorders are in fact cytoprotective (Arrasate et al., 2004; Taylor et al., 2003). With this
reasoning, Bodner et al. developed a fluorescence based protein aggregation assays to test
compounds that increase inclusion formation for their effect on proteasome dysfunction and
toxicity (Bodner et al., 2006). A HD assay was developed using a PC-12 cell line, 14A2.6
stably transfected with both the heterodimeric ecdysone receptor and an ecdysone-inducible
N-terminal fragment (N17) of Htt containing 103 glutamine repeats fused to eGFP. The
assay was used to screen 37,000 compounds including, the Diverse™ and CNS™ Sets, a
5,000 commercially available chemical compound library, and a 2,000 highly purified
natural products library. 116 compounds decreased eGFP signal by >35% and five
compounds increased the signal by >50%. These five compounds were further tested for
mHtt induced proteasome dysfunction in a Chinese hamster ovary (CHO)-K1stably
expressing an exon 1 Htt fragment with 97 polyglutamine repeats and a reporter for
proteasome function. Four out of five compounds rescued proteasome function in a dosedependent manner, and one compound stood above all in increasing reporter inclusions and
overall fluorescence. The compound was then tested in a Parkinson’s disease (PD) model
using CHO-K1 cells transiently expressing a fluorescence tagged α-synuclein construct.
The treated cells produced more α-synuclein inclusions and lowered α-synuclein toxicity
underscoring some possible commonality in the underlying pathology in both HD and PD.
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Cell death is another assay endpoint that is used in HTS to investigate HD and associated
disorders. Piccioni et al. developed a cell viability medium-throughput assay by transiently
expressing a truncated AR with an expanded tract of 112 glutamine repeats in a HEK293T
cell line, resulting in the appearance of intracellular inclusions and cell death within ~72
hours of transfection. Using a specific fluorogenic substrate, caspase-3 activation was
measured to assess cytotoxicity 72 hours after transfection. With this assay the authors
screened the 1,040 NINDS compound collection, identifying 15 compounds with caspase3 activity inhibition greater than 71% and low variability (<10%). Four compounds,
digitoxin, nerifolin, peruvoside, and suloctidil were found to reduced polyglutamine
induced cell death by 30 to 40%.
In an effort to develop a cell-based assay that would closely resemble a key neuronal target
of mHtt in HD, immortalized striatal neurons (STA14A) were stably transfected with a Nterminal fragment of 548 amino acids containing 120 polyglutamine repeats (Varma et al.,
2007). The high-throughput assay detecting cell viability via a flourenscent dye (calcein
acetomethoxy) in a 384-well plate format was used to screen 43,685 compounds. 29 novel
compounds were found to selectively rescue the cell viability in the mutant line, yet not in
the ST14A control. The compounds were tested in multiple screen rounds with STA14A
expressing other mutant constructs, PC12, yeast and Caenorhabditis elegans HD models,
with finally four were found to be active in multiple models. Furthermore, two compounds
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rescued degeneration in an in vivo brain slice HD model. These results point at the
possibility that mHtt’s targeted mechanisms are conserved across models.
Using an inducible expression system of mHtt fragments, Aiken et al. developed a broad
medium-throughput cell-based assays with cell death as the studied endpoint (Aiken et al.,
2004). The group transfected a PC12 cells with an ecdysone-responsive vector expressing
exon 1 of mHtt with 103 polyglutamine repeats, which upon expression causes rapid
aggregate formation and cell death within 48 to 72 hours. They screened the NINDS library,
finding a broad spectrum of caspase inhibitors and a group of cannabinoids to be effective
in preventing cell death in this mammalian model. Another group, Wang et al. developed a
similar inducible cell death model, this time using a nerve-derived growth factor (NGF)differentiated PC-12 cell line (Wang et al., 2005). PC-12 differentiates into neuron like
cells upon NGF treatment. The cell-based model used a tetracycline (Tet)-inducible system,
expressing a c-myc tagged mHtt exon 1 fragment containing the first 63 amino acids and
148 polyglutamine repeats which causes aggregate formation within two days, and cell
death within four days of induced expression. Lactate dehydrogenase (LDH) release by dead
cells was used as the measured endpoint in a compound screen from the NINDS library.
Twelve compounds were initially identified for significantly inhibiting LDH release
induced by mHtt expression. Seven of the twelve compounds were derivatives of
tetracycline, yet the five that were not suppressed cell death in a dose dependent manner in
a second screen. At the end three compounds, acivicin, nipecotic acid, and mycophenolic
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acid were found to also attenuate Htt aggregate formation. Although these two group’s
models had the PC-12 cell line in common, the generated hits were incongruent, and Aiken’s
screen results could not be verified in Wang’s model. This highlights the importance of
cellular context particularly in cell based screens, since small changes can dramatically alter
output hits (Sills et al., 2002).
6.6. Human isogenic cell-based model of HD by gene targeting at the HTT locus
To develop a cell-based model that fully recapitulates the key immense neuronal cell death
observed in HD, human and patient specific, bona fide human MSNs carrying the
polyglutamine repeat expansion mutation at the endogenous HTT gene could be generated
in-vitro. Towards this, Zhang et al. developed a process to MSN specific marker DARPP32 (derive dopamine- and cAMP-regulated phosphoprotein Mr∼32,000) positive striatal
neurons from HD iPSCs (Zhang et al., 2010). The iPSCs were generated from HD patient
fibroblast using the HD patient fibroblast using the Yamanaka factors in a previous effort
by Park et al. (Park et al., 2008; Takahashi and Yamanaka, 2006). The authors first
generated embryoid bodies (EB) intermediates from the HD iPSCs, which turn into neural
rosettes upon attachment onto polyornithine/laminin (pO/L) coated plates and sequentially
cultured in neural differentiation medium supplemented with basic fibroblast growth factor
(bFGF). After manual isolation and mechanical disruption of the rosettes, the cells are
passaged in neural proliferation medium finally generating neural stem cell (NSC)
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population at a 95% yield. The cells were verified by positive immunofluorescent staining
for markers in NSCs, but negative for the embryonic stem cell marker octamer-binding
transcription factor 4 (OCT4). Next, the HD NSCs were differentiated into striatal neurons
in a two-stage process. The cells are first treated with three protein factors, sonic hedgehog
(SHH), dickkopf WNT signaling pathway inhibitor 1 (DKK1) and BDNF for
differentiation, and the ROCK inhibitor Y27632 to promote cell survival, and cultured for
eight days. In the second stage, the cells were further differentiated with BDNF, Cyclic
adenosine monophosphate (cAMP), valproic acid and Y27632 for an additional one to three
days. At each stage the cells were verified for expression of the appropriate markers. For
example, at stage 1 cells expressed GABAergic neuron marker GABA, and some also
stained with striatal neuron marker calbindin, but no DARPP32 positive cells were
observed until stage 2. The approximate yield of DARPP-32 positive cells was ~10%. The
length of the polyglutamine repeats was checked in all cell lines including the HD iPSCs,
HD NSCs and the derived striatal neurons, as well as HDfibroblasts from which the HD
iPSCs originated, and the HD cell model contained the same length of polyglutamine
repeats, Q72 as the parental cell lines. The authors noted that although the amount of NSCs
was not a limiting factor, the low yield in the differentiation protocol from NSC to DARP32 positive neurons could be improved by introducing a specific striatal reporter and cell
sorting. An assay comparing caspase activity in the HD NSCs to a wild type NSC, showed
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enhanced activity upon growth factor deprivation in the HD NSC alone, assuring they could
be used in a HTS.
The same group in Dr. Ellerby’s lab genetically corrected the HD iPSCs derived from HD
patient fibroblasts by homologous recombination at the HTT locus (An et al., 2012). The
HD iPCs were nucleofected with a 16 kilobases (kb) bacterial artificial chromosome (BAC)based targeting vector using a protocol adapted to single-cell dissociated feeder free
cultures. The targeting constructs consisted of a 4.5 kb short homologous arm followed by
a removable selection cassette, after that a 1.5 kb upstream sequence of HTT containing a
normal 21 polyglutamine repeat and finally a 10 kb long homologous arm. The cassette has
both antibiotic selection marker neomycin, and fluorescence reporter eGFP under a CMV
promoter. The authors saw eGFP positive cells one day after nucleofection, and discrete
colonies were stablished for screening after 2 to 3 weeks of passage in selection medium.
The cells were screened for the absence of expanded allele product, first through PCR
followed by Southern blot analysis confirming ~1% of the colonies screened. Overall, the
gene expression profiles of the starting cell line and the corrected iPSCs showed similar
mRNA expression levels, suggesting the maintenance of pluripotency and no major
alterations in gene expression. Stabilization of several HD-associated phenotypes was
observed in NSCs derived from corrected HD iPSCs, including normal caspase-3/7 activity
after growth factor depravation, corrected BDNF levels, and normal bioenergetics in the
mitochondria. Interestingly, while investigating whether HD-associated phenotypes were
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present in the corrected and original iPSCs the authors noticed that the mutant
polyglutamine expansion made cells more vulnerable to cell death only after differentiation
into NSCs. The differentiation protocol described before with slight modifications was used
to derived striatal neurons with positive expression for DARPP-32, calbindin, and GABA.
As a proof of concept cell replacement therapy, corrected NSCs were transplanted into the
striatum of HD mouse model R6/2 brains. Survival of transplanted cells was confirmed
through confocal microscopy. In the context of modeling HD, the corrected cell line could
be used as a genetically identical control, rather than using the cells from an unaffected but
genetically diverse individual. The ability to conduct HTS with isogenic controls allows for
a more unbiased investigation of true genetic effect in a drug development and discovery
cell-based model.
Although these HD and corrected iPSC, NSC and striatal cell lines present best alternatives
as models of the disease, there are many issues when generating them in large quantities for
large screening experiments. The current technology for reprogramming differentiated cells
to iPSCs, and their subsequent re-programming into neural cells produce uncontrolled
heterogeneity in genomes and gene expression programs, which reduce their value for drug
screening (Wu and Tzanakakis, 2013).
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6.7. HEK293 cell line and its neuronal characteristics
A Google Scholar search for citations of the original paper describing the generation of
HEK293 cell line results in more than 5,000 citations including patents. HEK293 is a
permissive host cell for transfection with DNA. The cell line is widely distributed and used
in many different types of biomedical research including, disease modeling, recombinant
protein production, and virus production.
HEK293 cell line originated from an early transformation of a primary human embryonic
kidney derived cell line with sheared fragments of adenovirus type 5 DNA (Ad5) using the
calcium phosphate transfection method (Graham et al., 1977). Ad 5 DNA was first extracted
from purified virions from strain Ad 75 culture, then mechanically sheared by forcing
through a 22-gauge needle resulting in fragments of about 1/3 the size of intact Ad 5 DNA.
Subconfluent primary or early passage HEK cells were exposed to Ad5 sheared DNA
coprecipitated with calcium phosphate which are readily absorbed by the cells (Graham and
van der Eb, 1973). The transformation was extraordinarily inefficient, at least two logs
lower than that obtained with rat or hamster cells. Out of approximately 160 cultures in eight
transformation experiments, two resulted in successful single morphologically transformed
colonies 1 month after exposure to Ad 5 DNA. Attempts to isolate the colonies failed, but
the reaming cultures in the original plate grew after about 75 days. Since a dense monolayer
of normal cells was present, the serum concentration was lowered to select for the
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transformed cells. The transformed cells eventually outgrew the normal cells, and the serum
was increased back to normal concentration. After a dozen passages, the cells went through
a 100-day crisis phase were little or no growth was observed. Yet after a few more passages
the growth rate increased sharply and the cells could thereafter be split 1 in 3 about twice a
week. The morphology of the cell line was described by the author as grossly epithelioid in
character, with wide variation in size. They also noted swollen nuclei, perinuclear ovoid
bodies, and heterokaryons in many cells, and chromosome banding showed quasi tetraploid
pattern. More recent cytogenetic analysis established that the HEK293 line is pseudotriploid
(Bylund et al., 2004). HEK293 cells oncogenecity is low, inducing tumors in only a small
proportion of treated immunoincompetent nude mice.
The transformation resulted in the incorporation of 4.344 kb from the viral genome into
human chromosome 19 (19q13.2), located in the pregnancy-specific b-1-glycoprotein 4
(PSG 4) gene (Louis et al., 1997). It incorporated as a single collinear insertion of viral DNA
with no rearrangements. The adenovirus genes contained within the left ~12% of the viral
genome are key to oncogenic transformation of cells. HEK293 cells expressed gene product
from both transcription units of the early region 1 (E1), E1A and E1B which correspond to
the left end of the viral genome. E1 is one of five regions which are expressed prior to DNA
replication, and it is known to be involved in the regulation of gene expression, and in
control of expression of a number of host cell functions (Graham et al., 1984). HEK293
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cells have been extensively used for the production and propagation of E1 defective mutants
and recombinant Ad vectors.
Combining the results from immunostaining, immunoblot and microarray analysis the
Graham lab postulated that HEK293 cells were of neuronal lineage (Shaw et al., 2002).
They showed that the cells expressed the neurofilament (NF) subunits NF-L, NF-M, NF-H,
and α-internexin in a pattern similar to typical early differentiating neurons. A chip with the
Atlas Human Neurobiology array made of ~12,000 probes confirmed the protein
immunoanalysis, and identified the expression of several other neuron specific messenger
RNA (mRNA), including some associated with synaptic vesicles and electrically excitable
membranes. In addition, vimentin and keratins were highly detected, which is characteristic
of mesenchymal cells and early differentiating cells respectively. Recently, Arnhold et al.
had similar results in an Ad 5 transformed cell lines derived from amniotic fluid were
expression of neuronal and glial marker proteins was found (Arnhold et al., 2008).
Several variants have been established for retroviral production, gene expression and protein
production by stably transfecting HEK293 cells with plasmids containing a temperature
sensitive Simian Vacuolating Virus 40 (SV40) large T antigen (Tag), which is involved in
viral genome replication and regulation of host cell cycle, and with neomycin resistance.
The HEK293T cell line is competent to replicate vectors carrying the SV40 region of
replication such as retroviruses, producing higher titers. Another commercially available
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variant is HEK293FT, a supposedly fast growing, highly transfectable clonal isolate of
HEK293T.
A simple method for making a general disease in a dish model of HD that is amenable to
HTS using the HEK293FT cell line has been proposed (see Chapter 2). The aim for this
project is to develop a genetically uniform and epigenetically stable cell line that exhibits a
subset of neural gene expression signatures, for evaluating drug candidates against HD.
Here we present a general process for generating a human HD model with HEK293FT, and
if a syngeneic set of cell lines with multiple poly-Q expansions in HTT are generated, it
could potentially lead to better understanding of the disease mechanisms. The utility of the
human cell line HEK293 with neuron-like gene expression programs, expressing several
neuron-specific protein markers, to serve as a HD model could then be demonstrated by
screening a panel of drugs on the cell line to evaluate the system.
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7. Chapter 7- Gene Replacement at the HTT Locus of HEK293 Using TALENs
Recently developed genome engineering tools have made it possible to performed targeted
genomic modifications essentially in any sequence of interest in living cells and organism.
There are four families of designer engineered nucleases, transcription activator-like
effector nuclease (TALEN), clustered regularly interspaced short palindromic repeatsCRISPR associated protein system (CRISPR-Cas), zinc finger nuclease (ZFN), and
engineered mega-nuclease. Of these, TALEN will be reviewed in this chapter and CRISPRCas is reviewed in chapter 3. For reviews on ZFN and engineered mega-nucleases please
refer to Ramirez and Joung (Ramirez and Joung, 2013) and Epinat. et al. (Epinat et al., 2013)
respectively.
This chapter contains a description of the TALEN technology followed by a brief review of
TALEN-based cellular disease models constructed by both gene mutation and gene
correction. The rest of the chapter encompasses the effort towards developing a HEK293based model of HD by the addition of an extended poly-glutamine repeat into the HTT locus
using TALENs. These sections include details on TALEN design, transfection optimization,
transfection of pools, enrichment and single cell isolation efforts, and confirmation of gene
edit in pooled and clonal cell lines.
Transcription activator-like effectors (TALEs) are proteins secreted by Xanthomonas, a
proteobacteria to alter gene transcription in the host plant cells. TALE proteins have a
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central DNA binding domain consisting of repetitive sequence of residues with each tandem
repeat unit consisting of 33 to 35 amino acids. A pair of hypervariable residues at positions
12 and 13 are referred to as the repeat variable diresidue (RVD), determine the nucleotide
specificity by recognizing one specific nucleotide in the target DNA. Crystal structure of
TALE DNA binding domain bound to their cognate sites showed that the repeats stack to
form a right-handed, superhelical structure that wraps around the DNA with the RVD
positioned in the DNA major groove. The 12th residue is thought to stabilize the local
conformation of the RVD containing loop, while the 13th residue makes base specific
contact with the DNA. The RVDs His-Asp, Asn-Gly, Asn-Ile, His-Gly, and Asn-Asn target
C, T, A, T and G/A respectively (Boch et al., 2009; Moscou and Bogdanove, 2009). TALEs
are directed to the nucleus by a nuclear localization signal (NLS), which can be replaced by
an organism specific localization signal, such as the one from SV40 Tag. An array of tandem
repeats units can be engineered to work as DNA homing tools for endonucleases which are
fused to the C-terminus, such as the type II restriction enzyme FokI (Christian et al., 2010;
Li et al., 2011; Mahfouz et al., 2011). Since FokI is enzymatically active only as a dimer, a
pair of TALENs are needed to induced chromosomal double-strand breaks (DSB) into the
specified DNA site.
Induction of an artificial DSB improves the efficiency of the DNA repair mechanism known
as homologous recombination. When a homologous donor DNA is present, DSB are
repaired by homology directed repair (HDR). In the absence of a donor DNA, DSB are
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repaired by the error-prone mechanism known as non-homologous end-joining (NHEJ),
which results in small insertion and\or deletions (indels). Depending on the desire outcome
one can induced either DSB repair mechanism. NHEJ produces either a gene disruption, a
gene insertion, a gene deletion or an inversion, while HDR produces either a gene addition
or a gene correction in the targeted locus.
7.1. Cell-based disease modeling with TALENs
Genome editing nucleases enable the development of disease specific cell-based models,
allowing the investigation of pathological significance of specific sequence variants, and
directly assess the impacts of gene disruption on its function. Several groups have developed
cell-based models using TALENs and inducing modification by either NHEJ or HDR (Table
9). In 2010, Miller et al. at Sangamo Biosience targeted the site of the ∆32 deletion within
CCR5 gene in K562 an erythroleukemia human cell line with a panel of TALENs (Miller
et al., 2010). TALEN mediated gene editing by HDR was induced by introducing a donor
DNA fragment designed to transfer a 46-bp insert encoding a restriction site into the targeted
locus. Editing efficiency was checked by PCR followed by digestion, finding up to 16% of
alleles possessing the inserted sequence. Hockemeyer et al. at the Whitehead Institute in
Cambridge in collaboration with Sangamo Biosciences designed TALENs targeting PITX3
and other genes (Hockemeyer et al., 2011) Human embryonic stem cells (hESCs) and iPSCs
were electroporated with TALEN expression constructs targeting the last coding exon of
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PITX3 and donor plasmids designed to generate an in-frame fusion of eGFP to finally
produce a C-terminal fusion protein. Southern blot analysis showed that targeting was
highly efficient, with some clones even having biallelic insertion of eGFP. Mussolino et al.
engineered TALENs against two human loci, CCR5 and interleukin 2 receptor subunit
gamma (IL2RG) to evaluate their activities, specificities and potential cytotoxicity in
HEK293T cells, and later on primary newborn human foreskin fibroblast (NuFFs) cells
(Mussolino et al., 2011, 2014). Allele modifications efficiency in HEK293T cells was
reported at 14% and 17% at the IL2RG and CCR5 locus respectively. Lower TALEN
activity was seen in the NuFF cell line, with allelic mutation frequencies comparable to
those seen with ZFNs ranging from 6% to 17%. Interestingly, the authors found lower
nuclease-associated cytotoxicity by the TALENs compared to similarly designed ZFNs.
Targeting again the CCR5 gene Kim et al. at Seoul National University in Korea designed
TALENs and a surrogate reporter system for enrichment of HEK293T cells with nuclease
induced mutations (Kim et al., 2011). The surrogate reporter was designed with the targeted
sequence in CCR5 inserted between the sequences encoding for mRFP and eGFP, where
eGFP is fused out of frame. mRFP is under a constitutive promoter, but eGFP will not be
expressed unless a DSB is introduced by the CCR5 TALENs and it is subsequently repaired
by NHEJ often causing the compulsory frameshift mutation. Using this surrogate reporter
system mutated HEK293T cells were enriched 8.6-fold as compared to unsorted cells.
Another group from the University of Minnesota designed TALENs targeting the human
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hypoxanthine phosphoribosyltransferase 1 (HPRT1) gene and transmembrane conductance
regulator (CFTR) gene (Cermak et al., 2011). HEK293T cells were transfected with
mammalian expression vectors expressing the TALENs targeting the HPRT1 locus, and
extracted genomic DNA from these cell lines were subsequently sequenced to evaluate
mutations at the cleavage site. Since an enrichment step was used mutagenesis frequencies
could not be quantified, yet the authors reported 17 independent mutations in the HRPT1
gene which included substitutions and deletions approximately centered on the TALEN
spacer. Although no data were reported for the CFTR gene targeting, the authors developed
an online software tool for designing TALENs named TAL Effector-Nucleotide Targeted
(TALE-NT) and adapted a reporter-based yeast assay to examine TALEN activity. These
tools aid in designing TALENs for previously difficult targets for ZFN such as CFTR locus.
Using a high-throughput system name FLASH (fast ligation-based automatable solid-phase
high-throughput) Reyon et al. constructed 96 TALEN pairs targeting 78 genes implicated
in human cancer and 18 genes involved in epigenetic regulation (Reyon et al., 2012). Using
a modified T7 endonuclease I (T7EI) assay to test the nuclease activity of the TALENs, the
authors showed an 88% overall success rate for NHEJ-mediated mutagenesis at the targeted
loci, with efficiencies ranging between 2.5% and 55.8%. 11 of the mutant cell lines at the
targeted loci were confirmed by sequencing, revealing characteristic indels at the targeted
gene sites at similar frequencies as the T7EI assay. These various models demonstrate what
the TALEN technology is capable of, yet none of them published data for the phenotypic
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characteristics of the edited cell lines until Ding et al. (Ding et al., 2013). These authors
from Harvard generated TALEN pairs to target 14 genes associated with human diseases to
make various alterations in hESCs and iPSCs including various knockout mutations, a
knockin missense mutation and a frameshift mutation, and subsequently performed a
detailed phenotypic analysis of three genes, SORT1 encoding sortilin, AKT2 encoding
RAC-β serine\threonine-protein kinase, and PLIN1 encoding perilipin. The mutation
efficiencies achieved ranged between 1.6% and 33.5%. In an effort to generate isogenic cell
lines with matching genetic background, epigenetic state, differentiation capacity,
derivation history and adaption to culture, the authors decided to use multiple hESC with
stable normal karyotypes and differentiation capacity into all primary germ layers. Two
SORT1 loci were targeted with TALENs, exon 2 in the hESC line HUES 1 and exon 3 in
the hESC line HUES 9 at mutation efficiencies of 22.2% and 10.9% respectively. Multiple
clones were then differentiated into hepatocyte-like cells (HLCs) and expression of lipid
related genes was examined. The study revealed that SORT1 reduces lipid related protein
levels, such as apolipoprotein B (apoB) that leads to lowering of cholesterol, suggesting
protection from atherosclerosis. Additionally, the HUES 1 SORT1-mutant cell line was
differentiated into white adipocytes to investigate SORT1’s role in regulating blood glucose
levels in these cells. A difference in glucose uptake rate was observed in the wild-type
versus mutant cell lines, with only the wild-type’s rate increasing after treatment with
insulin, showing that SORT1 may play a critical role in insulin sensitivity in these cells.
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Lastly, the SORT1-mutant HUES 9 cell line was differentiated into motor neurons were
sortilin was confirmed to be required for pro-BDNF-induced (the pro-form of brain-derived
neurotrophic factor) programmed cell death. To help elucidate whether a missense mutation,
E17K in the AKT2 gene leads to deregulation of insulin sensitivity in hepatocytes and
abnormal glucose metabolism in adipocytes, which would confirm diabetic-like symptoms
observed in patients harboring this mutation, the authors generated an allelic series of
isogenic HUES 9 lines containing either wild-type AKT2, complete knockout of AKT2 or
the AKT2-E17K single mutation. An antisense single-stranded oligodeoxynucleotide with
the E17K missense variant was used to generate the AKT2-E17K mutant clones with 1.6%
efficiency. The allelic series of hPSC clones were differentiated into HLCs and white
adipocytes and examined further. The study showed that in mutant HLCs the AKT2
substrate transcription factor FoxO1 is deregulated, and that a decreased in glucose
production upon addition of insulin was only observed in the wild-type HLCs, making the
mutants insensitive. The white adipocytes harboring the AKT2 mutation were found to have
significant increase in triglyceride content compared to the wild-type and knock-out cell
lines, and higher levels of glucose uptake rate compared to wild-type. These results confirm
a dominant function for the AKT2-E17K mutation that caused the reported hypoglycemia,
hypoinsulinemia, and increase body fat in patients carrying this mutation. Similarly,
TALEN pairs were designed to target the PLIN1 gene in HUES 9 cells to generate
frameshift mutations in exon 8. The targeting efficiency was 23.8% and one of the
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characterized mutant clones contained a frameshift mutation that resulted in a C-terminal
elongation, similar to the observed effect of the naturally occurring mutation. When the
allelic series was differentiated into white adipocytes, a significant reduction in lipid-droplet
formation and triglyceride storage was observed only in the elongated variant cell line and
not in a line harboring a truncated form of PLIN1 although both mutations resulted in
increased lypolysis. These results show significant evidence for the C-terminal elongation
of perilipin as the cause for the lipodystrophy observed in patients harboring this mutation.
All of these TALEN-based cell models are good examples of what is possible with this
genome engineering tool, yet there are other examples where gene therapy via TALENs not
only provides a proof of concept for its therapeutic application, but also have generated the
crucial isogenic control cell lines for proper disease modeling. Sun et al designed TALENs
to cleave at specific sequences within the human β-globin (HBB) locus, which is associated
with sickle cell disease (Sun et al., 2012). Through a yeast reporter system, the authors
optimized the DNA cleavage efficiency by screening 100 TALEN pairs, testing 10 different
DNA substrates against 10 different TALEN architecture. The best designed TALEN pairs
stimulate the gene targeting rate by over a 1000-fold in a Hela-eGFP reporter cell line. The
authors found that although these results were on par with known ZFN targeting rates,
TALENs appear to be less toxic to human cells, as observed in a nuclease-associated toxicity
assay monitoring the phosphorylation of histone H2AX (γ-H2AX), which responds to
chromosomal DSB. Two years later, the same authors published results on generating a
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corrected human iPSC line derived from sickle cell disease patients by TALEN-mediated
gene targeting in combination with a piggyBac transposon in the donor plasmid (Sun and
Zhao, 2014). To correct the disease-causing mutation, a homozygous mutation replacing A
to T in the sixth codon of HBB gene (from glutamate to valine), the authors designed a
donor plasmid carrying ~2.5kb of homology sequence with the wild-type codon, a
removable piggyBac transposon containing a drug-selectable cassette under constitutive
promoter. After selection, the piggyBac transposon was seamlessly removed via a
transiently expressing transposase. The iPSC colonies were genotyped finding two positive
colonies out of 48, and then these were sequenced confirming seamless transposon excision
and TALEN-mediated gene correction.
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8. Chapter 8- Section II Methods
8.1. Sequencing HTT gene from HEK293FT cell line for genotyping and TALEN
design
A HEK293FT cell line obtained from LifeTechnologies, Inc. (ThermoFisher Scientific, cat.
no. R70007) was cultured in Dulbecco’s modified Eagle’s modified (DMEM) medium
(ThermoFisher Scientific, cat. no. 10313039) with 10% fetal bovine serum (FBS)
(ThermoFisher Scientific, cat. no. 10438034) and passaged every two to three days. Cells
were harvested enzymatically with a 0.05% trypsin solution (Life Technologies, cat. no.
15400054) in PBS, and pelleted by centrifugation. HEK293FT cells were suspended in
SDS/NaCl lysis buffer from the DNeasy Blood & Tissue Kit (Qiagen, Inc., cat. no. 69506),
and subsequently loaded the lysed cells into a silica-based membrane to isolate purified
genomic DNA. Polymerase Chain Reaction (PCR) primers were designed flanking the
transcription start site (TSS) and exon 1of the HTT gene, amplifying a 2.8 kb amplicon. The
amplicon was subsequently cloned, and three independent clones were sequence. 50ng of
amplicon were sent to Laragen Inc. (Culver City, CA) for Sanger sequencing in an ABI
Prism 3730. This sequence was used to design the TALENs (see below).
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8.2. TALEN and surrogate reporter design
The selected regions for targeted cleavage are shown in Figure 27. PNA BIO. Inc
synthesized ten TALEN pairs around region 2 and tested them for in vitro cleavage activity
at the cognate site. The top two active TALEN pair were chosen and the putative cleave
sites are shown in Figure 27. TALEN pairs one and two were designed to cleave at two sites
flanking a 13 bp fragment of the genomic DNA in the 5’ untranslated region (UTR) region
of HTT, just before exon 1.
The top two TALEN pairs were also provided to Dr. Lisa Ellerby at the Buck Institute Buck
for Research in Aging which they used to target iPS cells to correct the mutant allele (An et
al., 2014).
8.3. HEK293FT cell line passage number optimization for transfection
To choose the optimal number of passages for the TALEN transfection experiment the
HEK293FT cell line was passaged every three to four days and its doubling time and percent
viability were measured over an extended period. The seeding density was set between 2
and 5 × 104 viable cells and passaged in T-25 and T-75 flasks, respectively. The viable cell
density and percent viability was measured using an automated cell analyzer, Vi-Cell XR
(Beckman Coulter).
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8.4. Optimization of HEK293FT transfection by design of experiment
The transfection optimization experiment was conducted before the TALENs were
engineered. Three experiments were set to optimize the transfection of HEK293FT cell line.
Instead of plasmids for TALENs, the cells were transfected with a plasmid encoding peGFPN1 which has a CMV promoter. Cells were inoculated at a starting density of 1 × 106 viable
cells per well in a 6-well plate the day before transfection. The cells were then counted on
a hemocytometer and analyzed under the fluorescence microscope for eGFP expression.
The conditions tested in the first experiment were the amounts of peGFP-N1 DNA used at
three levels 1, 2 and 3µg; the amount of transfection reagent used, i.e. TransIT-LT1 (Mirus
Bio LLC, cat. no. MIR 2300) at three levels: 3, 5.25 and 7.5µl, respectively; and incubation
time for DNA:reagent complex formation at three levels: 5, 12.5 and 20 minutes,
respectively. Expression of eGFP and the efficiency of transfection were analyzed as
described above using the fluorescence microscope. The experiment was ended after 48
hours. Table 10 shows the full factorial design used in the first experiment with eight
experimental runs, plus two center point experimental runs, and two negative controls.
The second optimization experiment was set to further optimize the two transfection
parameters that were found to be the most statistically significant in the first experiment.
The two parameters tested were the amount of DNA used and the time of incubation for the
DNA:reagent complex to occur. The inoculation density was lowered to 3.5 × 105 viable
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cells per well, and the TransIT-LT1 reagent was set to 3µl. The conditions tested in the
second experiment were the amount of plasmid peGFP-N1 DNA set at 3, 4 and 5µg,
respectively; and incubation time for DNA:reagent complex formation set at 20, 32.5 and
45 minutes, respectively. The 2×2 factorial experiment is shown in Table 11. The cells were
harvested after 48 hours and analyzed by counting eGFP positive cells versus nonfluorescent cells under a microscope. The results were analyzed using the statistical software
JMP.
The third transfection efficiency experiment was set to look at a larger design space for two
parameters: transfection reagent amount used and plasmid DNA amount used. Based on the
results of the second experiment, the question whether there is a greater positive effect when
adding more DNA into the transfection mix arose. HEK293FT was inoculated again at 3.5
× 105 viable cells per well. Table 12 shows the conditions tested in the two-factor
experimental design with center points. The experimental runs consisted of TransIT-LT1
reagent amount set at 3, 5.25 and 7.5µl, respectively, along with plasmid pEFG-N1 DNA
amounts set at 5, 7.5 and 10µg, respectively. Once again, the cells were harvested after 48
hours and analyzed by counting under a fluorescence microscope.
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8.5. Transfection experiments with TALENs and surrogate reporters to demonstrate
in vivo activity
To determine the transfection efficiency of TALENs and TALEN activity based on
surrogate reporters an experiment was set with HEK293FT and the optimized transfection
parameters. The cells were thawed at passage four and transfected within three passages
afterwards. Cells were plated in 6-well plates at a starting density of 1 × 106 viable cells per
well and transfected the day after. 7.5µl of TransIT-LT1 transfection reagent was used along
with 10µg of each TALEN construct and 5µg of the surrogate reported construct. The
incubation time for DNA:reagent complex formation was 20 minutes. 48 hours post
transfection, the plated cells were checked with fluorescence microscope for the expression
of RFP and/or eGFP. The conditions tested are listed on Table 13.
8.6. Restriction digest of donor plasmid with 101CAG repeats
Prior to transfections, the donor plasmid was linearized using three different sets of
restriction endonuclease. The most frequently used restriction digestion was performed
using a mixture of all three enzymes, KpnI, HindIII and SspI, generating a 2.8kb fragment.
Two other double-enzyme digestions were performed, using SmaI and ApaI, or BamH1 and
EcoRI, to generate an 863bp and 1.6kb fragments respectively. In addition, SspI was used
in a single digestion to generate a 3.2kb fragment. The digestion was typically performed
for at least 3 hours and up to overnight in a 37°C water bath, followed by agarose gel
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separation and purification of the DNA bands using the QIAquick Gel Extraction Kit
(Qiagen, cat. no. 28704). Quantification of DNA and purity by A260/280 ratio was
measured using a NanoQuant absorbance reader from TECAN.
8.7. Transfection experiments with TALENs, surrogate reporters and donor DNA to
demonstrate gene editing in pooled HEK293T cell line
The day before transfection, the Donor DNA plasmid was either double or triple digested
(as described above) to generate the 1.6kb or 2.8kb fragments, respectively. In addition, 1
× 106 viable HEK293FT cells per well were plated in 6-well plates. The following day, 10µg
of DNA from each TALEN plasmid, 5µg of the surrogate reporter plasmid and >2.5µg of
purified digested Donor DNA was mixed with 7.5ul of TrasIT-LTI and incubated for 20
minutes for complex formation time. We added the DNA:reagent mixture to the cell cultures
and incubated the mixture in a 37ºC, 5% CO2 humidified incubator (Table 14). Transfection
efficiency was checked by fluorescence microscopy by observing the eGFP+ and/or RFP+
cells either at 48 or 72 hours after transfection. After some subculturing, DNA and protein
were extracted from the cultured cells for confirmation of gene addition by HR through PCR
and Western blotting, respectively. The generated cell lines were either used in enrichment
experiments and/or cryopreserved.
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8.8. Enrichment of eGFP/H-2KK Positive HEK293FT Cells
To enrich the population of eGFP+ cells, which also express the H-2KK transmembrane
protein, 1 × 106 HEK293FT cells were transfected in 6-well plates with both sets of
TALENs plasmids and their respective surrogate reporter plasmids, and cultured for 2 days
in a temperature controlled, humidified CO2 incubator at 37⁰C. Using a fluorescence
microscope, the cultures were examined to confirm for RFP+/eGFP+ cells. Magnetic
separation of the transiently transfected cells with the surrogate reporter plasmid expressing
truncated mouse MHC class I molecule H-2Kk was performed using the MACSelect
Kk System (Miltenyi Biotec, cat. no. 130-070-201). The cultures were trypsinized and the
collected cell suspensions were centrifuged. The pelleted cells were suspended in pre-cooled
PBS to wash and remove the dead cells. The viable cells were again centrifuged and
suspended in PBS supplemented with 0.5% bovine serum albumin (BSA) and 5 mM EDTA
(PBE). The cell suspension was then mixed with magnetic bead-conjugated antibody
against H-2Kk at 40ul per well and incubated for 15 minutes at 4°C. The volume of labeled
cells was adjusted to 2ml with PBE and mixed well to get well-dissociated cell suspensions.
The suspensions were then transferred to MACS MS columns for magnetic separation. We
washed the column with four column volumes of PBS-EDTA buffer to get rid of unlabeled
cells. We then detached the column from the magnet and the remaining labeled cells were
eluted from the column with fresh medium. Two 1ml eluates of the cells per column were
collected and plated in 6-well plates and placed in CO2 incubator. The cells were cultured
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overnight at 37°C and observed with fluorescence microscope for reporter expression. In
some cases, the eluates were sorted into single cells per well by limiting dilution.
8.9. Limiting Dilution of eGFP/H-2KK Positive HEK293FT Cells
A 200µl aliquot of the cell enrichment experiment was transferred to well A1 of a 96-well
plate. The well was serially diluted by drawing half the volume and transferring it to the
well below in the same column and so on. The cultures in column 1 were then further diluted
by transferring half of the volume from the preceding wells to the next ones on the same
rows A through H. The plates were place in a temperature controlled humidified CO2
incubator at 37⁰C and after three to five days the wells were inspected with a microscope
for single cell colonies. Once identified the individual cultures were grown to <60%
confluency which took eight to fourteen days. The cell cultures in the 96-well plates were
trypsinized for a short period of time and then diluted with equal parts of fresh medium
containing serum. The dislodged cells were transferred into 24-well plates also containing
fresh growth medium. The cultures were grown to <60% confluency which took between
three to seven days. Next, the cells were subcultured into T25 flask with fresh growth
medium and again the cultures were grown to <60% confluency which took between three
to five days. The cultures were then split into two aliquots. One aliquot contained 2 × 106
total cells and was used for cryopreservation. For each culture two vials were cryo-

127

preserved. The other aliquot which varies in the number of cells was used for genomic DNA
isolation as described below.
8.10. Flow Cytometry at City of Hope (COH)
The day before transfection, the inoculating culture reached a total of 1.5 × 106 viable cells
per ml and 95.7% viability. Six T25 flasks were inoculated with approximately 3.5 × 105
viable cells in 5ml of growth medium. The cultures were placed in the same incubator and
grown overnight before being transfected. Table 15 describes the transfection experiment
design which included three controls: a wild type, not transfected control, an RFP+ control
transfected with only the reporter plasmid, and an eGFP+ control set up by transfecting the
HEK293FT cell line with peGFP-N1 plasmid. The reporter plasmid has constitutive RFP
expression and a mutant eGFP-. The mutant eGFP- may become eGFP+ by the nucleolytic
activity of the TALENs followed by NHEJ to bring the open reading frame to register with
the start ATG codon. The reporter plasmid allowed for transient selection of RFP+
transfected clones and confirmation of the nucleolytic activity in eGFP+ clones.
A fourth flask was transfected with one TALEN set, the surrogate reporter and an 863b
DNA fragment that contains 101 CAG repeats. Flasks five and six were transfected with
both TALEN sets and surrogate reporter sets, and the 1.6 and 2.8kb donor DNA fragments,
respectively. The transfections were performed using the lipofection reagent TransIT-LT1
from Mirus with an incubation time of 20 minutes for DNA:reagent complex formation.
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The targeted microgram added ratio of TALEN: Surrogate Reporter: donor DNA fragment
was 2:1:1. The flask were placed in a humidified CO2 incubator set at 37ºC. The flasks were
cultured for another two days before transferring to City of Hope FACS core facility for
sterile single cell sorting.
The day of FACS sorting, thirty 96-well plates with 100ul of conditioned medium were
prepared. The conditioned medium was made by mixing day-two cultured medium (i.e.
fresh medium was first added to a sub-confluent culture of HEK293FT, cultured for 2 days,
and the cell-free medium was harvested) supplemented with 30% FBS with fresh medium
at 1:1. The control and the transfected cells were harvested by adding trypsin to the cultures,
then centrifuged, and the cells were re-suspended in serum free medium. The cell suspension
was filtered through a 40µm cell strainer to remove cell clumps. The cells were then loaded
into the sample injection chamber of the FACS machine, a customized ARIA II cytometer
from BD Biosciences and the controls were used to gate for the desire double positive
fluorescent cells. The wild-type, not transfected control cells were used to gate for single
cells, excluding the clumps of cells, as well as gating out the autofluorescence signal coming
from the cells. The RFP+ control cells were used to gate for RFP+ cells. The eGFP+ control
cells were used to gate for eGFP+ cells. And a gate for double positive cells, i.e. RFP+/GFP+
cells was set up
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The plates were kept at COH for two days at 37°C in a 5% CO2 incubator before transporting
them back. The medium was exchanged with fresh medium (with 10% FBS) after five days.
The cells were subcultured, and scaled-up to both establish the clonal cultures and extract
genomic DNA. The cell lines were cryopreserved, the extracted genomic DNA samples
were stored at -20°C until needed for analysis.
The three cultures transfected with the TALENs and donor DNA fragment were harvested
and filtered in preparation for sorting. Thirty 96-well plates were prepared with 100µl per
well of fresh medium without FBS mixed with conditioned growth medium with 30% FBS
at a 1:1 ratio. Single cells that were simultaneously RFP+ and eGFP+ were sorted into
individual wells of the plates with conditioned medium. For each of the transfected cell
lines, ten 96-well plates were inoculated. Each well was inoculated with a single cell with
the exception of three rows, row A on plates 10, 20 and 30. These wells were inoculated
with 10 cells per well as controls for positive growth for each of the transfected cell lines.
A total of 2,880 wells were inoculated (2,844 with single cells and 36 with 10 cells per
well). The inoculated plates were immediately place in the 37⁰C humidified incubator with
5% CO2. The plates were kept at COH for two days at 37°C in a 5% CO2 incubator before
transporting them back. The medium was exchanged with fresh medium (with 10% FBS)
after five days. The plates were then cultured for a total of ten to fourteen days before
proceeding to the next scale up step. The next step in the scale up was the inoculation of the
24-well plates. Each of the surviving 96-well plate monoclonal cell lines were split and used
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to inoculate two wells in a 24-well plate. After three to seven days the cultures were either
harvested for gDNA isolation or passage into a single well in a 24-well plates. The extracted
gDNA was stored at -20°C until needed for trinucleotide repeat sizing analysis. The cell
lines were then cultured for three to seven days before scaling them up to the T25 flask. The
cultures were grown for three to five days until <60% confluency was achieved. The T25
flask cultures were then cryopreserved.
8.11. Genomic DNA Extraction and Purification from Transfected HEK293FT cells
HEK293FT cells were suspended in SDS/NaCl lysis buffer from the DNeasy Blood &
Tissue Kit from Qiagen, Inc., and subsequently loaded the lysed cells into a silica-based
membrane to isolate purified genomic DNA. Quantification of DNA and purity by
A260/280 ratio was measured using a NanoQuant absorbance reader from TECAN.
8.12. Trinucleotide Repeat Sizing Analysis by Laragen
A total of 100 genomic DNA samples were sent to Laragen, Inc. (Culver City, CA) for
genotyping. The genomic DNA samples submitted consisted of four from the HEK293FT
wildtype cell line, eleven from non-clonal transfected cell lines and 93 from clonal
transfected cell lines. Laragen’s trinucleotide repeat analysis is based on Capillary Gel
Electrophoresis.
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8.13. PCRs for genotyping the HD CAG repeat region.
The final HD genotyping PCR protocol is based on one obtained from the Ellerby lab. The
forward primer used is Ellerby’s primer HD 344. The reverse primer was designed from the
sequencing results of the HEK293 cell line. The Ellerby lab uses a typical polymerase, Taq
DNA Polymerase with ThermoPol Buffer (New England BioLabs, cat. no. M0267), yet it
was not in our enzyme supply. Instead, PrimeSTAR GXL DNA Polymerase (Takara Bio,
cat. no. R050A), Quick-Load Taq 2× Master Mix (New England, BioLabs, cat. no.
M0271L) and Advantage-GC 2 Polymerase Mix (Takara Bio, cat. no. 639114) were all tried
in several PCR optimization experiments.
The thermocycler was programed to first do an initial denaturation step for 15 seconds at
95°C, followed by 17 cycles of first denaturation at 95°C for 30 seconds, then 30 seconds
of an annealing temperature gradient starting from 71°C and ending at 63°C dropping 0.5
degrees every cycle and a 72°C, 30 seconds extension time. Once the temperature reaches
63°C, 23 more cycles are performed at the same parameters for denaturation and extension.
There is a final extension time of 5 minutes at 72°C. The expected amplicon for the HEK293
wildtype cell line with 21 CAG repeats is 385bp.
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8.14. Protein Extraction from HEK293FT Transfected Cell Lines
The cell lines were thawed, subcultured, then all cells were harvested from a single T-75
flask after 3 days of culture (approximately 1 × 107 cells) for protein extraction. The cells
were pelleted by centrifugation at 2,500 × g for 10 minutes. The cell pellet was resuspended
in 500µl of M-PER Mammalian Protein Extraction Reagent (ThermoFisher Scientific, cat.
no. 78501) and incubated for ten minutes at room temperature while mixing gently. In
addition, we compared protein extraction methods using two different cell lysis buffers,
Radioimmunoprecipitation assay buffer (RIPA buffer) made in the lab and store-bought MPER buffer. On average, the total protein yield was marginally higher with M-PER buffer.
For convenience MPER was used for protein extractions. Centrifugated the samples at
14,000 × g for fifteen minutes and the supernatant was kept at -80°C until needed for
analysis via Polyacrylamide gel electrophoresis (PAGE). The protein concentration of each
sample was determined by reading the absorbance at 280nm using the NanoQuant for
TECAN.
8.15. Western Blots with Transfected HEK293FT
We attempted to optimize a Western blot protocol based on one shared by the Ellerby lab
(An et al., 2014). Although no control experiment was set up, multiple parameters in the 3day Western blotting protocol were adjusted one at a time. The samples were prepared by
mixing 15µl of protein supernatant (~30 µg of protein) with 15µl of Laemmli buffer with
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5% 2-mercaptoethanol, then boil them for minutes to denature. Each sample was loaded
onto a well of a NuPAGE 3-8% Tris-Acetate Protein Gel (ThermoFisher Scientific, cat. no.
EA0375BOX). We used multiple types of polyacrylamide gels at different concentrations
and gradients. Finally, we settled on using two types of gels exclusively: NuPAGE 3-8%
Tris-Acetate Protein Gel and NuPAGE 4-12% Bis-Tris Gel (ThermoFisher Scientific, cat.
no. NP0321BOX). The sieving effect of these gel’s matrices are low enough to allow large
molecular weight proteins like Htt penetrate them with more ease. The buffers used were
NuPAGE Tris-Acetate SDS Running Buffer (TermoFisher Scientific, cat. no. LA0041)
(50mM Tricine, 50mM Tris base and 0.1% SDS, pH 8.2) and NuPAGE MES SDS Running
Buffer (ThermoFisher Scientific, cat. no. NP0002) (50mM MES, 50mM Tris Base, 0.1%
SDS, 1mM EDTA, pH 7.3), respectively. The protein standard used was Kaleidoscope
Prestained Standards (Bio-Rad Laboratories, cat. no. 1610324). A relatively high PAGE
voltage is also required to allow better penetration of large proteins into the gels. We
typically used voltages between 180V and 210V, letting the 45.7kD standard run about
three-quarters down the length of the gel which typically took between 50 and 70 minutes.
This also meant that the high molecular weight standards near the top of the gel had properly
separated.
The protein was transferred from the gel onto an activated PVDF Membrane, Filter Paper
Sandwich 0.2µm pore size (ThermoFisher Scientific, cat. no. LC2002). On a few occasions,
a nitrocellulose membrane was used instead, but because the former offer higher sensitivity
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due to higher biding capacity, we decided to use PVDF exclusively. Blotted the membrane
overnight (at least fourteen and up to seventeen hours) submerged in transfer buffer, 25mM
Tris base, 192mM glycine, 0.1% SDS and 20% methanol with ice while mixing, inside the
4°C refrigerator. The transfer was typically done at a relatively low voltage. We tried
various voltage settings ranging between 20V and 60V. Yet to avoid heating the buffer
overnight, when higher voltages were used (40V to 60V), we decided to run the transfer at
30V or lower.
The membrane was then blocked in 5% Blotting-Grade Blocker, Non-Fat Dry Milk (BioRad Laboratories, cat. no. 1706404) made in TBS buffer with Tween 20 (TBST) buffer,
(20mM Tris and 150mM Sodium Chloride) and then washed twice with TBST and once
with TBS for ten minutes each. We incubated the membrane at 4ºC while agitating overnight
with

the

anti-polyglutamine

primary

antibody,

MAB1574

clone

5TF1-1C2

(MilliporeSigma, cat. no. MAB1574) diluted in TBST at 1:1,000. We also tested the primary
antibody diluted to a higher concentration (1:500) without any noticeable difference in the
results. We also probed the membrane with Anti-Huntingtin Protein Antibody, a.a. 181-810,
clone 1HU-4C8 (MilliporeSigma, cat. no. MAB2166) (1:1,000 dilution) which is a primary
antibody against both wild type and mutant Htt, yet it also did not produce positive results.
The blocking step lasted one hour, and the primary antibody probing was done at 4ºC while
gently shaking overnight (fourteen to seventeen hours).
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The membrane was then washed twice with TBST and once with TBS before being treated
with the secondary antibody. Each wash step lasted at least ten minutes. The goat anti-mouse
IgG (H+L) horseradish peroxidase (HRP)-conjugated secondary antibody (ThermoFisher
Scientific, cat. no. 62-6520) was used for detection, diluted at 1:4,000 in TBST. The
secondary antibody was also tested at 1:1,000 with negative results (overexposure). The
membrane was incubated while agitating with the secondary antibody for at least one hour
then washed twice with TBST and once with TBS. We also tested increasing the incubation
time up to two hours without any noticeable difference in the results.
We used the chemiluminescence detection kit, Novex ECL HRP Chemiluminescent
Substrate Reagent Kit (ThermoFisher Scientific, cat. no. WP20005) for signal development.
The developed blot was exposed to x-ray film, CL-XPosure Film (ThermoFisher Scientific,
34090) inside a radiographic cassette in the dark room. Several exposure times, ranging
from fifteen seconds to one minute were used depending on the results observed. Once a
good exposure was achieved, the exposure time was stopped.
The X-ray film developing steps were not optimized. Instead, we used ultrapure water to
prepared the buffers fresh on the day of use. The X-ray film was developed by incubating it
in L110 Liquid Film Developer (LegacyPro, cat. no. 10190) for 30 seconds while mixing.
We then transferred the film into the Indicator Stop Bath (LegacyPro, cat. no. 10145) and
then rinse with ultrapure water. The film was transferred to RAPID fixer solution (Ilford,
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Harman Technologies) and incubated while gently mixing for 30 seconds. Finally, the
developed X-ray film was rinsed with ultrapure water for 30 seconds. We used ultrapure
water to prepared the buffers fresh, on the day of use.
8.16. Hydrogen Peroxide Oxidative Stress Assay
For each tested cell line, a 3-day culture in a T25 flask was used to inoculate an entire 24well plate with 7.5 × 104 cells per well. A control plated was also set up with the wild type
HEK293FT cell line. The plates were then placed in a humidified, 5% CO2 incubator set at
37C and cultured overnight. The next day, the growth medium was exchanged with media
containing hydrogen peroxide at three concentrations, 0.4, 0.6 and 0.8mM (N=6). A control
condition without any hydrogen peroxide was also set up. The treated plates were placed
back in the incubators and cultured overnight. The next day the six wells per condition were
harvested to determine the cultures’ viability by trypan blue exclusion assay using an
automated cell analyzer, Vi-Cell XR (Beckman Coulter).
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9. Chapter 9- Section II Results
9.1. Genotyping HTT gene from HEK293FT cell line for TALEN design
The HEK293FT cell line sequencing results showed 23 CAG repeats in the exon 1 of HTT.
The exact number of repeats at the two homologous chromosomes might be slightly
different due to possible PCR artifacts during repeat amplification. Yet the actual sequence
is unlikely to vary by more than two to three CAG repeats. Therefore, either this cell line is
homozygous for 23 CAG repeats at HTT, an aneuploid at HTT, or, more likely, heterozygous
at the two loci with approximately 23±3 CAG repeats.
Carefully scanning a 2.5 kb section of the sequenced exon 1 of the HEK293 HTT gene, 1.5
kb upstream and 1 kb downstream around the first exon, three regions were selected for
targeted cleavage. Region 1 was located 5’ to -1032. Region 2 was located between +256
and +300. And Region 3 was located 3’ to +584. It was decided that the highest efficiency
in CAG allele replacement might be achieved by cleaving in the region 2 on Figure 28,
nearest to the transcription start site (TSS). Out of 10 TALEN pairs designed around this
region 2 and tested for activity, two final pairs were chosen, which were labeled TALEN
pair 1 and TALEN pair 2, respectively.
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9.2. HEK293FT cell line passage number optimization for transfection
We subcultured the HEK293FT cell line for 29 passages and monitored the percent viability
and doubling time. The percent viability remained high at an average of 96.8% (+/-1.9%)
for the 29 passages (Figure 29). On the other hand, the doubling time increased with the
number of passages (Figure 30). In the first 16 passages the doubling time averaged 31.6
hours (+/- 9.9 hours). To produce a master cell bank, vials of cells were cryo-preserved on
passages 0, 1, 2 and 3. It was decided that experiments would be performed with HEK293FT
cells from passage 16 or lower.
9.3. HEK293FT Transfection Parameter Optimization
The first set of experiments were performed before the TALENs had been engineered. Three
experiments were set to optimize the transfection of HEK 293FT cell line. In lieu of
TALENs plasmids, the cells were transfected with a plasmid encoding peGFP-N1 which
has a constitutive CMV promoter.
Three parameters were chosen to perform the optimization experiments. These were:
amount of DNA used, amount of transfection reagent used, and the time of incubation for
the complex to occur. Although there are many other variables, these three parameters were
perceived as the key parameters that could be controlled first in the optimization process.
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The design and analysis of the experiments were performed using a design of experiment
software JMP (SAS Institute).
9.3.1. Transfection Optimization Experiment 1
The first optimization experiment was designed to optimize three parameters in a 3 × 2
factorial design (three factors each at two levels). The eight conditions tested in the first
experiment are listed on Table 9. These include amount of transfection reagent used,
TransIT-LT1 at three levels, amount of plasmid DNA used at three levels, and incubation
time for complex formation at three levels. In addition, two conditions with the factors at
the center points of the design and two negative controls, one without DNA and the other
without the transfection reagent were set up.
We plated 1 × 106 viable HEK293FT cells from passage 12 and transfected them the next
day. After 48 hours the cells were harvested and analyzed under a fluorescence microscope,
by counting the eGFP+ cells to assess the transfection efficiency. Figure 31 is a plot of the
percent of eGFP+ cells in the observed population across the tested conditions. The percent
transfection results ranged between 1.4 and 16%. The condition with the three factors at the
lowest tested concentrations had the lowest number of transfected cells. The condition with
the highest number of transfected cells was: 3µg of DNA, 3µl of transfection reagent and
20 minute incubation time for DNA:reagent complex formation.
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We performed a statistical analysis, which included an Analysis of Variance test of the
model built from results (Figure 32). The Analysis of Variance report provides the
calculations for comparing the fitted model to a simple mean model. The P value was 0.0299
which is less than 0.05 and is considered evidence that there is at least one significant effect
in the model. In this case, three factors had significant effect on the transfection efficiency,
and are further discussed below. The calculated R square value was 0.96. The R square
(RSq) estimates the proportion of variation in the transfection efficiency that can be
attributed to the model rather than to random error. The root-mean-square error (RMSE)
estimates the standard deviation of the random error. It tells how far on average the error is
from 0. The model had a value of 1.287 which is considered acceptable since the lower the
value the better.
In addition, the statistical analysis provided a Parameter Estimates report that shows the
estimates of the parameters and a t-test for the hypothesis that each parameter is zero (Figure
33). The lists of parameter estimates are the coefficients in the model used to predict the
response, which in this case is the percent of transfected cells. In addition, the Parameter
Estimate report provides the probability of significance value from a t-test for each single
factor and the first order interactions. Three factors were found to be significant: incubation
time had the highest effect, followed by the interaction between incubation time and
transfection reagent amount, and, lastly, the amount of DNA. Incubation time was positively
correlated to the percent of transfected cells with a high P-value. The higher the incubation
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time, the higher the percent of transfected cells. It appears that in this experiment the higher
the amount of transfection reagent used with a longer incubation time is negatively
correlated with the percent of transfected cells. The DNA amount was also found to be
statistically significant, having a positive correlation with percent transfection. The
maximum predicted value for percent transfection is between 9.9% and 17.4%, with 95%
confidence.
9.3.1. Transfection Optimization Experiment 2
The next optimization experiment was set to optimize the two transfection parameters that
were statistically significant in the first experiment; these are: amount of DNA used, and
time of incubation for DNA:reagent complex to occur. The experiment was designed as a 2
× 2 factorial design (2 factors at two levels) for a total of four conditions (Table 10). In
addition, two runs were set at the center points of the tested ranges.
We plated 3.5 × 106 viable HEK293FT cells from passage 12 and transfected them the next
day. 48 hours after transfection, the cells were harvested and analyzed under a fluorescence
microscope. We assessed the transfection efficiency by counting the eGFP+ cells. Figure
34 is a plot of the percent of eGFP+ cells in the observed population across the four tested
conditions. The percent transfection results ranged between 4.2 and 22%. The condition
with the lowest percent of transfected cells was the one with both factors at the lowest tested
amounts. The condition with the highest percent of transfected cells was the one with the
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shortest time of incubation time for DNA:reagent complex formation (20 minutes) and the
highest amount of DNA used (5µg).
The Analysis of Variance report for this experiment showed a P value of 0.165 which is
higher than 0.05 (Figure 35). This is considered evidence that there is no significant effect
in the model. The R square value was 0.98 meaning that 98% of the variation of the results
can be explained by the model. The RMSE was 1.4132. Although none of the parameters
are statistically significant one can still extract some general trends from this experiment
(Figure 36). The incubation time and the interaction between the two tested parameters had
a negative correlation with the results. Therefore, it appears that 20 minutes is sufficient for
complex formation and other unaccounted factors may be negatively affecting the
transfection efficiency. The amount of DNA used had a positive correlation with the percent
transfected cells. On average, the higher amount of DNA used the higher the percent of
transfected cells present.
9.3.2. Transfection Optimization Experiment 3
We ran another 2 × 2 factorial experiment to further optimize the transfection efficiency by
testing a larger design space for two parameters, amount of DNA and amount of transfection
reagent used (Table 11). Based on the results of experiment two, we wished like to observe
whether there is a greater positive effect in adding even more DNA into the transfection
mix. Therefore, we tested conditions with up to 10µg of DNA. The knowledge gained in
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this experiment was helpful in designing the transfections of multiple plasmids (i.e. two
TALEN and one Surrogate reported plasmids, and the Donor DNA) in the experiments that
followed.
The same protocol as Experiment 2 was followed with cells from passage 15. Again, the
cells were harvested and analyzed under a fluorescence microscope 48 hours after
transfection. The transfection efficiency was assessed by counting eGPF+ cells. Figure 37
is a plot of the percent of eGFP+ cells in the observed population across the four tested
conditions. The percent transfection results ranged between 18 and 38%. Again, the
condition with the lowest percent of transfected cells was the one with both factors at the
lowest tested amounts. The condition with the highest percent of transfected cells was the
one with the highest amount of DNA used (10µg) and the highest amount of transfection
reagent used (7.5µl). Unlike the results from the first transfection optimization experiment,
the transfection efficiency increased with higher amount of transfection reagent used; yet
the highest amount of DNA tested in the latter was only 3ug.
The Analysis of Variance report provided the calculations for comparing the fit of the
model, and with a P value of 0.0413 is enough evidence that there is at least one significant
effect in the model (Figure 38). The R square value for the model was at 1 which means that
all of the variation of the response can be explained by the model. The RMSE for this model
was acceptable at a value of 0.5277.
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The Parameter Estimates report shows that both amount of DNA and amount of transfection
reagent used were statistically significant and had positive correlations with the response,
percent transfected cells (Figure 39).
For practical purpose, the amount of transfection reagent used in the upcoming transfection
was kept at 7.5µl. The DNA amount was always maximized (17.5-35 ug) for each
experiment and the incubation time for DNA:reagent complex formation was kept at 20
minutes.
9.4. Transfection with TALENs and Surrogate Reporter Plasmids
A surrogate reporter system was used to monitor the TALEN activity and enable enrichment
of HTT gene modified cells. The reporter plasmid encodes RFP and eGFP fusion protein as
well as the H2KK membrane bound protein (Figure 40). A programmable nuclease target
site is inserted between the DNA sequences encoding RFP and eGFP/H2K K. This makes
the two set of proteins fused out of frame, thus cells transfected with only the reported
plasmid and no TALENs express RFP alone. If the cells are transfected with both the
reporter plasmid and the TALENs plasmids, they can express all three proteins if the
nuclease cleaves at the target site in the reporter plasmid. The generated double-strand break
forms indels by nonhomologous end-joining, putting the downstream genes for eGFP and
H2KK in-frame.
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Passage four cells were thawed, then used three passages later for the transfection
experiment. 1 × 106 cells were plated in 6-well plates the day before transfection. We used
7.5µl of TransIT-LT1 Transfection Reagent for all conditions. We added 10µg of each
TALEN plasmid and 5µg of MRS plasmid (surrogate reporter) and used 20 min of
incubation time for DNA:reagent complex formation. Tested the transfection efficiency and
nucleases activity by transfecting HEK293FT cells with the TALENs and surrogate reporter
plasmids and counting the RFP+ and eGFP+ cells using a fluorescence microscope. The
conditions tested are listed on Table 12 and include six controls: four negative controls for
each TALEN and two conditions transfected with each of the surrogate reporter alone.
As expected, the two conditions of cells transfected with all three plasmids were both RFP+
and eGFP+. The results also showed that in this transfection experiment all of the controls
performed as expected. Since all conditions were transfected with the surrogate reporter,
they were all RFP+. The samples transfected with either one or no TALEN DNA constructs
were all eGFP-. The overall transfection efficiency for TALEN1 set was 23%, and its
activity based on the reporter was 29%. The efficiency for TALEN2 set was lower at 17%
and 20%, respectively (Figures 41 – 47).
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9.5. Pooled Transfections with TALENs, Surrogate Reporter Plasmids and Donor
DNA
Typically, we transfected the individual TALEN sets with their respective surrogate
reporter, and Donor DNA at 8:2:>1, respectively (Figures 48 – 49). On other occasions, we
transfected with both TALEN set and both surrogate reporters combined together, doubling
the amount of plasmid DNA transfected (Figures 51 – 52). The Donor DNA was either
single, double or triple digested to generate the 1.6kb, 2.8kb and 3.2kb plasmid fragments,
respectively. The 863bp fragment was not used in the pooled transfections. Two
transfections methods were performed: one with just TALEN1 set and the other using two
both TALEN1&2 sets (Table 13). The total amount of combined DNA transfected was
17.5µg when only one set of TALENs was used and 35µg when both sets were used. Each
time, a transfection control was set up by transfecting with only the MRS reporter plasmids
(Figures 50 and 53).
48 hours post transfection, all of the experimental transfections gave yielded both eGFP+
and RFP+ cells. In addition, the transfection controls performed as expected. The pooled
transfected cell lines were subcultured until at least 1 × 106 cells were generated for gDNA
extraction. The gDNA from eight cell lines transfected with both TALEN sets and five from
the single TALEN1 set transfections were submitted for trinucleotide repeat sizing analysis
by Laragen.
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All thirteen cell lines gave evidence of increased trinucleotide repeat sizes in their respective
gDNA samples, averaging 103 CAG repeats. Eight cell lines gave a >1000 signal intensity
for peak size at ~350nt (corresponding to ~117 CAG repeats) and the other five cell lines
gave a low signal intensity (between 600 and 800). According to these results there appeared
to be no difference between the two transfection methods used, (i.e. transfecting with one
or both sets of TALENs).
9.6. MACS Enrichment of eGFP/H-2KK Positive HEK293FT Cells
Paramagnetic beads labeled with anti-H-2KK IgG were used to enrich the HEK293FT
cultures transiently expressing eGFP and H-2KK membrane protein. Enrichment was used
to increase the probability of attaining a successfully edited clone since the reporter was
activated by TALEN nucleolytic activity. Figures 54 through 59 show the results for an
enrichment experiment of transfected cells with both TALEN sets and surrogate reporters.
Two days after transfection, the cells were harvested and the RFP+ and eGFP+ cells were
counted before and after MACS enrichment. The RFP+ cell population increased with the
magnetic sorting, encompassing 26.9% of the total initial population and finishing at 53.4%
after enrichment. The GFP+ cell population also increased, going from 21.3% of the total
initial cell population (79.2% of RFP+ cells) to 32.9% (61.6% of RFP+ cells) in the enriched
cell population.
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Five transfections were enriched for H-2KK + cells using the labeled paramagnetic beads.
Forty-three picked clones (i.e. selected using cloning cylinders) were established. The
cultures were subcultured until enough cells are grown to extract DNA from > 1 × 106 cells
and cryo-preserve two vials at > 1 × 106 cells per ml. The DNA was sent to Laragen for
trinucleotide repeat sizing analysis. Only 14.3% (eight clones) had positive high CAG
signals with high confidence. Twelve clones or 21.4% of clones had positive high CAG
signals with low confidence and twenty-three clones (41%) had negative results for high
CAG signal. Since the single cell cloning by cloning cylinders procedure appears to have
low efficiency, it was decided to investigate other methods of single cell isolation and
enrichment.
9.7. Limiting Dilution Derived Clonal Cell Lines
Limiting dilution was used to obtain monoclonal cells starting from a polyclonal population
of cells. The cells from two pooled transfections using both TALEN sets, the surrogate
reported and the 2.8kb donor DNA were enriched using the MACS enrichment method
described above. The cells were serially diluted and subcultured as described in the methods
section 8.9.
After three to five days of growth in temperature controlled humidified CO2 incubator set
at 37⁰C, the wells were inspected with a microscope for single cell colonies. The identified
monoclonal cultures were grown to <60% confluency which took eight to fourteen days.
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Genomic DNA was isolation from twenty-four clonal cell lines and submitted for
trinucleotide repeat sizing analysis. In addition, two vials with 1 × 106 cells each were
cryopreserved.
Of the twenty-four clones submitted, four or 16.7% had positive high CAG signal with high
confidence. Nine clones (37.5%) had positive high CAG signal but with low confidence and
eleven (45.8%) had no high CAG signal. The efficiency of this method, enrichment
followed by limiting dilution appears to be slightly better than the previous method which
used cloning cylinders. We next investigated a method for both enrichment and monoclonal
selection by taking advantage of the surrogate reported fluorescent signals.
9.8. Fluorescence-Activated Cell Sorting (FACS) of GFP+/RFP+ cells at COH
A total of 102 cell lines were successfully scaled up from the thirty FACS sorted 96-well
plates. Of these, seven were from the growth controls with ten cells per well and ninety-five
were monoclonal lines. gDNA from these cell lines was submitted for trinucleotide repeat
sizing analysis.
Out of ninety-five monoclonal cell lines submitted, thirty-six (37.9%) lines had positive
high CAG signal with high signal intensity. Six cell lines (6.3%) had high CAG signal with
lower signal intensity and fifty-three (55.8%) had no high CAG signal. The gDNA from
seven cell lines from the ten cells per well controls were also submitted for trinucleotide
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repeat sizing analysis and four lines (57.1%) had positive high CAG signal with high signal
intensity. The efficiency for the identification of cell lines positive for high CAG repeat edit
achieved with this method was approximately twice the percentages achieved with the
previously used enrichment and single cell selection methods.
9.9. HTT Genotyping by PCR
A reproducible 96-well PCR protocol was an important factor for the establishment of a
high-throughput assay to identify clones positive for the CAG repeats expansion in the HTT
gene after transfection, enrichment and single cell selection methods. The donor DNA
plasmid with 101 CAG repeats was used during the optimization experiments. The high GC
content in the high CAG repeat HTT Exon 1 sequence makes it difficult to amplify since
base stacking makes these regions more stable and therefore the melting point of the DNA
is higher.
Many attempts were made to optimize the PCR protocols with the three master mixes,
including testing an annealing temperature gradient (60ºC to 70ºC), increasing the extension
time (up to three minutes) and the number of cycles (up to forty), but none made a
difference. In addition, we attempted to improve the PCR master mixes by adjusting the
magnesium chloride concentration starting from 1mM and up to 4mM and adding DMSO
(10%), but again it did not make a difference. Included with the Advantage-GC 2 kit there
is a buffer named GC-Melt which contains DMSO and an additional reagent that weakens
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base-pairing in GC-rich sequences. We tested the GC-Melt concentration in the PCR master
mix and found 1.5M to be optimal, giving a strong signal when the donor DNA plasmid was
used (Figure 60), but when tested with the gDNA from multiple clones, it failed to give a
clear signal for the expected amplicon (Figure 61).
9.10. Identification of Poly-Glutamine Repeat Expansion by Western Blots
It would be ideal if we could detect the expression of the mutant Htt protein in an edited
HEK293FT clonal cell line. The high molecular weight of Htt (350kD) makes it a difficult
protein to load into the gel and transfer into the membrane. On one occasion, four protein
samples from clonal cell lines appear to give positive signal for the mutant Htt protein
(Figure 62). Because the voltage used during the protein transfer from the gel to the
membrane was set relatively high at 50V, the buffer inside the transfer chamber got
overheated and the gel melted onto the membrane. This cause the membrane to look unclear.
Unfortunately, we were not able to clearly detect Htt in any attempt to replicate (~20) this
Western blot (Figure 63).
9.11. Oxidative Stress Test by Hydrogen Peroxide Treatment
There is plenty of evidence pointing at oxidative stress as a primary event in HD
neuropathology, yet it is still unclear whether it is a cause or a consequence of the
pathogenesis of the disease (Kumar et al., 2014b). Oxidative stress occurs as a result of an

152

imbalance between oxidants and anti-oxidants, favoring oxidative species that can
potentially steal electrons from cellular components. During oxidative phosphorylation, the
mitochondrion inappropriately produces superoxide radicals (e.g. O2-) which is the
precursor of most reactive oxygen species (ROS). Hydrogen peroxide is produced either
spontaneously from or by superoxide dismutases catalysis of O2-, which may be reduced to
water or partially reduced to hydroxyl radical (OH). OH formation is catalyzed by reduced
transition metals, which may be reduced by O2-, promulgating this process (Turrens, 2003).
It has been shown that immortalized a striatal precursor mouse cells expressing mHtt are
highly sensitive to oxidative stress (Jin et al., 2012; Ribeiro et al., 2013). In an attempt to
recapitulate the mHtt induced oxidative stress phenotype in our cell lines, we treated four
of the clonal lines that gave positive results in the trinucleotide repeat sizing analysis, with
varying concentrations of hydrogen peroxide.
The ANOVA results of the hydrogen peroxide assay show that there are no significant
differences between the naïve cell line and the four tested clones (Tables 16 and 17). The
sensitivity to hydrogen peroxide of all tested cell lines, including the naïve HEK293FT
appear to be similar at the tested concentration range (0.4 to 0.8µM) (Figures 64 and 65). It
is possible that the assay was not properly optimized, and that shorter incubations times (i.e.
< 15 hours) at a higher concentration range (i.e. 1 to 100µM) could potentially reproduce
the phenotypes observed by others. Other possible reasons for these and other negative
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results for the high-CAG repeat modification in the HTT locus are discussed further in
chapter 10.
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10. Chapter 10- Section II Discussion
We have attempted to edit the normal HTT locus of HEK293FT cells to mutant HTT (101
CAG repeats) allele. To achieve this, we successfully designed two set of TALENs that
were proven to work and were part of published data through a collaboration. We optimized
a transfection protocol of HEK293T cell line with a three plasmids system, TALENs,
surrogate reporter and donor plasmid that was used in multiple experiments to generate HTT
gene edited cells. We found clonal cell lines from edited cells by two methods, limiting
dilution and by FACS. Trinucleotide Repeat Sizing analysis indicated the presence of high
CAG allele at an estimated targeting frequency (without the use of any selectable marker)
of 17% for edited cell lines produced by limiting dilution and 38% for the FACS selected
edited cell lines. Unfortunately, after many attempts these results could not be confirmed by
Western Blot.
It is possible that single-cell clones that showed altered CAG repeats by the trinucleotide
repeat sizing analysis exhibited instability in the repeat number. The mutant protein could
be toxic to these cell line, leading to selective loss of cells expressing mHtt. Additionally,
since the HEK293 cell line is triploid for chromosome 4, it is possible that the mutant gene
expression was downregulated either transcriptionally or by hypermethylation of DNA or
any epigenetic modification on chromatin. We observed that the presence of the high CAG
allele was associated with reduced growth rates compared to the wild type cell line, that
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spontaneously recovered after a short period of culturing. Since these cell lines lack a
selectable marker associated with the targeted allele it makes it difficult to keep them from
losing the mutant HTT allele.
It is also probable that the targeted HTT allele was not modified at all. Assuming that the
probability of selecting a single clone with the targeted event is 1/100, the probability that
it will not be selected from a pool is (1 – P) or (1 – 1/100). If one picks N number of single
clones, the probability that none will be the targeted event is (1 – 1/100)N. The probability
that at least one out of N will be the targeted event is 1– (1 – 1/100)N. For 99% probability
that at least one targeted clone will be selected 1– (1 – 1/100)N = 0.99. Solving for N gives
458, which is the number of clonal cell lines that would need to be generated from each
transfected pool in order to get one successfully targeted clonal cell line.
Recently, a group at the Novosibirsk State University, in Novosibirsk, Russia reported the
generation of a HEK293 based HD model (Malankhanova et al., 2017). They constructed a
donor plasmid with 215 CAG repeats and introduced it into the genome of HEK293 cell
line by HDR using CRISPR/Cas9. They found no intracellular aggregates in the mutant cell
lines, even after treatment with a proteasome inhibitor. In addition, they confirmed the
expression of several neuronal markers including markers of neuronal precursors Vimentin
and transcription factor Islet-1 (ISL-1) and astrocyte makers Glial fibrillary acidic protein
(GFAP) and S100 calcium-binding protein B (S100B). They also demonstrated that after
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the addition of the mutation the obtained cell lines had decreased proliferation rates and
increased apoptosis compared to the naïve cell line.
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Section I Figures
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Figure 1- EGF Receptor Components and Tyrosine Kinase Domain Mutations

Map showing the location of ligand-independent receptor activating mutations within the seven
exons belonging to the EGFR tyrosine kinase domain. The two classical mutations, deletion in
exon 19 (△LRE) and the point mutation L858R in exon 21 are both in patients with NSCLC.
T790M is a secondary point mutation arising in TKI resistant tumors. Also depicted are the rare
G719 point mutations on exon 18 and insertions on exon 20. The locations of the glutamic acid
(Glu) and lysine (Lys) residues in the catalytic cleft are shown. The right diagram depicts the four
domains in a monomer of EGFR. (Adapted from (Kumar et al., 2008)
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Figure 2- EGFR Tyrosine Kinase Activation

Monomeric epidermal growth factor receptor (EGFR) resides inactive in the cellular membrane until
an extracellular ligand (see Table 1) binds its receptor, leading to dimerization and activation of
cytoplasmic tyrosine kinase activity. Homodimers, as well as heterodimers can form with other ErbB
family members, leading to autophosphorylation of several tyrosine (Y) residues (i.e. Y992, Y1045,
Y1068, Y1148 and Y1173). Autophosphorylation prompts downstream activation and signaling of
several signal transduction cascades, e.g. MAPK, STAT and Akt pathways leading to DNA
synthesis and cell proliferation, migration and differentiation. Due to a mutation, EGFR may have
ligand independent deregulated activation of these signaling pathways leading to tumorigenesis.
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Figure 3- Models for the Activation Mechanism of Exon 19 C-helix Deletions and Exon
21 A-Loop Point Mutation

Model EGFR tyrosine kinase domain illustrating conformational changes in the catalytic cleft in the
wild type and two classical activating mutations. A deletion (△LRE) in the N-Lobe of the domain
leads to the shortening of the C-helix which changes the domain’s conformation to an active state.
The point mutation c.2573>G (Substitution, position 2573, T➞G) in the C-Lobe of the domain leads
to a residue change from lysine to arginine at position 858 in the activation loop (A-Loop) that also
changes the domain’s conformation to an active state independent of ligand binding. (Adapted from
(Foster et al., 2016; Shan et al., 2012).
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Figure 4- Novel Approach to Target Identification

Novel approach to target identification, applying systems biological methods that employ genomewide techniques, next-generation sequencing, and high-volume computational data mining, to
develop this innovative class of drugs.
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Figure 5- Blasticidin S Selection Scheme for dCas9-VP64 Transductants

Schematic of Blasticidin S selection process used for the eight dCas9-VP64 transduced cell lines.
Four MOIs levels were used (i.e. 2, 4, 6 and 8) to transduced the HCC827 NSCLC cell line with the
single dCas9-VP64 vector both with and without polybrene. Seven cell lines were successfully
transduced and subcultured in media containing Blasticidin S at three levels, 0.75, 1.5 and 3 µg/ml
for a total of four days. The Blasticidin S concentration was raised to 3 µg/ml in all conditions and
subcultured for four additional days. A decision point was reached where the cell lines were either
subcultured or stopped and cryopreserved depending on the selection phenotype observed. The two
cell lines that exhibited high selection, i.e. lowered cell density and viability yet still proliferating at
a slower rate were subcultured for an additional thrity-one days with medium containing Blasticidin
S at 3 µg/ml until their growth rate had recovered reaching <60% confluency in three days or less.
The two selected cell lines were cryopreserved for storage until needed for further testing.
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Figure 6- Hygromycin B Selection Scheme for MS2-P65-HSF1 Transductants

Schematic of Hygromycin B selection process used for the eight MS2-P65-HSF1 transduced cell lines. Four MOIs levels
were used (i.e. 2, 4, 6 and 8) to transduced the HCC827 NSCLC cell line with the single MS2-P65-HSF1 vector both with
and without polybrene. Eight cell lines were initially selected for four days in media containing Hygromycin B at three
concentrations, i.e. 10, 20 and 40 µg/ml. Because low selection was observed, i.e. normal growth rate reaching <60%
confluency in three days, the Hygromycin B concentration was raised, first in the 10 µg/ml condition then in all conditions
up to 80 µg/ml. After a total of eight days under selection, a decision point was reached where the cell lines were either
subcultured or stopped and cryopreserved depending on the selection phenotype observed. The cell lines where low
selection was observed (i.e. normal growth rate reaching <60% confluency in three days or less) were stopped and
cryopreserved. Continued to subculture sixteen cell lines with some observed selection, (i.e. cell death and slowing of
growth) with medium containing 40 µg/ml of Hygromycin B for two days. Another decision point was reached since low
confluency (<30%) was observed in all cell lines that were originally transduced without polybrene. Also, because four
cell lines originally selected at the highest Hygromycin B concentration, 40 µg/ml were also growing well, the four
remaining cell lines originally selected with 20 µg/ml were cryopreserved. Continued to grow the four remaining cell lines
for thirty days in medium containing 40 µg/ml, yet lost two cell lines (4 and 6 MOIs) due to contamination. The remaining
two cell lines were cryopreserved for storage until needed for further testing.
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Figure 7- Hygromycin B and Blasticidin S Selection Scheme for dCAS9-VP64/MS2-P65HSF1 Transductants

Schematic of Blasticidin S and Hygromycin B double selection process for six dCas9-VP64 and MS2-P65-HSF1 double
transduced cell lines. Three MOIs levels were used (i.e. 4, 8 and 12) to transduced the HCC827 NSCLC cell line with the
two vectors, dCas9-VP64 and MS2-P65-HSF, in medium with and without polybrene. Three selection schemes were used,
two single selections with either Blasticidin S or Hygromycin B at 1.5 and 10 µg/ml, respectively, and the third with both
selection agents in combination at the same concentrations. The single selected cell lines were subculture for eight days,
then either subcultured or stopped. For nine days, five Blasticidin S selected cell line were subcultured with medium
containing Hygromycin B at 10 µg/ml where high selection and low viability was observed in all conditions. The three
surviving cell lines were then selected with Hygromycin at a lower concentration for eleven days until the viability and
growth rate recovered to normal levels (i.e. normal growth rate reaching <60% confluency in three days or less and <90%
viability). The two surviving cell lines were again selected with Blasticidin S at a higher final concentration of 3 µg/ml for
a total of ten days. The two surviving cell lines were cryopreserved for long term storage. The six cell lines originally
selected with 10 µg/ml of Hygromycin had low observed selection and therefore were stopped and cryopreserved. Six cell
lines were selected with third double selection scheme for a total of ten days. A decision point was reached where the cell
lines originally transduced in medium without polybrene had slow growth rates, not reaching <60% confluency by three
days or less and therefore were stopped and cryopreserved for storage. The three remaining cell lines, transduced by using
polybrene were subculture for ten more days in medium with both selection agents at the original concentrations. The two
surviving cell lines were selected with two more selection schemes, either in Blasticidin S at 3 µg/ml and Hygromycin B
at 40 µg/ml for ten days. The selection media were then switched at the same concentrations and the cell lines were
subcultured for another ten days. The four surviving cell lines were cryopreserved and stored until needed for further
testing.
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Figure 8- dCAs9 Protein RT-PCR Results

dCas9 protein RT-PCR results showing the quantitation cycle (Cq) for the HCC827 naïve
cell line and eight transduced cell lines. Lower Cq values mean higher initial copy
numbers of the target. Housekeeping gene GAPDH expression level was used the internal
control. Cell lines 13 and 19 are single dCas9-VP64 construct transductans. While the
other six cell lines are double transductans with dCas9-VP64 and MS2-P65-HSF1
constructs. Each cell line selection method is described on Table 5. Four cell lines, 52, 53,
66 and 67 were chosen to perform further analysis.

166

Figure 9- dCAs9 Protein and p65 Transactivation Domain RT-PCR Results

dCas9 protein and P65 transactivation domain RT-PCR results showing the quantitation cycle (Cq) for the HCC827 naïve
cell line and four transduced cell lines. Lower Cq values mean higher initial copy numbers of the target. Housekeeping
gene GAPDH expression level was used the internal control. All tested cell lines were double transductants with dCas9VP64 and MS2-P65-HSF1 constructs. Each cell line selection method is described on Table 5. Two cell lines, 52 and 66
were chosen for transductions with SAM sgRNA library.
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Figure 10 - SAM sgRNA Library Lentivirus Transduction Experiment 1

Experiment 1- SAM sgRNA library transduction 29-day process flow chart describing the
steps taken in the generation of Erlotinib resistant cell line. Cell line 52 was transduced at a
low MOI by spinfection and subsequently subcultured under Puromycin selection for 16
days. The selected cells were then treated with increasing concentration of Erlotinib for nine
days. After a total of twenty-nine days, the genomic DNA was collected and stored until
needed for NGS analysis.
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Figure 11- SAM sgRNA Library Lentivirus Transduction Experiment 2

Experiment 2- SAM sgRNA library transduction process flow chart describing the steps
taken in the generation of Erlotinib resistant cell line with cell line 66. The cells were
transduced at a low MOI by spinfection and subsequently subcultured under Puromycin
selection for a total of four days before the cultures completely perished.
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Figure 12- SAM sgRNA Library Lentivirus Transduction Experiment 3

Experiment 3- SAM sgRNA library transduction process flow chart describing the steps
taken in the generation of Erlotinib resistant cells. The cells were transduced at a low MOI
by spinfection and subsequently subcultured under Puromycin selection for a total of four
days before a contamination was noticed. The cells were treated with various antibiotics
and fungicide for a total of 14-days until no further signs of contamination were present.
Puromycin selection was continued for a total of eighteen days until 1.5 × 108 cells were
generated. Treated an aliquot of 6 × 107 cells with increasing Erlotinib concentrations for
eighteen days. After a total of sixty-one days, the genomic DNA was collected and stored
until needed for NGS analysis.
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Figure 13-Possible Mechanisms of Erlotinib Resistance and Anti-evolution of Resistance
Therapy

A. Cancer Progression- Mutations in the TK domain activates cytoplasmic tyrosine kinase activity of EGFR independently of a ligand
binding. Autophosphorylation prompts downstream signaling of several transduction cascades, e.g. MAPK, STAT and Akt pathways
leading to deregulated transcriptional activation of cell proliferation, differentiation, and survival genes. B. Cancer Remission- TK
inhibitor (TKI) Erlotinib competitively blocks EGFR activation by ATP by reversibly binding to the catalytic cleft, stopping the
deregulated transcriptional activation in NSCLC tumors, ultimately leading to cell death. C. Cancer Resistance- Cancer cells deploy
adaptive strategies, evolving specific genetic alterations that allow them to escape from Erlotinib treatment by the deregulated reactivation of oncogenic signaling pathways. D. Anti-evolution Drugs- Resistance gene(s) may be targeted by therapies designed to stopped
the adaptive deregulated transcriptional activation of signaling pathways in cancer cells, finally leading to cell death.
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Figure 14- Blasticidin S Dose Response with HCC827 Naïve Cell Line

Dose response curve for the log of Blasticidin S concentration in µg per ml versus percent
relative viability of HCC827 naïve cell line. The cells were treated with Blasticidin S at
increasing concentrations (Table 2) for a total of seven days. Six replicates were set for
each condition.
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Figure 15- Hygromycin B Dose Response with HCC827 Naïve Cell Line

Dose response curve for the log of Hygromycin B concentration in µg per ml versus
percent relative viability of HCC827 naïve cell line. The cells were treated with
Hygromycin B at increasing concentrations (Table 2) for a total of seven days. Six
replicates were set for each condition.
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Figure 16- Blasticidin S and Hygromycin B Dose Response with HCC827 Naïve Cell Line

Dose response curves for the log of Blasticidin S concentration in µg per ml combined
with Hygromycin B at four concentrations versus percent relative viability of HCC827
naïve cell line. The cells were treated with increasing concentrations of the seven
combinations of Blasticidin S and Hygromycin B (Table 2) for a total of seven days. Six
replicates were set for each condition.
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Figure 17- Puromycin Dose Response with the Double Transduced HCC827 Cell Line, 52

Dose response curve for the log of Puromycin concentration in µg per ml versus percent
relative viability of double transduced HCC827 cell line 52. The cells were treated with
increasing concentrations of Puromycin (Table 2) for a total of five days. Six replicates
were set for each condition.
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Figure 18- Erlotinib Dose Response with the Double Transduced HCC827 Cell Line, 52

Dose response curve for the log of Erlotinib concentration in µM versus percent relative
viability of double transduced HCC827 cell line 52. The cells were treated with increasing
concentrations of Erlotinib (Table 2) for a total of nine days. Six replicates were set for
each condition.
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Figure 19- Model of Possible Mechanism of Resistance of MAPKAP1

Model of possible mechanism of resistance of through the overexpression of MAPKAP1
in Erlotinib sensitive NSCLC cells. Mapkap1 binds with mTOR and Rictor to form the
mTORC2 complex. EGFR along with mTORC2 activate the PI3-K/AKT pathway leading
to cancer progression. Erlotinib blocks EGFR deregulated activation of the PI3-K/AKT
leading to cell death and cancer remission. Overexpression of MAPKAP1 may confer
Erlotinib resistance by increasing Mapkap1-Rictor-mTOR protein complex formation, that
leads to the activation of the Akt pathway promoting cell survival.
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Figure 20-Model of Possible Mechanism of Resistance of ARMCX5-GPRASP2

Model of a probable mechanism of resistance through the overexpression of ARMCX5GPRASP2 in Erlotinib sensitive NSCLC cells. During Erlotininb treatment and cancer
remission both GPCR and the Notch pathway remain inactive. The overexpression of
GRASP1/2 (genes in the transcriptional read-through ARMCX5-GRASP2) modulate GPCR
activity, controlling the activity of metalloproteinases which cleave pro-ligands leading to
the deregulated activation EGFR of signaling pathways. Overexpression of Linc00630,
also in the read-through, activates of the Notch pathway promoting metastasis and
proliferation of NSCLC cells.
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Figure 21- Model of Possible Mechanism of Resistance of SH3D19

Model of a probable mechanism of resistance through the overexpression of SH3D19 in
Erlotinib sensitive NSCLC cells. ADAM12 metalloprotease levels and/or activity
increases by SH3D19 dependent signaling, leading to increased ectodomain shedding of
EGFR ligand, HB-EGF. The increase in levels of bioactive HB-EGF leads to a
concentration-dependent activation of cell survival pathways, circumventing the
competitively TKI inactivated EGFR by Erlotinib
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Figure 22- Model of Possible Mechanism of Resistance of NARFL

Model of possible mechanism of resistance through the overexpression of NARFL
in Erlotinib sensitive NSCLC cells. NARFL plays a key role in the cellular defense against
hyperoxia-induced stress in human cells. A proposed mechanism of action of Erlotinib
induced cytotoxicity after EGFR inhibition is the generation of metabolic oxidative stress
by NOX4 signaling leading to cancer remission. The overexpression of NARFL
potentially lead to the reduction of hydrogen peroxide production leading to Erlotinib
resistance.
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Figure 23- Network of Top Thirteen Erlotinib Resistance Genes

Network generated with GeneMania app. Thirteen out of fourteen genes entered produced a cohesive network with
forty-two nodes and 305 edges. The stripe nodes are the original input genes. The edges are based on multiple
independent studies, thereby multiple edges may form from each interaction. The green edges signify genetic
interactions between nodes. The blue edges signify that the nodes may share pathways. The red edges signify the
physical interactions between genes, and the gold edges signify that the genes have shared protein domains. The network
was weighted based on Gene Ontology (GO) terms (GO biological process). The green colored nodes are enriched for
the epidermal growth factor receptor signaling pathway, red colored nodes for T cell costimulation and blue colored
nodes for G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger (FDR 0.041).
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Figure24- Histogram of Frequency Distribution Data
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Figure 25- Age at Motor Onset vs Number of Repeat Units Plot

Diagram showing the relationship between CAG and age at motor onset and effects of
modifiers. On the Y-axis, age at onset of diagnostic motor signs are plotted against HTT
CAG repeat length on the X-axis. A statistical model relating the relationship between age
at onset and CAG repeat length–based quality control passed data is shown (black line). The
blue lines indicate that a difference of 35 years in mean age at onset are within 12 CAG
units. The red line indicates that naturally occurring genetic modifiers potentially delay
onset by 20 to 25 years later than the mean within a single repeat length. (Gusella et al.,
2014)
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Figure 26- Pathogenic Mechanism of Mutant Huntingtin

Adapted from Bates et. al
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Figure 27- Selected Regions for TALEN Targeted Cleavage
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Figure 28- Section of the Sequenced Exon 1 of the HEK293 HTT Gene
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Figure 29- Plot of Percent Viability Against Passage Number for the HEK293FT cell line

Percent viability on the Y-axis plotted against passage number of HEK 293FT cell line.
Subcultured the naïve HEK293FT cell line for 29 passages. The percent viability remained
high at an average of 96.8% (+/-1.9%) during the 29 passages. Cryo-preserved vials on
passages 0, 1, 2 and 3. All TALENs experiments were performed with cells from passages
2 through 16.
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Figure 30- Plot of Doubling Time Against Passage Number for the HEK293FT cell line

Doubling time of HEK293FT cell line plotted versus passage number. Subcultured the
naïve HEK293FT cell line for 29 passages. The doubling time averaged was 31.6 hours
during the first 16 passages, which increased to 37.9 hours during the final 14 passages.
All TALENs experiments were performed with cells from passages 2 through 16.
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Figure 31- Transfection Optimization Experiment 1 Results
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Figure 32- Transfection Optimization Experiment 1 Actual Model by Predicted Model Plot

191

Figure 33- Transfection Optimization Experiment 1 Sorted Parameter Estimates
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Figure 34- Transfection Optimization Experiment 2 Results
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Figure 35- Transfection Optimization Experiment 2 Actual Model by Predicted Model Plot
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Figure 36- Transfection Optimization Experiment 2 Sorted Parameter Estimates
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Figure 37- Transfection Optimization Experiment 3 Results
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Figure 38- Transfection Optimization Experiment 3 Actual Model by Predicted Model Plot
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Figure 39- Transfection Optimization Experiment 3 Sorted Parameter Estimates
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Figure 40- Surrogate Reporter Design
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Figure 41- Transfection Experiment with TALENs and Surrogate Reporter Condition 1
Results
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Figure 42- Transfection Experiment with TALENs and Surrogate Reporter TALEN1 Right
Control Results
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Figure 43- Transfection Experiment with TALENs and Surrogate Reporter TALEN1 Left
Control Results
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Figure 44- Transfection Experiment with TALENs and Surrogate Reporter MRS1 Control
Results
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Figure 45- Transfection Experiment with TALENs and Surrogate Reporter Condition 5
Results
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Figure 46- Transfection Experiment with TALENs and Surrogate Reporter TALEN2 Left
Control Results
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Figure 47- Transfection Experiment with TALENs and Surrogate Reporter MRS2 Control
Results
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Figure 48- Pooled Transfection Experiment with TALEN1 set and Surrogate Reporter MRS1
and Double Digested Donor Plasmid
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Figure 49- Pooled Transfection Experiment with TALEN1 set and Surrogate Reporter MRS1
and Triple Digested Donor Plasmid
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Figure 50- Pooled Transfection Experiment Control with Surrogate Reporter MRS1 as
Transfection
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Figure 51- Pooled Transfection Experiment with TALEN1&2 sets and Surrogate Reporter
MRS1&2 and Double Digested Donor Plasmid
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Figure 52- Pooled Transfection Experiment with TALEN1&2 sets and Surrogate Reporter
MRS1&2 and Triple Digested Donor Plasmid
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Figure 53- Pooled Transfection Experiment Control with Surrogate Reporter MRS2 as
Transfection
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Figure 54- MACS Treated Cells Before Enrichment Bright Field

Count: 197 total cells
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Figure 55- MACS Treated Cells Before Enrichment RFP

Cell count= 53 RFP positive cells 26.9% of total cells
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Figure 56- MACS Treated Cells Before Enrichment eGFP

Count= 42 eGFP Positive cells, 79.2% of transfected cells
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Figure 57- Elution Post Enrichment Bright Field

Cell count= 669 total cells
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Figure 58- Elution Post Enrichment RFP

Cell count= 357 RFP positive cells, 53.4% of total cells
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Figure 59- Elution Post Enrichment eGFP

Cell count= 220 eGFP positive cells, 61.6% of transfected cells
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Figure 60- PCR Results for Advantage GC Melt Buffer
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Figure 61- Results of PCR of Transfected Clones with Advantage GC Melt Buffer
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Figure 62- Western Blot Results for HEK293FT Clonal Cell Lines
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Figure 63- Western Blot Results for HEK293FT Clonal Cell Lines
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Figure 64- Oxidative Stress Test by Hydrogen Peroxide Treatment with HEK293FT
Transfected Clonal Cell Lines
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Figure 65- Oxidative Stress Test 2 by Hydrogen Peroxide Treatment with 21E3,
HEK293FT Transfected Clonal Cell Line
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Table 1- ErbB Receptors Ligands

Receptor
Ligand

EGFR
(ErbB-1)

ErbB-2 ErbB-3 ErbB-4

amphiregulin

+

-

-

-

betacellulin

+

-

-

+

EGF

+

-

-

-

epigen

+

-

-

-

epiregulin

+

-

-

+

HB-EGF

+

-

-

+

neuregulin 1

-

-

+

+

neuregulin 2

-

-

+

+

neuregulin 3

-

-

-

+

TGF-α

+

-

-

+
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Table 2- Selection Agents Tested Concentrations

Blasticidin S

Hygromycin B

Puromycin

Erlotinib

Tested
Concentration
(µg per ml)
Log10 (Tested
Concentration)

0

0.5

1

1.5

2

2.5

3

3.5

4

5

NA

-0.3

0.0

0.2

0.3

0.4

0.5

0.5

0.6

0.7

Tested
Concentration
(µg per ml)
Log10 (Tested
Concentration)

0

5

10

15

20

25

30

40

60

100

NA

0.7

1.0

1.2

1.3

1.4

1.5

1.6

1.8

2.0

Tested
Concentration
(µg per ml)
Log10 (Tested
Concentration)

0

0.25

0.1

0.5

1

2

3

4

5

6

7

10

NA

-0.6

-1.0

0.3

0.0

0.3

0.5

0.6

0.7

0.8

0.8

1.0

Tested
Concentration
(µM)
Log10 (Tested
Concentration)

0

0.001

0.01

0.1

1

2.5

5

7.5

10

15

NA

-3.0

-2.0

1.0

0.0

0.4

0.7

0.9

1.0

1.2
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Table 3- RT-PCR primers

NAME

SEQUENCE

LENGTH
(nt)

GC
CONTENT
(%)

MELT
TEMP
(ºC)

GAPDH
Forward
Primer

5'- ATG GGG AAG GTG
AAG GTC GGA GTC -3'

24

58.3

65.8

Amplicon
(bp)

219
GAPDH
Reverse
Primer

5'- GGG ATT TCC ATT
GAT GAC AAG CTT
CCC G -3'

28

50

66.1

dCas9
Forward
Primer

5'- CTT GCG CAG CAA
ATC TTC ACG ATT
TAG TTT CAC C -3'

34

47.7

62.7

262
dCas9
Reverse
Primer

5'- GGT GAA ACT AAA
TCG TGA AGA TTT
GCT GCG CAA G -3'

34

44.1

62.6

P65
Forward
Primer

5'- GAC TCT GAG TGA
AGC TCT GCT GCA C 3'

25

56

61.3

P65
Reverse
Primer

5'- GTG TCC ATG TCT
CAT AGT ACA GCC
GAA CC -3'

174
29
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51.7

61.7

Table 4- NGS gDNA amplification primers

NAME

SEQUENCE

LENGTH (nt)

GC
CONTENT
(%)

MELT
TEMP (ºC)

NGS SAM
Library Fw1

5'- AAT GAT ACG GCG ACC
ACC GAG ATCTAC ACT CTT
TCC CTA CAC GAC GCT CTT
CCG ATC TTA AGT AGA
GGC TTTATA TAT CTT GTG
GAA AGG ACG AAA CAC C 3'

32

46

78.8

NGS SAM
Library Fw2

5'- AAT GAT ACG GCG ACC
ACC GAG ATCTAC ACT CTT
TCC CTA CAC GAC GCT CTT
CCG ATC TAT CAT GCT TAG
CTTTAT ATA TCT TGT GGA
AAG GAC GAAA CA CC -3'

32

45.5

78.6

NGS SAM
Library
barcode Rv1

5'- CAA GCA GAA GAC GGC
ATA CGA GATATA GCG TCG
TGA CTG GAG TTC A GACGT
GTG CTC TTC CGA TCT GCC
AAGTTG ATA ACG GAC TAG
CCT T -3'

29

50.5

80.1

NGS SAM
Library
barcode Rv2

5'- AAG CAG AAG ACG GCA
TAC GAG ATATAG CGT CGT
GAC TGG AGT TCA G
ACGTG TGC TCT TCC GAT
CTG CCA AGTTGA TAA CGG
ACT AGC CTT -3'

28

50

79.8

NGS SAM
Library
barcode Rv3

5'- CAA GCA GAA GAC GGC
ATA CGA GATGAA GAA
GTG TGA CTG GAG TTC A
GACGT GTG CTC TTC CGA
TCT GCC AAGTTG ATA ACG
GAC TAG CCT T -3'

29

49.5

79.7
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Table 5- Summary of Transduction Experiments and Selection Schemes for All Cell Lines
Produced
Cell
line

Lentiviral
Vector

MOI

Polybrene

First
Selection
Agent

No

1

2

Selection
Agent Initial
Concentration
(µg per ml)

Second
Selection
Agent

Third
Selection
Agent

RT-PCR
Signal
dCas
P65
9

Did not grow after
transduction

NA

0.75

2

3

Notes

ND

ND

1.5

Low selection
observed, cryopreserved

Yes
4

3

5

0.75

6

Good selection, slower
growing, cryopreserved
Low selection
observed, cryopreserved

1.5
No

7

Good selection, slower
growing, cryopreserved

3
4

ND

8
9

10

ND

0.75

Low selection
observed, cryopreserved

1.5
Yes

dCas9VP64

Blast. S

NA

Good selection, slower
growing, cryopreserved

NA

3

0.75

11
12

ND

Low selection
observed, cryopreserved

Yes

Finished entire
selection, cryopreserved

1.5
No

13

3

ND

6
14

0.75

15

Low selection
observed, cryopreserved

1.5
Yes

ND

16

3

17

0.75

Good selection, slower
growing, cryopreserved
Low selection
observed, cryopreserved

ND
18

1.5
8

19

No

ND
3

Yes
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Finished entire
selection, cryopreserved

Table 5 (Continued)- Summary of Transduction Experiments and Selection Schemes for
All Cell Lines Produced
Cell
line

Lentiviral
Vector

MOI

Polybrene

First
Selection
Agent

20

21

Selection
Agent Initial
Concentration
(µg per ml)

Second
Selection
Agent

Third
Selection
Agent

RT-PCR
Signal
dCas
P65
9

0.75
dCas9VP64

8

Yes

Blast. S

1.5

22

3

23

10
No

24

NA

NA

ND

ND

20

25

10

2

27

Low selection
observed, cryopreserved
Low selection
observed, cryopreserved
Good selection, slower
growing, cryopreserved

Low selection
observed, discarded

40

26

Notes

ND

ND

20

Low selection
observed, discarded

Yes
28

40

Finished entire
selection, cryopreserved

29

10

Low selection
observed, discarded

No

30

20

31

Low confluency
observed, discarded

40
4

ND

32
33

ND

10
MS2-P65HSF1

Hygro. B
Yes

NA

NA

20

Low selection
observed, discarded
Not selected, cryopreserved

34

40

Lost to contamination

35

10

Low selection
observed, discarded

No

36
37

20

Low confluency
observed, discarded

40
6

ND

38

ND

10
Yes

39

20

Low selection
observed, discarded
Not selected, cryopreserved

40

40

Lost to contamination

41

10

Low selection
observed, discarded

42
43

8

No

ND

20
40
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ND

Low confluency
observed, discarded

Table 5 (Continued)- Summary of Transduction Experiments and Selection Schemes for
All Cell Lines Produced
Cell
line

Lentiviral
Vector

MOI

Polybrene

First
Selection
Agent

44
45

Selection
Agent Initial
Concentration
(µg per ml)

MS2-P65HSF1

8

Yes

Hygro B

20

NA

Blast. S

1.5

Hygro. B

10

49

Blast. S
and
Hygro. B

1.5 / 10

50

Blast. S

1.5

48

4

No

51

NA

ND

ND

NA

1.5 / 10

53

Blast. S
and
Hygro. B

54

Blast. S

1.5

4

dCas9VP64 and
MS2-P65HSF1

Low selection
observed, discarded
Not selected, cryopreserved
Finished entire
selection, cryopreserved

NA

ND

ND

Low selection
observed, cryopreserved
Low confluency
observed, discarded
Lost to contamination

10

NA

NA

ND

ND

Low selection
observed, cryopreserved

Blast. S

Hygro. B

Yes

Yes

Hygro. B

Blast. S

Yes

Yes

Finished entire
selection, cryopreserved

NA

NA
ND

ND

Yes

52

Notes

Lost to contamination

Hygro. B

57

RT-PCR
Signal
dCas
P65
9

40

47

56

Third
Selection
Agent

10

46

55

Second
Selection
Agent

Lost to contamination

Hygro. B

10

NA

NA

Lost to contamination

Blast. S
and
Hygro. B

1.5 / 10

NA

NA

Blast. S

1.5

NA

NA

Lost due to technical
error

Hygro. B

10

NA

NA

Low selection
observed, cryopreserved

No

8

58
Yes
59

ND

ND

ND

ND

Low confluency
observed, discarded

1.5 / 10

NA

NA

60

Blast. S
and
Hygro. B

61

Blast. S

1.5

Hygro. B

Blast. S

Yes

ND

Finished entire
selection, cryopreserved

Hygro. B

10

NA

NA

ND

ND

Low selection
observed, cryopreserved

12
62

Lost to contamination

No

232

Table 5 (Continued)- Summary of Transduction Experiments and Selection Schemes for
All Cell Lines Produced

No

63

64

65

66
67

dCas9VP64 and
MS2-P65HSF1

Blast. S
and
Hygro. B

1.5 / 10

NA

NA

ND

ND

Low confluency
observed, discarded

Blast. S

1.5

Hygro. B

Blast. S

Yes

ND

Finished entire
selection, cryopreserved

Hygro. B

10

NA

NA

ND

ND

Low selection
observed, cryopreserved

Blast. S
and
Hygro. B

Blast. S

Hygro. B

Yes

Yes

1.5 / 10
Hygro. B

Blast. S

Yes

Yes

12
Yes
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Finished entire
selection, cryopreserved

Table 6- FastQC Quality Control Checks Results
Quality control checks
Sample
Name
Experiment 1
Day 0 NGS
Control
Result 1
Experiment 1
Day 0 NGS
Control
Result 2
Experiment 1
Day 9
Erlotinib
Negative
Control
Result 1
Experiment 1
Day 9
Erlotinib
Negative
Control
Result 2
Experiment 1
Day 9
Erlotinib
Result 1
Experiment 1
Day 9
Erlotinib
Result 2
Experiment 3
Day 0 NGS
Control
Result 1
Experiment 3
Day 0 NGS
Control
Result 2

Per base
sequence
quality

Per tile
sequence
quality

Per sequence
quality scores

Per base N
content

Sequence
Length
Distribution

VERY
UNUSUAL

NORMAL

NORMAL

NORMAL

SLIGHTLY
ABNORMAL

VERY
UNUSUAL

VERY
UNUSUAL

NORMAL

VERY
UNUSUAL

SLIGHTLY
ABNORMAL

VERY
UNUSUAL

NORMAL

NORMAL

NORMAL

SLIGHTLY
ABNORMAL

VERY
UNUSUAL

VERY
UNUSUAL

SLIGHTLY
ABNORMAL

VERY
UNUSUAL

SLIGHTLY
ABNORMAL

VERY
UNUSUAL

NORMAL

NORMAL

NORMAL

SLIGHTLY
ABNORMAL

VERY
UNUSUAL

VERY
UNUSUAL

NORMAL

VERY
UNUSUAL

SLIGHTLY
ABNORMAL

NORMAL

NORMAL

NORMAL

NORMAL

NORMAL

NORMAL

NORMAL

NORMAL

NORMAL

NORMAL
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Table 6- FastQC Quality Control Checks Results (continued)

Quality control checks
Sample
Name
Experiment 3
Day 18
Erlotinib
Negative
Control
Result 1
Experiment 3
Day 18
Erlotinib
Negative
Control
Result 2
Experiment 3
Day 18
Erlotinib
Result 1
Experiment 3
Day 18
Erlotinib
Result 2

Per base
sequence
quality

Per tile
sequence
quality

Per sequence
quality scores

Per base N
content

Sequence
Length
Distribution

NORMAL

NORMAL

NORMAL

NORMAL

NORMAL

NORMAL

NORMAL

NORMAL

NORMAL

NORMAL

NORMAL

NORMAL

NORMAL

NORMAL

NORMAL

NORMAL

NORMAL

NORMAL

NORMAL

NORMAL
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Table 7- NGS Results Calculated Difference Between Samples and Controls
Genes
SPATA31A5
MAPKAP1
RGPD8
ARMCX5GPRASP2
NARFL
IGFL1
ZNF701
SH3D19
MUC7
SPATA31A2
RIMBP2

D18 Erlo/D0 Control
129
11
74
70

D18 Erlo/CtrlD18 D18 Control/D0 Control
22
6
16
1
15
5
14
5

783
59
5
10025
17
3
47

13
10
8
7
7
5
5

236

59
6
1
1503
3
1
9

Table 8- Candidate genes

Genes

Score

RefSeq ID

Cytogenic
Location

Description

SPATA31A5

4.47

NM_001113541

9q12

Highly expressed in the testis,
spermatogenesis

MAPKAP1

4.02

NM_024117

9q33.3

Activation promotes NSCLC cell
proliferation and metastasis

RGPD8

3.89

NM_001164463

2q14.1

Suggested role in the nuclear pore
complex

ARMCX5GPRASP2

3.76

NM_001199818

Xq22.1

Protein homodimerization activity,
learning and memory

NARFL

3.73

NM_022493

16p13.3

Mediates the incorporation of Fe/S
cluster into extramitochondrial Fe/S
proteins, corneal edema and globe
disease

IGFL1

3.26

NM_198541

19q13.32

Likely act as growth modulators,
dermatological disorders

ZNF701

2.91

NM_018260

19q13.41

Regulation of gene transcription

SH3D19

2.74

NM_001128924

4q31.3

Plays a role in the regulation of cell
morphology and cytoskeletal
organization

MUC7

2.73

NM_001145007

4q13.3

Promotes the clearance of bacteria
in the oral cavity, bladder cancer

SPATA31A2

2.36

NM_001040065

9p12

Spermatogenesis, male
reproductive system disease
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Table 9 TALEN-based cellular disease models

Targeting
Targeted
Cell line

efficiency

Editing event

Publication

∆32 deletion

(Miller et al.,

addition by HDR

2010)

In-frame C-

(Hockemeyer et

terminal fusion of

al., 2011)

gene
(%)
K562 (human
CCR5

erythroleukemia

16

cells)
hESCs
OCT4
(WIBR#3)
hESCs
PPP1R12C
(WIBR#3)

hESCs
PITX3

13
(WIBR#3)

eGFP/Puro
OCT4

iPSC

PPP1R12C

iPSC

PITX3

iPSC

CCR5

HEK293T

14

(Mussolino et

IL2RG

HEK293T

17

al., 2011)

239

CCR5

NuFF

(Mussolino et

IL2RG

NuFF

al., 2014)

CCR5

HEK293T

Frameshift

(Kim et al.,

mutation by NHEJ

2011)

HPRT1

HEK293T

(Cermak et al.,

CFTR

HEK293T

2011)
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Table 10- Transfection Optimization Experiment 1 Design

Incubation time
Pattern

DNA (µg)

Reagent (µl)
(minutes)

−++

1

7.5

20

++−

3

7.5

5

−−−

1

3

5

+−−

3

3

5

−+−

1

7.5

5

−−+

1

3

20

+++

3

7.5

20

+−+

3

3

20

0

2

5.25

12.5

0

2

5.25

12.5

DNA Control

2

0

12.5

Reagent Control

0

5.25

12.5
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Table 11- Transfection Optimization Experiment 2 Design

Pattern Incubation time (minutes) DNA (µg)
−−

20

3

++

45

5

0

32.5

4

+−

45

3

0

32.5

4

−+

20

5
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Table 12- Transfection Optimization Experiment 3 Design

Pattern DNA (µg) Reagent (µl)
−−

5

3

++

10

7.5

−+

5

7.5

+−

10

3

0

7.5

5.25

0

7.5

5.25
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Table 13- Transfection Experiment with TALENs and Surrogate Reporters (MRS) Design

Conditions
1
2
3
4
5
6
7

TALEN1 TALEN1
TALEN2 TALEN2
MRS1
MRS2
L
R
L
R
+
+
+
+
+
+
+
+
+
+
+
+
+
+
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Table 14- Experiment Design of Pooled Transfections with TALENs and Surrogate
Reporter (MRS) Plasmids, and Donor DNA

Conditions

TALEN1
L

TALEN1
R

MRS1

TALEN2
L

TALEN2
R

MRS2

1
2
3
4
5
6

+
+
+
+
-

+
+
+
+
-

+
+
+
+
+
-

+
+
-

+
+
-

+
+
+
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Donor
DNA
(1.6kb)
+
+
-

Donor
DNA
(2.8kb)
+
-

Table 15- COH Transfections Experiment Design

Plasmid/DNA
fragment
TALENLeft 1
TALENRight 1
MRS1
TALENLeft 2
TALENRight 2
MRS2
pEGFP/N1
863b DNA
fragment
1.6kb DNA
fragment
2.8kb DNA
fragment

Flask 1
(wt)
-

Flask 2
(RFP+
control)
+
+
-

Flask 3
(eGFP+
control)
+

Flask 4
+
+
+
-

Flask 5
+
+
+
+
+
+
-

Flask 6
+
+
+
+
+
+
-

-

-

-

+

-

-

-

-

-

-

+

-

-

-

-

-

-

+
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Table 16- ANOVA Summary of Hydrogen Peroxide Assay Results
ANOVA summary
F
P value
P value summary
Significant diff. among means
(P < 0.05)?
R square

0.1274
0.9420
ns
No
0.03087

Brown-Forsythe test
F (DFn, DFd)
P value
P value summary
Are SDs significantly different
(P < 0.05)?
Bartlett's test
Bartlett's statistic (corrected)
P value
P value summary
Are SDs significantly different
(P < 0.05)?
ANOVA table
Treatment (between columns)
Residual (within columns)
Total
Data summary
Number of treatments
(columns)
Number of values (total)

0.2349 (3,
12)
0.8703
ns
No

0.434
0.9331
ns
No
SS
275.6
8652
8927

DF
3
12
15

4
16
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MS
91.86
721

F (DFn, DFd)
F (3, 12) = 0.1274

P value
P=0.9420

Table 17- t-Test Analysis of Hydogen Peroxide Assay Results
t-Test Summary
Column B
vs.
Column A
Unpaired t test
P value
P value summary
Significantly different (P < 0.05)?
One- or two-tailed P value?
t, df
How big is the difference?
Mean ± SEM of column A
Mean ± SEM of column B
Difference between means
95% confidence interval
R squared (eta squared)
F test to compare variances
F, DFn, Dfd
P value
P value summary
Significantly different (P < 0.05)?

21E3
vs.
HEK293FT
0.8279
ns
No
Two-tailed
t=0.2271 df=6
69.94 ± 15.7, n=4
64.62 ± 17.41, n=4
-5.324 ± 23.45
-62.7 to 52.05
0.008519
1.23, 3, 3
0.8691
ns
No
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Appendix
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Figure 1- Experiment 1 Day 0 NGS Control PCR Amplicons in Agarose Gel
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Figure 2- Experiment 1 Day 9 Erlotinib Negative Control PCR Amplicons in Agarose Gel

251

Figure 3- Experiment 1 Day 9 Erlotinib PCR Amplicons in Agarose Gel
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Figure 4- Experiment 3 Day 0 NGS Control PCR Amplicons in Agarose Gel
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Figure 5- Experiment 3 Day 9 Erlotinib Negative Control PCR Amplicons in Agarose Gel
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Figure 6- Experiment 3 Day 9 Erlotinib PCR Amplicons in Agarose Gel
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